# 2025年11月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. JAK2/JAK2V617F 异源二聚体通过激活 STAT1 和 AhR 促进血小板增多症。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41217440](https://pubmed.ncbi.nlm.nih.gov/41217440)
**期刊：** The Journal of experimental medicine
**PMID：** 41217440
**DOI：** 10.1084/jem.20251880

### 第一部分 原文与翻译

**英文原标题：** JAK2/JAK2V617F heterodimers activate STAT1 and AhR to promote thrombocytosis.

**英文摘要原文：**
In this issue of JEM, Zhou et al. (https://doi.org/10.1084/jem.20250153) report that hematopoietic progenitors heterozygous for the JAK2V617F mutation preferentially activate STAT1, promoting platelet production and thrombocythemia, whereas homozygous progenitors activate STAT5, leading to erythrocytosis and polycythemia.

**中文摘要译文：**
在本期《实验医学杂志》（JEM）中，Zhou等人（https://doi.org/10.1084/jem.20250153）报道，携带JAK2V617F突变基因杂合子的造血祖细胞会优先激活STAT1，从而促进血小板生成和血小板增多症；而纯合子祖细胞则激活STAT5，导致红细胞增多和真性红细胞增多症。

### 第二部分 AI 大师评价

这篇评述重点介绍了一项重要研究，该研究精准揭示了JAK2V617F突变状态（杂合与纯合）如何决定不同骨髓增殖性肿瘤表型的分子机制。其核心发现是，杂合突变通过优先激活STAT1通路驱动血小板增多症，而纯合突变则转向激活STAT5通路导致真性红细胞增多症。这一发现为理解疾病的临床异质性提供了关键的分子解释，并为开发基于基因型的精准治疗策略指明了新方向，具有重要的科研价值和临床转化潜力。

---

## 2. EB病毒表达的长链非编码RNA (lncBARTs) 调控EBV潜伏期基因组复制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41216873](https://pubmed.ncbi.nlm.nih.gov/41216873)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41216873
**DOI：** 10.1002/advs.202507286

### 第一部分 原文与翻译

**英文原标题：** Epstein-Barr Virus Expressed Long Non-Coding RNA (lncBARTs) Regulate EBV Latent Genome Replication.

**英文摘要原文：**
Epstein-Barr virus (EBV) is a ubiquitous human virus that is also linked to various human cancers. In EBV-associated nasopharyngeal carcinoma and gastric carcinoma cells, EBV expresses only essential viral antigens but high levels of long non-coding RNAs known as BamHI-A rightward transcripts (lncBARTs). The exact roles lncBARTs in the EBV life cycle and the development of EBV-associated cancers are largely not understood. This study demonstrates that lncBARTs play a role in maintaining viral genome replication by affecting the tethering of EBV oriP region to chromosome. Mechanistically, lncBARTs interact functionally with a complex consisting of Bromodomain-containing protein 4 (BRD4), CCTC-binding factor (CTCF), and EBV nuclear antigen 1 (EBNA1), anchoring their binding at oriP to facilitate EBV episome replication. Additionally, the lncBARTs-BRD4/CTCF complex contributes to the regulation of MYC and BCL2 expression. These findings suggest that lncBARTs modulate EBV latency through interactions with oriP region, while lncBARTs-BRD4/CTCF complexes promote host epigenome reprogramming and drive tumorigenesis in EBV-associated epithelial tumors.

**中文摘要译文：**
EB病毒（EBV）是一种普遍存在的人类病毒，与多种人类癌症相关。在EB病毒相关的鼻咽癌和胃癌细胞中，EBV仅表达必需的病毒抗原，但高水平表达被称为BamHI-A右向转录本（lncBARTs）的长链非编码RNA。lncBARTs在EBV生命周期及EBV相关癌症发展中的确切作用在很大程度上尚不清楚。本研究表明，lncBARTs通过影响EBV oriP区域与染色体的锚定，在维持病毒基因组复制中发挥作用。从机制上讲，lncBARTs与一个由含溴结构域蛋白4（BRD4）、CCCTC结合因子（CTCF）和EBV核抗原1（EBNA1）组成的复合物发生功能性相互作用，将它们的结合锚定在oriP上，以促进EBV附加体复制。此外，lncBARTs-BRD4/CTCF复合物还参与调控MYC和BCL2的表达。这些发现表明，lncBARTs通过与oriP区域的相互作用来调节EBV的潜伏状态，同时lncBARTs-BRD4/CTCF复合物促进宿主表观基因组重编程，并驱动EBV相关上皮性肿瘤的发生。

### 第二部分 AI 大师评价

本研究旨在阐明EB病毒编码的长链非编码RNA（lncBARTs）在病毒潜伏期基因组复制和相关肿瘤发生中的作用。研究通过分子机制的深入探索，揭示了lncBARTs通过与BRD4、CTCF和EBNA1蛋白形成复合物，锚定于病毒复制起始点oriP，从而维持病毒附加体的复制。此项工作的关键创新在于，不仅阐明了lncBARTs在维持病毒潜伏感染中的新功能，还发现其形成的复合物能调控宿主关键癌基因（MYC和BCL2），直接将病毒复制与宿主细胞的癌变过程联系起来，为开发针对EBV相关上皮性肿瘤的新型治疗策略提供了重要理论依据和潜在靶点。

---

## 3. ZFPL1通过稳定ASS1驱动尿素循环及M2巨噬细胞介导的转移定植来促进结直肠癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41216870](https://pubmed.ncbi.nlm.nih.gov/41216870)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41216870
**DOI：** 10.1002/advs.202505291

### 第一部分 原文与翻译

**英文原标题：** ZFPL1 Promotes Colorectal Cancer Progression by Stabilizing ASS1 to Drive the Urea Cycle and M2 Macrophage-Mediated Metastatic Colonization.

**英文摘要原文：**
Colorectal cancer (CRC) progression is driven by diverse molecular mechanisms, underscoring the urgent need for novel therapeutic strategies, especially for liver metastases. Through an integrated analysis of multiple single-cell RNA sequencing databases, zinc finger protein-like 1 (ZFPL1) is identified as a gene specifically enriched in malignant cells from both primary and metastatic CRC. Multi-omics investigations demonstrate that high ZFPL1 expression correlates with aggressive clinicopathological features and poor survival. Functionally, ZFPL1 promotes tumor proliferation, invasion, and migration both in vivo and in vitro. Mechanistically, ZFPL1 directly binds argininosuccinate synthase 1 (ASS1), shielding its K57 residue from tripartite motif containing 33-mediated ubiquitination to prevent proteasomal degradation. This stabilization activates urea cycle metabolism, driving CRC progression. Crucially, ZFPL1 deficiency remodels the tumor microenvironment by reducing immunosuppressive populations-M2 macrophages, and promoting pro-inflammatory M1 polarization. Virtual screening identifies Salvianolic acid B (Sal B) as a ZFPL1 inhibitor, which disrupts ZFPL1-ASS1 binding, triggering ASS1 ubiquitination and degradation. In vivo, Sal B synergized with anti-PD-1 therapy, significantly reducing tumor burden versus monotherapy. These findings establish ZFPL1 as a key regulator of CRC progression through ASS1-dependent urea cycle activation and immunomodulation, nominating the ZFPL1-ASS1 axis as a therapeutic target, with Sal B demonstrating combinatorial potential with immunotherapy.

**中文摘要译文：**
结直肠癌（CRC）的进展由多种分子机制驱动，这凸显了开发新型治疗策略（尤其是针对肝转移）的迫切需求。通过对多个单细胞RNA测序数据库的综合分析，锌指蛋白样1（ZFPL1）被鉴定为在原发性和转移性CRC的恶性细胞中特异性富集的一个基因。多组学研究表明，ZFPL1的高表达与侵袭性临床病理特征及不良预后相关。功能上，ZFPL1在体内和体外均能促进肿瘤的增殖、侵袭和迁移。机制上，ZFPL1直接结合精氨酸琥珀酸合酶1（ASS1），保护其K57残基免受含三联基序蛋白33介导的泛素化，从而防止蛋白酶体降解。这种稳定作用激活了尿素循环代谢，进而驱动CRC的进展。关键的是，ZFPL1的缺失通过减少免疫抑制性细胞群体——M2巨噬细胞，并促进促炎性的M1极化，从而重塑了肿瘤微环境。虚拟筛选发现丹酚酸B（Sal B）是一种ZFPL1抑制剂，它能破坏ZFPL1-ASS1的结合，从而引发ASS1的泛素化和降解。在体内实验中，丹酚酸B与抗PD-1疗法产生协同作用，与单一疗法相比，显著降低了肿瘤负荷。这些发现确立了ZFPL1作为通过ASS1依赖的尿素循环激活和免疫调节来调控CRC进展的关键因子，并提名ZFPL1-ASS1轴作为一个治疗靶点，同时丹酚酸B也展示了其与免疫疗法联合应用的潜力。

### 第二部分 AI 大师评价

本研究通过多组学分析，精准定位了在结直肠癌恶性细胞中特异性富集的关键蛋白ZFPL1。研究团队不仅在体内外实验中证实了ZFPL1通过稳定ASS1蛋白、激活尿素循环来促进肿瘤增殖与转移，更创新性地揭示了其调控肿瘤免疫微环境、促进M2巨噬细胞极化的双重促癌机制。尤为重要的是，该研究通过虚拟筛选发现并验证了小分子抑制剂丹酚酸B的有效性，并证实其与PD-1抑制剂联用具有协同抗肿瘤效应，为结直肠癌的治疗提供了极具潜力的靶点和联合用药新策略。

---

## 4. SLPI⁺ AT2样细胞通过激活Wnt通路和基质串扰在空间定义的边缘微环境中协同调控肺腺癌的侵袭

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41216859](https://pubmed.ncbi.nlm.nih.gov/41216859)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41216859
**DOI：** 10.1002/advs.202516580

### 第一部分 原文与翻译

**英文原标题：** SLPI⁺ AT2-Like Cells Orchestrate Lung Adenocarcinoma Invasion via Wnt Pathway Activation and Stromal Crosstalk in a Spatially Defined Margin Niche.

**英文摘要原文：**
The spatial organization of the tumor microenvironment (TME) profoundly influences cancer biology. However, the cell types and spatial distribution driving lung adenocarcinoma (LUAD) invasion remain poorly understood. By integrating spatially resolved transcriptomics with scRNA-seq data, we identify a novel secretory leukocyte protease inhibitor (SLPI)-expressing AT2-like subpopulation that localizes specifically at the invasive tumor margin, which drives the transition from minimally invasive (MIA) to invasive (IA) LUAD. Functional characterization reveals that SLPI-expressing AT2-like cells upregulated Dickkopf-1(DKK1), enhancing tumor cell stemness and epithelial-mesenchymal transition (EMT). Furthermore, spatially co-localized MRC1-expressing resident tissue macrophages (RTM-TAMs) secrete pro-tumor cytokines upon interaction with SLPI tumor cells, alongside cancer-associated myofibroblasts (myo-CAFs) exhibiting reduced type I collagen production. These TME components establish a pro-tumorigenic niche and engaged in synergistic interactions with SLPI AT2-like cells to facilitate LUAD invasion. These findings reveal the specific cellular composition, spatial architecture, and functional crosstalk between tumor cells and TME subpopulations that orchestrated LUAD progression. The frontier molecular targets at the tumor invasive identified in this study can serve as a basis for developing novel therapeutic targets in the future and assist pathologists in accurately assessing patients' disease progression and survival outcomes.

**中文摘要译文：**
肿瘤微环境（TME）的空间组织深刻影响着癌症生物学。然而，驱动肺腺癌（LUAD）侵袭的细胞类型和空间分布仍知之甚少。通过将空间分辨转录组学与scRNA-seq数据相结合，我们发现了一个新的表达分泌性白细胞蛋白酶抑制剂（SLPI）的AT2样细胞亚群，该亚群特异性地定位于侵袭性肿瘤边缘，驱动了从微小侵袭性腺癌（MIA）到侵袭性腺癌（IA）的转变。功能性鉴定表明，表达SLPI的AT2样细胞上调了Dickkopf-1（DKK1），从而增强了肿瘤细胞的干性和上皮-间质转化（EMT）。此外，在空间上共定位的表达MRC1的组织驻留巨噬细胞（RTM-TAMs）在与SLPI肿瘤细胞相互作用后分泌促肿瘤细胞因子，同时癌症相关肌成纤维细胞（myo-CAFs）的I型胶原蛋白生成减少。这些TME组分共同建立了一个促肿瘤微环境，并与SLPI AT2样细胞协同作用，以促进LUAD的侵袭。这些发现揭示了调控LUAD进展的肿瘤细胞与TME亚群之间特定的细胞组成、空间结构和功能性串扰。本研究在肿瘤侵袭前沿识别出的分子靶点，可为未来开发新的治疗靶点提供基础，并协助病理学家准确评估患者的疾病进展和生存结局。

### 第二部分 AI 大师评价

本研究巧妙地结合了空间转录组学与单细胞测序技术，旨在揭示驱动肺腺癌（LUAD）从微小侵袭向侵袭性转变的关键细胞及其空间互作机制。研究的核心发现是，在肿瘤侵袭边缘存在一个特异性的SLPI⁺ AT2样细胞亚群，它们通过激活Wnt通路并与肿瘤微环境中的巨噬细胞、成纤维细胞等基质细胞进行串扰，共同构建了一个促侵袭的“微环境壁龛”。这项工作不仅在空间维度上精细解析了LUAD侵袭的复杂生态系统，更指出了SLPI等前沿分子作为潜在治疗靶点和病理评估新标志物的巨大价值，为理解和干预肿瘤进展提供了重要见解。

---

## 5. 整合单细胞全转录组孟德尔随机化与差异表达基因分析以优先筛选癌症的动态免疫相关药物靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41216857](https://pubmed.ncbi.nlm.nih.gov/41216857)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41216857
**DOI：** 10.1002/advs.202507451

### 第一部分 原文与翻译

**英文原标题：** Integrating Single-Cell Transcriptome-Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune-Related Drug Targets for Cancers.

**英文摘要原文：**
Single-cell expression quantitative trait loci data offer promising opportunities to inform immune-related drug development in cancer. However, pleiotropy can complicate causal inference. We introduce MR-DEG, a framework that integrates Mendelian randomization (MR) and differential expressed gene (DEG) to strengthen causal inference. Using eight coventional MR and colocalization methods, we estimated effects of 11 021 dynamic gene expression profiles during CD4+ T cell activation on the risk of six cancer types. This identified 1000 gene-cancer pairs with putative effects (https://www.omicsharbour.com/sc-eqtl-mr). Of these 1000 pairs, 517 involved 205 unique genes that were differentially expressed in relevant cancer tissuesbased on single-cell RNA-sequencing data. Of these 517 pairs, 265 were classified as likely causal using the conventional MR methods. After applying MR-DEG to the remaining 252 potentially pleiotropic pairs, an additional 89 were classified as likely causal. 64Sixty-four and 391 of the 1000 original pairs exhibited time- and non-time dependent effects on cancer risk, respectively. Integrating the 1000 gene-cancer pairs of MR findings and clinical trial evidence, we identified 200 pairs corresponding to 33 uniquegenes that encode drug targets under clinical investigation. These results demonstrate how combining genetic, transcriptomic and clinical trial evidence canreduce pleiotropic bias, and prioritize immune-related drug targets for cancer prevention.

**中文摘要译文：**
单细胞表达数量性状基因座数据为癌症的免疫相关药物开发提供了充满希望的机会。然而，基因多效性可能会使因果推断复杂化。我们引入了一个名为MR-DEG的框架，该框架整合了孟德尔随机化（MR）和差异表达基因（DEG）分析，以加强因果推断。通过使用八种常规的孟德尔随机化和共定位方法，我们评估了CD4+ T细胞活化过程中11021个动态基因表达谱对六种癌症风险的影响。该分析识别出1000个具有推定效应的基因-癌症关联对（https://www.omicsharbour.com/sc-eqtl-mr）。在这1000个关联对中，有517个涉及205个独特基因，这些基因基于单细胞RNA测序数据在相关癌组织中存在差异表达。在这517个关联对中，有265个被传统孟德尔随机化方法归类为可能存在因果关系。在对其余252个可能具有基因多效性的关联对应用MR-DEG框架后，又有89个被归类为可能存在因果关系。在最初的1000个关联对中，分别有64个和391个对癌症风险表现出时间依赖性和非时间依赖性效应。通过整合这1000个基因-癌症关联对的孟德尔随机化发现与临床试验证据，我们识别出200个关联对，它们对应着33个正在临床研究中作为药物靶点的独特基因。这些结果表明，结合遗传学、转录组学和临床试验证据可以减少基因多效性带来的偏倚，并优先筛选用于癌症预防的免疫相关药物靶点。

### 第二部分 AI 大师评价

本研究旨在解决利用遗传学数据进行药物靶点识别时普遍存在的基因多效性难题。研究者创新性地开发了MR-DEG框架，该框架巧妙地整合了单细胞孟德尔随机化（MR）与差异表达基因（DEG）分析，显著增强了因果推断的准确性。通过分析T细胞动态基因表达与癌症风险的关联，该研究不仅识别出大量潜在的免疫治疗靶点，还验证了其中一部分已进入临床研究，充分展示了该方法在加速癌症免疫药物开发中的巨大潜力与临床转化价值。

---

## 6. XPC缺陷通过限制新型PHRF1介导的p53蛋白泛素化来激活膀胱癌中顺铂介导的自噬

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215711](https://pubmed.ncbi.nlm.nih.gov/41215711)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41215711
**DOI：** 10.1002/advs.202517563

### 第一部分 原文与翻译

**英文原标题：** XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein.

**英文摘要原文：**
Muscle-invasive bladder cancers (MIBC) are biologically heterogeneous and have widely variable conventional chemotherapy responses and clinical outcomes. This study demonstrates that XPC deficiency in bladder cancer cells can promote autophagy in response to the cisplatin-mediated DNA damage response (DDR). This process is closely related to both the overexpression of KDM4A and the downregulation of PHRF1 induced by the overactivation of ATM phosphate. The overaccumulation of KDM4A can suppress PHRF1 expression and result in significant nuclear accumulation of the p53 protein. Notably, this study defines a new mechanism by which PHRF1 regulates p53 posttranslationally through the ubiquitin-proteasome system. In XPC low expression cells, PHRF1 performs a more critical E3 ubiquitin ligase function than MDM2. Especially under conditions of cisplatin-mediated DNA damage where MDM2 function is impaired, PHRF1 retains its functionality. In a mouse xenograft model, combining a KDM4 inhibitor with cisplatin results in superior antitumor effects compared with cisplatin alone. These findings provide new insights into the phenotypic plasticity of bladder cancer under drug resistance and highlight the potential of KDM4A inhibition and preservation of PHRF1 function in overcoming cisplatin resistance. Therefore, KDM4A or PHRF1 may be potential novel targets for the treatment of bladder cancer.

**中文摘要译文：**
肌层浸润性膀胱癌（MIBC）具有生物学异质性，其对常规化疗的反应和临床结局差异很大。本研究表明，膀胱癌细胞中的XPC缺陷能够响应顺铂介导的DNA损伤反应（DDR）而促进自噬。这一过程与过度活化的ATM所诱导的KDM4A过表达及PHRF1下调密切相关。KDM4A的过度累积可抑制PHRF1的表达，并导致p53蛋白在细胞核内显著积聚。值得注意的是，本研究揭示了PHRF1通过泛素-蛋白酶体系统对p53进行翻译后调控的新机制。在XPC低表达的细胞中，PHRF1比MDM2发挥着更关键的E3泛素连接酶功能。尤其是在顺铂介导的DNA损伤导致MDM2功能受损的情况下，PHRF1仍能保持其功能。在小鼠异种移植模型中，与单独使用顺铂相比，将KDM4抑制剂与顺铂联合使用可产生更优的抗肿瘤效果。这些发现为膀胱癌在耐药性下的表型可塑性提供了新的见解，并凸显了抑制KDM4A和保留PHRF1功能在克服顺铂耐药性方面的潜力。因此，KDM4A或PHRF1可能成为治疗膀胱癌的潜在新靶点。

### 第二部分 AI 大师评价

本研究旨在阐明XPC缺陷如何通过激活自噬通路导致膀胱癌对顺铂产生耐药。研究通过细胞及动物模型，揭示了一条由XPC缺陷引发的ATM-KDM4A-PHRF1-p53信号轴，创新性地发现PHRF1是调控p53蛋白稳定性的关键E3泛素连接酶，在顺铂诱导的DNA损伤条件下其作用甚至超越了MDM2。该发现不仅深化了对膀胱癌耐药机制的理解，还验证了联合使用KDM4A抑制剂与顺铂的治疗策略，为克服临床顺铂耐药提供了极具价值的新靶点和实验依据。

---

## 7. MASLD患者中FIB-4与肝脏硬度测量值不一致者的组织学严重程度及肝脏结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215583](https://pubmed.ncbi.nlm.nih.gov/41215583)
**期刊：** Clinical and molecular hepatology
**PMID：** 41215583
**DOI：** 10.3350/cmh.2025.0888

### 第一部分 原文与翻译

**英文原标题：** Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurement.

**英文摘要原文：**
BACKGROUND/AIMS: Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using FIB-4 followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography. However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.

METHODS: This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.

RESULTS: F3-F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.2) and high-FIB-4-high-LSM (aSHR 21.3) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.

CONCLUSIONS: Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.

**中文摘要译文：**
背景/目的：当前指南推荐采用两步法来识别代谢功能障碍相关脂肪性肝病（MASLD）患者的晚期纤维化，即先使用FIB-4指数，然后通过振动控制瞬时弹性成像技术进行肝脏硬度测量（LSM）。然而，部分患者的检测结果可能出现不一致。本研究旨在评估FIB-4与LSM结果不一致患者的组织学严重程度及临床结局。

方法：本研究是对VCTE-Prognosis研究的二次分析，共纳入在16个三级医疗中心接受MASLD评估的12,950名患者，其中2,915名接受了肝活检。根据既定的FIB-4（1.3）和LSM（8 kPa）临界值，将患者分为四组。

结果：在低FIB-4-低LSM组（n=6,403）、高FIB-4-低LSM组（n=3,017）、低FIB-4-高LSM组（n=1,363）和高FIB-4-高LSM组（n=2,167）中，F3-F4期肝纤维化的发生率分别为6.4%、13.7%、30.6%和62.4%。在47.4个月的中位随访期内，有248名患者经历了肝脏失代偿、肝细胞癌、肝移植或肝相关死亡。各组的肝脏相关事件（LREs）发生率分别为每1000人年0.67、1.19、2.58和21.30。与低FIB-4-低LSM组患者相比，低FIB-4-高LSM组（校正亚分布风险比[aSHR]为4.2）和高FIB-4-高LSM组（aSHR为21.3）的LREs风险显著升高，而高FIB-4-低LSM组则无显著差异。当分别对肝脏失代偿和肝细胞癌进行分析时，也观察到了相似的结果。

结论：在三级医疗中心，约30%的患者表现出FIB-4与LSM结果不一致，其中LSM更可能反映真实的疾病严重程度。虽然部分结果不一致的患者可能已存在晚期纤维化，但其肝脏相关事件的总体发生率仍然较低。

### 第二部分 AI 大师评价

本研究聚焦于临床常见的难题：当无创肝纤维化评估指标FIB-4与肝脏硬度测量（LSM）结果不一致时，如何判断MASLD患者的真实病情与预后。该研究通过对大规模队列的二次分析，发现LSM在结果不一致时能更准确地反映组织学严重程度和预测不良肝脏事件风险。这项发现具有重要的临床指导价值，提示在FIB-4与LSM结果冲突时，应更重视LSM的结果来进行患者风险分层与决策，从而优化诊疗路径。

---

## 8. 在伴有中低度纤维化的MASLD和2型糖尿病患者中，SGLT2抑制剂与DPP-4抑制剂对纤维化进展风险的比较研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215582](https://pubmed.ncbi.nlm.nih.gov/41215582)
**期刊：** Clinical and molecular hepatology
**PMID：** 41215582
**DOI：** 10.3350/cmh.2025.0825

### 第一部分 原文与翻译

**英文原标题：** Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate Fibrosis.

**英文摘要原文：**
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing cause of cirrhosis and its complications. Given its close association with type 2 diabetes mellitus (T2DM), evaluating whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) can mitigate the progression of liver fibrosis is clinically important. We examined the association between SGLT2i use and liver fibrosis progression in patients diagnosed with MASLD and T2DM.

METHODS: We conducted a target trial emulation study using a retrospective, active comparator new-user design among adults with MASLD, T2DM, and low-to-intermediate Fibrosis-4 (FIB-4 ≤2.67) scores who initiated treatment with either SGLT2is or dipeptidyl peptidase-4 inhibitors (DPP4is) at Mass General Brigham or Asan Medical Center from 2013 to 2023. The primary outcome was the progression to advanced fibrosis (FIB-4 >2.67), confirmed on ≥2 occasions within 1 year. The secondary outcome was the development of major adverse liver outcomes (MALO), including incident cirrhosis, decompensation events, hepatocellular carcinoma, or liver transplantation.

RESULTS: Among 16,901 eligible patients, 2,571 propensity score-matched pairs were identified with balanced baseline characteristics. During follow-up (median, 3.7 years), fibrosis progression occurred at a rate of 3.46/100 person-years in SGLT2i users and 4.44 in DPP4i users. SGLT2i use was associated with a lower risk of fibrosis progression (HR, 0.78; 95% CI, 0.67-0.89; p<0.001). No significant difference in MALO incidence was observed. Subgroup analyses showed a consistent association among users of metformin, statins, and aspirin.

CONCLUSIONS: SGLT2i use was associated with reduced risk of fibrotic progression compared to DPP4i use in adults with MASLD and T2DM.

**中文摘要译文：**
背景与目的：代谢功能障碍相关脂肪性肝病（MASLD）是导致肝硬化及其并发症的一个日益重要的原因。鉴于其与2型糖尿病（T2DM）的密切关联，评估钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）是否能减缓肝纤维化进展具有重要的临床意义。本研究旨在探讨在确诊为MASLD和T2DM的患者中，使用SGLT2i与肝纤维化进展之间的关联。

方法：我们采用回顾性、活性药物比较剂、新用户设计，进行了一项目标试验模拟研究。研究对象为2013年至2023年间，在麻省总医院布里格姆分校或峨山医学中心首次接受SGLT2i或二肽基肽酶-4抑制剂（DPP4i）治疗的成年MASLD、T2DM且纤维化-4指数（FIB-4）为中低度（≤2.67）的患者。主要结局是进展为重度纤维化（FIB-4 >2.67），并在1年内经≥2次确认。次要结局是发生主要不良肝脏事件（MALO），包括新发肝硬化、失代偿事件、肝细胞癌或肝移植。

结果：在16,901名符合条件的患者中，通过倾向性评分匹配确定了2,571对基线特征均衡的患者。在随访期间（中位时间3.7年），SGLT2i使用者的纤维化进展率为3.46/100人年，而DPP4i使用者为4.44/100人年。使用SGLT2i与较低的纤维化进展风险相关（HR, 0.78; 95% CI, 0.67-0.89; p<0.001）。在主要不良肝脏事件（MALO）的发生率上未观察到显著差异。亚组分析显示，在二甲双胍、他汀类药物和阿司匹林的使用者中，这种关联保持一致。

结论：在患有MASLD和T2DM的成年人中，与使用DPP4i相比，使用SGLT2i与肝纤维化进展风险的降低相关。

### 第二部分 AI 大师评价

本研究通过一项大规模、多中心的目标试验模拟研究，旨在比较SGLT2抑制剂与DPP-4抑制剂在伴有中低度纤维化的MASLD及2型糖尿病患者中，对延缓肝纤维化进展的真实世界效果。核心发现表明，与DPP-4抑制剂相比，SGLT2抑制剂能显著降低患者肝纤维化进展的风险，为SGLT2抑制剂在MASLD治疗中的肝脏保护作用提供了有力证据。该研究的设计严谨（采用活性药物比较和倾向性评分匹配），其结论对于临床医生在合并MASLD和2型糖尿病的患者中选择降糖药物具有重要的指导价值，突显了SGLT2抑制剂超越降糖本身的潜在多重获益。

---

## 9. 肿瘤源性CDC37抑制树突状细胞的抗原交叉呈递并损害乳腺癌的抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215476](https://pubmed.ncbi.nlm.nih.gov/41215476)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41215476
**DOI：** 10.1002/advs.202506518

### 第一部分 原文与翻译

**英文原标题：** Tumor-Derived CDC37 Inhibits Antigen Cross-Presentation in Dendritic Cells and Impairs Anti-Tumor Immunity in Breast Cancer.

**英文摘要原文：**
Tumor mutational burden (TMB), usually representing high immunogenicity, cannot always predict treatment response of immune checkpoint blockade (ICB). Here, it is showed that defective antigen cross-presentation in type 1 conventional dendritic cells (cDC1) is responsible for lacking tumor-specific cytotoxic T lymphocytes (CTLs) in triple-negative breast cancer (TNBC) patients. Mechanistically, tumor cytosolic CDC37, shuttled via extracellular vesicles (EVs) into the endosomes of intratumor dendritic cells (DCs), inhibits antigen cross-presentation by locking antigen binding to HSP90 and precluding their translocation from endosomes to cytoplasm. CDC37 knockdown in tumor cells or inhibiting CDC37/HSP90 interaction in DCs efficiently promotes antigen translocation and enhances their cross-presentation, which improves ICB therapeutic responses. Clinically, high tumor CDC37 expression is associated with low infiltration of antigen-specific CTLs and poor ICB efficacy in TNBC patients. Therefore, tumor EV-shuttled CDC37 locks antigen/chaperone interaction and impairs antigen cross-presentation in DCs. Moreover, targeting CDC37 is promising to enhance anti-tumor immunity and reverse ICB resistance.

**中文摘要译文：**
肿瘤突变负荷（TMB）通常代表高免疫原性，但并不总能预测免疫检查点阻断（ICB）的治疗反应。本研究表明，1型常规树突状细胞（cDC1）中抗原交叉呈递的缺陷是导致三阴性乳腺癌（TNBC）患者缺乏肿瘤特异性细胞毒性T淋巴细胞（CTL）的原因。从机制上讲，肿瘤细胞质中的CDC37通过细胞外囊泡（EVs）穿梭进入肿瘤内树突状细胞（DCs）的内涵体，通过锁定抗原与HSP90的结合并阻止其从内涵体易位至细胞质，从而抑制抗原交叉呈递。在肿瘤细胞中敲低CDC37或在DC中抑制CDC37/HSP90相互作用，能有效促进抗原易位并增强其交叉呈递，从而改善ICB的治疗反应。临床上，肿瘤中CDC37的高表达与TNBC患者中抗原特异性CTL的低浸润和较差的ICB疗效相关。因此，肿瘤EV穿梭的CDC37锁定了抗原/分子伴侣的相互作用，并损害了DC中的抗原交叉呈递。此外，靶向CDC37有望增强抗肿瘤免疫并逆转ICB耐药。

### 第二部分 AI 大师评价

该研究旨在揭示三阴性乳腺癌（TNBC）对免疫检查点阻断（ICB）治疗反应不佳的潜在机制。研究通过对临床样本和细胞模型的分析发现，肿瘤细胞可通过细胞外囊泡（EVs）将其内部的CDC37蛋白转运至树突状细胞，进而抑制关键的抗原交叉呈递过程，导致抗肿瘤免疫失效。这一发现不仅阐明了肿瘤通过CDC37/HSP90轴介导免疫逃逸的新途径，更重要的是，它指出了靶向CDC37作为增敏ICB疗法、克服耐药性的新策略，具有重要的临床转化潜力。

---

## 10. GSH作为PKM2的A-A型别构激活剂：调节癌细胞稳态与铁死亡易感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215470](https://pubmed.ncbi.nlm.nih.gov/41215470)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41215470
**DOI：** 10.1002/advs.202519368

### 第一部分 原文与翻译

**英文原标题：** GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility.

**英文摘要原文：**
This study identifies glutathione (GSH) as an endogenous A-A type allosteric activator of pyruvate kinase M2 (PKM2), stabilizing it in its active tetrameric form through binding at the A-A interface. This PKM2-GSH interaction links GSH metabolism to ferroptosis regulation. Transcriptomic analyses across cancers demonstrate strong correlations between GSH, SLC7A11, PKM2, glycolysis, and ferroptosis pathways. By depleting GSH and activating PKM2, ferroptosis is enhanced in PKM2-dependent cancer models. This approach leads to significant changes in central carbon and lipid metabolism, disrupts mitochondrial function, and drives ferroptotic cell death. The combined treatment markedly suppresses tumor growth in a xenograft model. Elevated PKM2 and SLC7A11 expression levels correlate with poorer survival outcomes, indicating their potential as biomarkers for ferroptosis-based therapy. The findings demonstrate a dual role for GSH in cellular homeostasis and identify the PKM2-GSH-SLC7A11 axis as a therapeutic target for aggressive cancers.

**中文摘要译文：**
本研究发现，谷胱甘肽（GSH）是丙酮酸激酶M2（PKM2）的一种内源性A-A型别构激活剂，通过在A-A界面结合，将其稳定在具有活性的四聚体形式。这种PKM2-GSH相互作用将GSH代谢与铁死亡调控联系起来。跨多种癌症的转录组分析表明，GSH、SLC7A11、PKM2、糖酵解及铁死亡通路之间存在强相关性。在PKM2依赖的癌症模型中，通过耗尽GSH并激活PKM2，可增强铁死亡。该方法导致中心碳代谢和脂质代谢发生显著变化，扰乱线粒体功能，并驱动铁死亡性细胞死亡。在异种移植模型中，联合治疗显著抑制了肿瘤生长。PKM2和SLC7A11表达水平的升高与较差的生存结局相关，表明它们可作为基于铁死亡疗法的潜在生物标志物。这些发现揭示了GSH在细胞稳态中的双重作用，并将PKM2-GSH-SLC7A11轴确定为治疗侵袭性癌症的靶点。

### 第二部分 AI 大师评价

本研究创新性地揭示了谷胱甘肽（GSH）作为丙酮酸激酶M2（PKM2）内源性别构激活剂的新功能，并阐明了其在连接细胞代谢与铁死亡中的关键作用。通过转录组学分析、细胞及动物模型实验，研究证实了耗尽GSH与激活PKM2的协同策略能有效诱导癌细胞铁死亡并抑制肿瘤生长。此发现不仅深化了对GSH双重生理角色的理解，更提出了一个极具潜力的“PKM2-GSH-SLC7A11”分子轴作为治疗侵袭性癌症的新靶点，为开发基于铁死亡的抗癌疗法提供了坚实的理论基础和新颖的策略。

---

## 11. 亚细胞糖基化图景的纳米级图谱绘制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214908](https://pubmed.ncbi.nlm.nih.gov/41214908)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41214908
**DOI：** 10.1002/advs.202506731

### 第一部分 原文与翻译

**英文原标题：** Nanoscale Mapping of the Subcellular Glycosylation Landscape.

**英文摘要原文：**
Glycosylation is a crucial biochemical modification of proteins and other biomolecules in cells that generates an exceptional structural and functional diversity. Aberrant glycosylation is implicated in numerous diseases, including neurodegenerative disorders and cancer. While glycan organization at the cell surface is studied extensively, the nanoscale spatial arrangement of glycans inside cells and within organelles remains largely unexplored. Here, super-resolution imaging with fluorophore-labeled lectins, combined with a dedicated multiplexing strategy (Glyco-STORM), was used in thin neuronal tissue sections and permeabilized cells to systematically map glycosylation across multiple organelles and cellular compartments. Lectin markers were identified that enabled the visualization of nanodomains within the endoplasmic reticulum, subdomains along the Golgi axes, diverse glycosylation states in the endolysosomal system, and a polarized lysosomal clathrin coat. At neuronal synapses, mature glycans were found to demarcate the synaptic cleft and subsynaptic tubules adjacent to the postsynaptic density. In summary, Glyco-STORM establishes one of the first comprehensive nanoscale maps of intracellular glycosylation and provides entry points into health- and disease-related studies.

**中文摘要译文：**
糖基化是细胞内蛋白质和其他生物分子的一种关键生化修饰，它能产生非凡的结构和功能多样性。异常糖基化与多种疾病有关，包括神经退行性疾病和癌症。尽管细胞表面的聚糖组织已得到广泛研究，但细胞内部及细胞器内聚糖的纳米级空间排列在很大程度上仍未被探索。在此，研究人员利用荧光标记的凝集素进行超分辨率成像，并结合专门的多重成像策略（Glyco-STORM），在薄层神经元组织切片和透化细胞中系统地绘制了跨多个细胞器和细胞区室的糖基化图谱。研究人员鉴定出了多种凝集素标记物，这些标记物使得内质网内的纳米域、高尔基体轴向的子域、内体-溶酶体系统中的多样化糖基化状态以及极化的溶酶体网格蛋白包被得以可视化。在神经元突触处，成熟的聚糖被发现标示出突触间隙以及邻近突触后致密区的突触下微管。总之，Glyco-STORM技术建立了首批全面的细胞内糖基化纳米级图谱之一，并为健康与疾病相关的研究提供了切入点。

### 第二部分 AI 大师评价

本研究旨在解决细胞内糖基化纳米级空间分布研究不足的难题。作者巧妙地将超分辨率成像与荧光标记凝集素及多重成像策略相结合，开发出Glyco-STORM技术，成功绘制了神经元等细胞中多个细胞器的精细糖基化图谱。其关键发现揭示了内质网、高尔基体、溶酶体以及神经突触等亚细胞结构中前所未见的聚糖分布模式。这项研究极具创新性，不仅为理解糖基化在正常生理功能中的作用提供了高清“地图”，更为深入探索其在癌症、神经退行性疾病等病理过程中的异常变化开辟了新途径，具有重大的科研价值。

---

## 12. 新辅助免疫疗法在头颈部鳞状细胞癌中的应用：当前证据与未来展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214710](https://pubmed.ncbi.nlm.nih.gov/41214710)
**期刊：** Molecular cancer
**PMID：** 41214710
**DOI：** 10.1186/s12943-025-02487-4

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives.

**英文摘要原文：**
Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly aggressive malignant tumor. Traditional therapeutic approaches have limited efficacy in locally advanced HNSCC patients, and neoadjuvant immunotherapy has emerged as a new hope. However, the current outcomes of neoadjuvant immunotherapy for HNSCC are not yet optimal and urgently need improvement. This article comprehensively reviews the clinical research progress of neoadjuvant immunotherapy in the field of HNSCC treatment. By integrating perspectives from the regulatory mechanisms of the immune microenvironment, we propose future research directions for enhancing the efficacy of neoadjuvant immunotherapy for HNSCC patients.

**中文摘要译文：**
头颈部鳞状细胞癌（HNSCC）是一种高度侵袭性的恶性肿瘤。传统治疗方法对局部晚期HNSCC患者的疗效有限，而新辅助免疫疗法已成为新的希望。然而，目前HNSCC的新辅助免疫疗法效果尚不理想，亟待改善。本文全面回顾了新辅助免疫疗法在HNSCC治疗领域的临床研究进展。通过整合免疫微环境调控机制的观点，我们提出了旨在提高HNSCC患者新辅助免疫疗法疗效的未来研究方向。

### 第二部分 AI 大师评价

该综述文章系统总结了新辅助免疫疗法在头颈部鳞状细胞癌（HNSCC）治疗中的应用现状，并明确指出当前疗效尚不理想的挑战。本文的价值在于，它不仅回顾了临床研究进展，还创新性地结合了免疫微环境的调控机制，为优化治疗策略提出了具有前瞻性的研究方向。这篇综述为该领域的临床医生和研究人员提供了宝贵的参考，对指导未来的研究设计具有重要意义。

---

## 13. 出版商更正：放疗诱导的双调蛋白驱动肿瘤转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214352](https://pubmed.ncbi.nlm.nih.gov/41214352)
**期刊：** Nature
**PMID：** 41214352
**DOI：** 10.1038/s41586-025-09862-7

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇出版商更正，而非原创性研究论文，因此没有提供摘要。根据其标题推断，其更正的原始研究揭示了放射治疗在诱导肿瘤转移中的一个关键分子机制，即放疗能够上调双调蛋白（amphiregulin）的表达，从而促进肿瘤的远处扩散。这一发现对于理解放疗的潜在副作用、探索联合治疗策略以抑制转移具有重要的临床和科研价值。

---

## 14. T-DXd在HER2阳性乳腺癌新辅助治疗中展现应用前景

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214245](https://pubmed.ncbi.nlm.nih.gov/41214245)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41214245
**DOI：** 10.1038/s41571-025-01103-0

### 第一部分 原文与翻译

**英文原标题：** T-DXd shows promise in neoadjuvant therapy for HER2 breast cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献（很可能是一篇发表于顶尖期刊的评论或研究亮点）聚焦于抗体药物偶联物T-DXd在HER2阳性乳腺癌新辅助治疗领域的应用前景。文章标题直接揭示了其核心观点：T-DXd作为新辅助疗法显示出巨大潜力，这可能意味着它能有效缩小肿瘤体积，提高手术切除率，并可能带来更高的病理学完全缓解率。此进展对临床实践具有重要指导意义，或将改变HER2阳性乳腺癌的现有术前治疗标准，为患者提供更优的治疗选择。

---

## 15. 更正：全基因组CRISPR筛选确定MAD2L1BP和ANAPC15作为CD30阳性外周T细胞淋巴瘤中维布妥昔单抗敏感性的靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214141](https://pubmed.ncbi.nlm.nih.gov/41214141)
**期刊：** Leukemia
**PMID：** 41214141
**DOI：** 10.1038/s41375-025-02811-3

### 第一部分 原文与翻译

**英文原标题：** Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

这篇文献是一篇更正声明，其原始研究利用了全基因组CRISPR筛选技术，旨在揭示影响CD30阳性外周T细胞淋巴瘤对靶向药物维布妥昔单抗（brentuximab vedotin）敏感性的关键基因。研究的核心发现锁定了MAD2L1BP和ANAPC15这两个基因为新的潜在靶点，这为理解耐药机制及开发增敏策略提供了重要的分子基础。尽管此条目本身无摘要，但从标题即可看出，该研究对于优化淋巴瘤的靶向治疗方案具有重要的临床转化潜力与科研价值。

---

## 16. 剪接因子PTBP1与RUNX1相互作用且为白血病细胞生存所必需

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214140](https://pubmed.ncbi.nlm.nih.gov/41214140)
**期刊：** Leukemia
**PMID：** 41214140
**DOI：** 10.1038/s41375-025-02799-w

### 第一部分 原文与翻译

**英文原标题：** The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.

**英文摘要原文：**
Runt-related Transcription Factor 1 (RUNX1) is essential for definitive hematopoiesis and is among the most frequently mutated genes in leukemia. Previous work from our lab demonstrated that Histone Deacetylase 1 (HDAC1), a known RUNX1 partner, is unexpectedly required for active transcription suggesting a non-histone role for HDAC1 in regulating components of the RUNX1 complex. Here, we use proteomics, genomics, and long-read transcriptomics to identify novel RUNX1 interacting partners and decipher their role in gene regulation and RNA splicing in leukemia cells. We demonstrate that Polypyrimidine Tract Binding Protein 1 (PTBP1) interacts with RUNX1 in an HDAC1-dependent manner. Chromatin profiling revealed extensive genome-wide overlap in sites occupied by RUNX1 and PTBP1, with significant enrichment at promoters of actively transcribed genes. Loss of PTBP1 in AML cells led to widespread alterations in RNA splicing and decreased expression of genes whose promoters are bound by both factors, including metabolic genes. In agreement with these findings, we found that loss of PTBP1 reduced glycolysis and glucose uptake and ultimately caused cell death. Based on our data, we propose that the interaction between RUNX1 and PTBP1 facilitates expression of metabolic proteins essential for leukemia cell growth and survival.

**中文摘要译文：**
矮小相关转录因子1（RUNX1）对定型造血至关重要，并且是白血病中最常发生突变的基因之一。我们实验室先前的研究表明，组蛋白去乙酰化酶1（HDAC1），一个已知的RUNX1伴侣蛋白，出乎意料地是激活转录所必需的，这表明HDAC1在调控RUNX1复合物组分中发挥着非组蛋白相关的作用。在此，我们运用蛋白质组学、基因组学和长读长转录组学技术，旨在鉴定与RUNX1相互作用的新型伴侣蛋白，并解析它们在白血病细胞中基因调控和RNA剪接中的作用。我们证明了多嘧啶束结合蛋白1（PTBP1）以HDAC1依赖的方式与RUNX1相互作用。染色质分析揭示了RUNX1和PTBP1所占据的位点在全基因组范围内存在广泛重叠，并且在活跃转录基因的启动子区域显著富集。在急性髓系白血病（AML）细胞中，PTBP1的缺失导致了RNA剪接的广泛改变，并降低了那些启动子同时被这两种因子结合的基因（包括代谢相关基因）的表达。与这些发现一致，我们发现PTBP1的缺失会减少糖酵解和葡萄糖摄取，并最终导致细胞死亡。基于我们的数据，我们提出RUNX1与PTBP1之间的相互作用促进了对白血病细胞生长与存活至关重要的代谢蛋白的表达。

### 第二部分 AI 大师评价

本研究旨在探究白血病中转录因子RUNX1的新型相互作用蛋白及其功能。研究综合运用了蛋白质组学、基因组学和长读长转录组学等高通量技术，关键性地发现剪接因子PTBP1是RUNX1的一个HDAC1依赖性相互作用伴侣。该研究创新地揭示了RUNX1与PTBP1共同调控下游基因表达（特别是代谢相关基因）以支持白血病细胞存活的新机制。这一发现不仅深化了对白血病发病机理的理解，也提示PTBP1可能成为一个潜在的治疗新靶点。

---

## 17. TGF-β特异性T细胞在骨髓增殖性肿瘤患者的外周血和骨髓中普遍存在。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41214139](https://pubmed.ncbi.nlm.nih.gov/41214139)
**期刊：** Leukemia
**PMID：** 41214139
**DOI：** 10.1038/s41375-025-02798-x

### 第一部分 原文与翻译

**英文原标题：** TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究的核心目的在于探究在骨髓增殖性肿瘤（MPN）患者中是否存在靶向转化生长因子-β（TGF-β）的特异性T细胞。根据标题推断，研究通过分析患者的外周血和骨髓样本，发现了这类T细胞的普遍存在。这一发现具有重要的潜在价值，因为它揭示了在MPN患者体内可能存在针对关键纤维化和免疫调节因子TGF-β的细胞免疫应答，为理解MPN（特别是骨髓纤维化）的发病机制提供了新的免疫学视角，并可能为未来开发靶向免疫治疗策略提供新思路。然而，由于缺乏摘要，本研究的具体方法、样本量、以及这些T细胞的功能状态和临床意义尚不明确。

---

## 18. 一种发现潜在结直肠癌化疗药物的高通量筛选方法：通过药物重利用识别14-3-3蛋白的新型干扰剂

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213973](https://pubmed.ncbi.nlm.nih.gov/41213973)
**期刊：** Cell death & disease
**PMID：** 41213973
**DOI：** 10.1038/s41419-025-08150-6

### 第一部分 原文与翻译

**英文原标题：** A high-throughput screening approach to discover potential colorectal cancer chemotherapeutics: repurposing drugs to identify novel disruptors of 14-3-3 proteins.

**英文摘要原文：**
Selectively inducing apoptosis of cancer cells is an effective therapeutic strategy, but the success of existing chemotherapeutics is compromised by emergent tumor cell resistance and systemic off-target effects. Therefore, the discovery of new pro-apoptotic compounds with minimal systemic side effects remains an urgent need. 14-3-3 proteins are molecular scaffolds that serve as important regulators of cell survival. We previously demonstrated that 14-3-3ζ can sequester BAD, a pro-apoptotic member of the BCL-2 protein family, in the cytoplasm to inhibit the induction of apoptosis. Despite 14-3-3ζ being a critical regulator of cell survival, the identification of molecules that potently disrupt 14-3-3ζ actions has yet to materialize as a chemotherapeutic approach. Herein, we established a BRET-based, high-throughput drug screening approach (Z'-score = 0.52) to identify molecules that disrupt the binding of 14-3-3ζ to a BAD-derived fragment containing serine residues critical for their interactions. A drug library containing 1971 compounds was used for screening, and the capacity of identified hits to induce cell death was examined in NIH-3T3 fibroblasts and colorectal cancer cell lines, HT-29 and Caco-2. These results were mechanistically supported by both in silico structural analysis that suggest the possible mode of binding and direct biophysical measurements that demonstrate concentration-dependent target engagement. Terfenadine, penfluridol, and lomitapide have potential to either be repurposed as chemotherapeutics, or more likely, used as starting points for novel lead development. The described assay cascade demonstrates the feasibility of both expanding on these compounds and identifying novel disruptors of 14-3-3ζ to develop pro-apoptotic agents to treat pathogenic aberrant cell growth.

**中文摘要译文：**
选择性诱导癌细胞凋亡是一种有效的治疗策略，但现有化疗药物的成功率因肿瘤细胞出现耐药性和全身性脱靶效应而受到影响。因此，发现具有最小全身性副作用的新型促凋亡化合物仍是一项迫切的需求。14-3-3蛋白是作为细胞存活重要调节剂的分子支架。我们先前已证明，14-3-3ζ蛋白能将BCL-2蛋白家族的促凋亡成员BAD隔离在细胞质中，从而抑制细胞凋亡的诱导。尽管14-3-3ζ是细胞存活的关键调节因子，但鉴定能有效干扰其功能的分子尚未成为一种成熟的化疗方法。在本研究中，我们建立了一种基于生物发光共振能量转移（BRET）的高通量药物筛选方法（Z'-score = 0.52），旨在识别能够破坏14-3-3ζ与源自BAD蛋白且包含对两者相互作用至关重要的丝氨酸残基的片段结合的分子。我们使用了一个包含1971种化合物的药物库进行筛选，并在NIH-3T3成纤维细胞以及结直肠癌细胞系HT-29和Caco-2中检验了筛选出的命中化合物诱导细胞死亡的能力。这些结果得到了机制上的支持，包括提示可能结合模式的计算机模拟结构分析，以及证明存在浓度依赖性靶点结合的直接生物物理测量。特非那定、五氟利多和洛美他派有潜力被重新用作化疗药物，或者更可能的是，作为开发新型先导化合物的起点。本研究所描述的筛选流程证明了基于这些化合物进行扩展研究以及识别新型14-3-3ζ干扰剂以开发用于治疗病理性异常细胞增殖的促凋亡药物的可行性。

### 第二部分 AI 大师评价

本研究的核心目的是建立一个高通量筛选平台，以发现能破坏14-3-3ζ/BAD蛋白相互作用的结直肠癌新疗法。研究采用基于BRET的技术筛选了近2000种化合物，成功鉴定出特非那定、五氟利多和洛美他派三种潜力药物。此项工作的创新价值在于，它不仅验证了一个针对14-3-3这一难成药靶点的有效筛选方法，还通过药物重利用策略快速锁定了先导化合物，为后续开发更精准的促凋亡抗癌药物提供了重要方向和化学基础。

---

## 19. 开发一种选择性靶向错误折叠SOD1的BioPROTAC降解剂

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213972](https://pubmed.ncbi.nlm.nih.gov/41213972)
**期刊：** Nature communications
**PMID：** 41213972
**DOI：** 10.1038/s41467-025-65481-w

### 第一部分 原文与翻译

**英文原标题：** Development of a targeted BioPROTAC degrader selective for misfolded SOD1.

**英文摘要原文：**
The accumulation of misfolded proteins underlies a broad range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Due to their dynamic nature, these misfolded proteins have proven challenging to target therapeutically. Here, we specifically target misfolded disease variants of the ALS-associated protein superoxide dismutase 1 (SOD1), using a biological proteolysis targeting chimera (BioPROTAC) composed of a SOD1-specific intrabody and an E3 ubiquitin ligase. Screening of intrabodies and E3 ligases for optimal BioPROTAC construction reveals a candidate capable of degrading multiple disease variants of SOD1, preventing their aggregation in cells. Using CRISPR/Cas9 technology to develop a BioPROTAC transgenic mouse line, we demonstrate that the presence of the BioPROTAC delays disease progression in the SOD1 mouse model of ALS. Delayed disease progression is associated with protection of motor neurons, a reduction of insoluble SOD1 accumulation and preservation of innervated neuromuscular junctions. These findings provide proof-of-concept evidence and a platform for developing BioPROTACs as a therapeutic strategy for the targeted degradation of neurotoxic misfolded species in the context of neurodegenerative diseases.

**中文摘要译文：**
错误折叠蛋白的累积是多种神经退行性疾病（包括肌萎缩侧索硬化症，ALS）的发病基础。由于其动态变化的特性，这些错误折叠的蛋白已被证明是难以靶向治疗的靶点。在本研究中，我们利用一种由SOD1特异性胞内抗体和E3泛素连接酶组成的生物蛋白水解靶向嵌合体（BioPROTAC），特异性地靶向与ALS相关的超氧化物歧化酶1（SOD1）的错误折叠致病突变体。通过筛选胞内抗体和E3泛素连接酶以优化BioPROTAC的构建，我们发现了一个能够降解多种SOD1致病突变体并阻止其在细胞内聚集的候选分子。利用CRISPR/Cas9技术，我们开发了一个BioPROTAC转基因小鼠品系，并证明该BioPROTAC的存在延缓了ALS的SOD1小鼠模型的疾病进展。疾病进展的延缓与运动神经元的保护、不溶性SOD1累积的减少以及神经肌肉接头支配的保留有关。这些发现为开发BioPROTACs作为一种在神经退行性疾病中靶向降解神经毒性错误折叠蛋白的治疗策略，提供了概念验证证据和一个平台。

### 第二部分 AI 大师评价

本研究旨在开发一种靶向降解错误折叠SOD1蛋白的新疗法，以应对肌萎缩侧索硬化症（ALS）。研究团队创新性地构建了一种生物蛋白水解靶向嵌合体（BioPROTAC），并利用CRISPR/Cas9技术在ALS小鼠模型中验证了其效果。关键发现表明，该BioPROTAC能有效降解致病蛋白、延缓疾病进展并保护运动神经元。这项工作为利用BioPROTAC技术治疗由蛋白质错误折叠引起的神经退行性疾病提供了重要的概念验证和平台，展现了巨大的临床转化潜力。

---

## 20. 深度免疫谱分析阐明肺外结核的疾病异质性特征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213960](https://pubmed.ncbi.nlm.nih.gov/41213960)
**期刊：** Nature communications
**PMID：** 41213960
**DOI：** 10.1038/s41467-025-65561-x

### 第一部分 原文与翻译

**英文原标题：** Deep immune profiling delineates hallmarks of disease heterogeneity in extrapulmonary tuberculosis.

**英文摘要原文：**
Our understanding of the immune response in tuberculosis (TB) remains incomplete. This applies in particular to extrapulmonary TB (EPTB), a highly heterogeneous disease affecting up to 30% of patients in certain regions. Based on data-driven clustering of blood transcriptomes in an EPTB patient cohort, we define three highly distinct immunotypes. Combining bulk with single-cell RNA-sequencing delineates immunological trajectories characterized by dynamic IFN- and IL-1-mediated signalling in monocytes, alongside hyperactivation of T and NK cells, ultimately resulting in extensive immune dysregulation. Integrative analysis of multi-omics data provides deep insights into different layers of the anti-tuberculous immune response and the identification of immunotypes enabling stratification strategies for personalized host-directed treatments. In addition, our comprehensive approach helps to develop an accurate diagnostic gene expression signature for both EPTB and pulmonary TB highlighting the translational potential of our data.

**中文摘要译文：**
我们对结核病（TB）免疫应答的理解仍不完整。这一点尤其适用于肺外结核（EPTB），这是一种高度异质性的疾病，在某些地区影响高达30%的患者。基于对一个EPTB患者队列的血液转录组进行数据驱动的聚类分析，我们定义了三种截然不同的免疫分型。结合批量与单细胞RNA测序技术，我们描绘了以单核细胞中动态的IFN和IL-1介导的信号传导，以及T细胞和NK细胞的过度活化为特征的免疫轨迹，最终导致广泛的免疫失调。多组学数据的综合分析为了解抗结核免疫应答的不同层面提供了深刻见解，并且所识别出的免疫分型有助于为个性化的宿主导向治疗制定分层策略。此外，我们的综合方法有助于为EPTB和肺结核开发准确的诊断性基因表达特征，突显了我们数据的转化潜力。

### 第二部分 AI 大师评价

本研究通过深度免疫谱分析方法，旨在揭示高度异质性的肺外结核（EPTB）的免疫学特征。研究团队结合血液转录组的批量与单细胞测序技术，成功将患者划分为三种截然不同的免疫分型，并阐明了其背后由IFN和IL-1信号通路驱动的免疫失调机制。这项工作的创新性在于利用多组学数据对复杂的EPTB进行分层，其发现不仅为开发个性化宿主导向治疗策略提供了坚实基础，还鉴定出具有诊断潜力的基因表达特征，展示了巨大的临床转化价值。

---

## 21. 血液系统恶性肿瘤治疗耐药的“基因优先”与“表型优先”路径

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213958](https://pubmed.ncbi.nlm.nih.gov/41213958)
**期刊：** Cell death & disease
**PMID：** 41213958
**DOI：** 10.1038/s41419-025-08127-5

### 第一部分 原文与翻译

**英文原标题：** Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.

**英文摘要原文：**
Despite the outstanding achievements of precision medicine in hematology, many targeted therapies eventually fail due to the emergence of resistance mechanisms. Traditionally, a genocentric approach has been adopted to uncover the molecular underpinnings of treatment resistance. This has contributed to identifying resistance gene mutations and designing novel therapeutic molecules with increased potency for the mutant target. However, over the last five years, additional non-genetic adaptations have become increasingly recognized as crucial promoters of treatment resistance. In parallel, emerging works in the field of evolutionary biology suggest that advantageous phenotypic traits appear most often due to cell-intrinsic phenotypic plasticity and can arise independently of gene mutations. In selected cases, single genetic abnormalities such as those involving TP53 can prime human cells for plasticity and facilitate phenotypic variability. In this narrative review, we retrace the resistance mechanisms to targeted therapies in the framework of these novel evolutionary concepts. We highlight the dichotomy between genes-first and phenotypes-first pathways of treatment adaptation, with the former being driven by traditional single-point mutations and the latter initiated by the phenotypic diversity and the high-level plasticity of cancer cells. Focusing on resistance mechanisms to kinase inhibitors and BH3 mimetics in leukemias and lymphomas, we describe how each drug can trigger both escape routes, which may even coexist within the tumor bulk of individual patients. Lastly, we provide a three-step translational perspective on how to counteract phenotypes-first resistance mechanisms, with the aim of prolonging disease control in hematological malignancies.

**中文摘要译文：**
尽管精准医学在血液学领域取得了卓越成就，但许多靶向治疗最终因耐药机制的出现而失败。传统上，研究人员采用以基因为中心的方法来揭示治疗耐药的分子基础。这有助于识别耐药基因突变，并设计出对突变靶点效力更强的新型治疗分子。然而，在过去五年中，其他非遗传性适应机制日益被认为是促进治疗耐药的关键因素。与此同时，演化生物学领域的新兴研究表明，有利的表型性状通常源于细胞内在的表型可塑性，并且可以在没有基因突变的情况下出现。在某些情况下，单一的遗传异常（例如涉及TP53的异常）可以启动人类细胞的可塑性并促进表型变异。在这篇叙述性综述中，我们基于这些新颖的演化概念，回顾了靶向治疗的耐药机制。我们重点阐述了“基因优先”和“表型优先”这两种治疗适应途径的二元对立关系，前者由传统的单点突变驱动，而后者则由癌细胞的表型多样性和高度可塑性引发。我们聚焦于白血病和淋巴瘤中对激酶抑制剂和BH3模拟物的耐药机制，描述了每种药物如何能够触发这两种逃逸途径，而这些途径甚至可能在单个患者的肿瘤主体中并存。最后，我们提出了一个三步走的转化医学视角，旨在阐明如何对抗“表型优先”的耐药机制，以期延长血液系统恶性肿瘤的疾病控制时间。

### 第二部分 AI 大师评价

该综述创新性地从演化生物学视角出发，系统阐述了血液系统恶性肿瘤治疗耐药的两种核心途径：“基因优先”的突变驱动模式与“表型优先”的细胞可塑性驱动模式。文章通过回顾激酶抑制剂和BH3模拟物的耐药案例，深刻揭示了非遗传因素在耐药中的关键作用，打破了传统以基因为中心的认知局限。其提出的三步转化策略为克服表型驱动的耐药性提供了新的临床思路，对于延长患者疾病控制、优化未来治疗方案具有重要的指导价值。

---

## 22. RIG-I的可变剪接异构体PTIR1在宿主抗病毒防御与免疫稳态中的双重作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213949](https://pubmed.ncbi.nlm.nih.gov/41213949)
**期刊：** Cell death & disease
**PMID：** 41213949
**DOI：** 10.1038/s41419-025-08159-x

### 第一部分 原文与翻译

**英文原标题：** Dual effects of the alternative spliced RIG-I isoform PTIR1 on host antiviral defense and immune homeostasis.

**英文摘要原文：**
Efficient pathogen recognition must be tightly regulated to prevent immunopathology. Here, we identify PTIR1, a primate-specific splice variant of DDX58 lacking exon 4 and encoding a truncated RIG-I isoform, as a negative regulator of innate immune signaling. PTIR1 is selectively induced upon viral infection or interferon (IFN) stimulation, and its ectopic expression via adenoviral delivery broadly suppresses inflammatory responses in vivo. Mechanistically, PTIR1 activates the deubiquitinase UCHL5 to limit STAT1 ubiquitination at lysine 525, thereby impairing STAT1 nuclear translocation and dampening type I and type II IFN responses. Accordingly, in a model of autoimmune hepatitis, PTIR1 restricts IFN-γ-driven inflammation, and in a viral infection model, it attenuates type I IFN responses. PTIR1 also modulates RIG-I signaling by interfering with its dimerization, reducing its ubiquitination, and disrupting its interaction with MAVS, thereby limiting RIG-I-mediated antiviral recognition and facilitating viral immune evasion. These findings identify PTIR1 as an inducible post-transcriptional checkpoint that fine-tunes antiviral and inflammatory signaling to preserve tissue integrity.

**中文摘要译文：**
有效的病原体识别必须受到严格调控，以防止免疫病理损伤。在此，我们鉴定出PTIR1——一种灵长类特有的DDX58剪接变体，其缺失外显子4并编码一个截短的RIG-I异构体——是先天性免疫信号的负向调节因子。PTIR1在病毒感染或干扰素（IFN）刺激下被选择性诱导，其通过腺病毒递送的异位表达能在体内广泛抑制炎症反应。机制上，PTIR1激活去泛素化酶UCHL5，以限制STAT1在赖氨酸525位点的泛素化，从而削弱STAT1的核转位，并抑制I型和II型IFN应答。相应地，在自身免疫性肝炎模型中，PTIR1能限制IFN-γ驱动的炎症；在病毒感染模型中，它能减弱I型IFN应答。PTIR1还通过干扰RIG-I的二聚化、减少其泛素化并破坏其与MAVS的相互作用来调节RIG-I信号通路，从而限制RIG-I介导的抗病毒识别，并促进病毒的免疫逃逸。这些发现将PTIR1鉴定为一个可诱导的转录后检查点，它能精细调节抗病毒和炎症信号，以维持组织完整性。

### 第二部分 AI 大师评价

本研究旨在鉴定并阐明RIG-I剪接变体PTIR1在宿主抗病毒防御和免疫稳态中的调控作用。研究发现，这种灵长类特有的蛋白PTIR1作为一个可诱导的负向调节因子，通过两种不同机制发挥双重作用：一方面，它通过激活UCHL5来抑制STAT1信号通路，从而减弱I/II型干扰素应答；另一方面，它直接干扰RIG-I的激活过程，限制了病毒识别。该研究揭示了一个精巧的转录后调控检查点，它在维持免疫平衡、防止过度炎症方面至关重要，同时也可能成为病毒免疫逃逸的靶点，为相关疾病的治疗提供了新思路。

---

## 23. 消融联合免疫治疗对比单用免疫治疗用于抗PD-1/L1治疗后出现寡残留病灶的晚期非小细胞肺癌患者（BOOSTER）：一项随机2期临床试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213939](https://pubmed.ncbi.nlm.nih.gov/41213939)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41213939
**DOI：** 10.1038/s41392-025-02460-z

### 第一部分 原文与翻译

**英文原标题：** Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

**英文摘要原文：**
Local consolidative therapy (LCT) has been demonstrated to enhance the survival benefits of immunotherapy in non-small cell lung cancer (NSCLC) patients with oligometastatic or oligoprogressive disease. This randomized, phase 2 trial investigated the efficacy and safety of ablation combining continuous immunotherapy in NSCLC patients with oligo-residual disease (ORD) after anti-PD-1/L1 therapy (ChiCTR, identifier: ChiCTR2000032479). From March 2021 to March 2024, 65 patients were randomly assigned (2:1) to ablation combination group (n = 43) and immunotherapy maintenance group (n = 22), and the full analysis set finally included 42 patients in ablation plus immunotherapy group and 20 patients in immunotherapy maintenance group. With a median follow-up duration of 17.8 months, patients receiving ablation combination were associated with significantly longer PFS (median 26.7 vs. 11.7 months, p < 0.001, HR = 0.213, 95%CI 0.099-0.461) and a trend of longer OS (p = 0.036, HR = 0.242, 95%CI 0.057-1.019) than those without ablation. Subgroup analysis showed that cryoablation (n = 13) yielded potentially superior survival than thermal ablation (n = 31) (mPFS: NA vs. 22.4 months, p = 0.011), which might induced by the elevated level of IFN-α after cryotherapy compared to thermal ablation (p = 0.078). Additionally, ablation combination group showed a decreased rate of systemic progression pattern compared with immunotherapy maintenance group. Regarding safety, the combination of ablation and immunotherapy was well tolerated, with only 1 patient experiencing grade 3 pneumothorax after ablation. In conclusion, the addition of ablation is well-tolerated and prolongs the survival of immunotherapy in patients with advanced NSCLC who develop ORD after anti-PD-1/L1 therapy, while cryoablation showing potentially superior survival benefit compared to thermal ablation.

**中文摘要译文：**
局部巩固治疗（LCT）已被证明能增强免疫治疗在寡转移或寡进展性非小细胞肺癌（NSCLC）患者中的生存获益。这项随机、2期临床试验旨在研究消融联合持续免疫治疗在抗PD-1/L1治疗后出现寡残留病灶（ORD）的NSCLC患者中的有效性和安全性（ChiCTR注册号：ChiCTR2000032479）。从2021年3月至2024年3月，65名患者被随机（2:1）分配至消融联合组（n=43）和免疫维持组（n=22），最终全分析集纳入消融联合免疫治疗组42例患者和免疫维持组20例患者。中位随访时间为17.8个月，与未接受消融的患者相比，接受消融联合治疗的患者具有显著更长的无进展生存期（PFS）（中位数26.7个月 vs. 11.7个月, p < 0.001, HR = 0.213, 95%CI 0.099-0.461）和更长的总生存期（OS）趋势（p = 0.036, HR = 0.242, 95%CI 0.057-1.019）。亚组分析显示，冷冻消融（n=13）可能比较热消融（n=31）带来更优的生存获益（中位PFS：未达到 vs. 22.4个月, p = 0.011），这可能与冷冻治疗后IFN-α水平相较于热消融后有所升高有关（p = 0.078）。此外，与免疫维持组相比，消融联合组的全身性进展模式发生率更低。在安全性方面，消融与免疫治疗的联合方案耐受性良好，仅有1名患者在消融后出现3级气胸。总之，对于抗PD-1/L1治疗后出现寡残留病灶的晚期NSCLC患者，联合消融治疗耐受性良好，并能延长免疫治疗带来的生存获益，其中冷冻消融显示出可能优于热消融的生存优势。

### 第二部分 AI 大师评价

该BOOSTER研究是一项重要的随机2期临床试验，旨在探索对于抗PD-1/L1治疗后病情稳定但存在寡残留病灶的晚期非小细胞肺癌患者，在持续免疫治疗基础上联合局部消融是否优于单纯免疫维持治疗。研究关键发现表明，联合消融策略显著延长了患者的无进展生存期（PFS），并显示出改善总生存期（OS）的趋势，且安全性良好。此研究的创新性在于首次聚焦“寡残留”这一特定临床状态，为该患者群体提供了强有力的循证医学证据，提示联合局部消融有望成为新的治疗标准。尤其值得关注的是，亚组分析初步揭示了冷冻消融可能比热消融更具优势，为后续治疗选择和机制探索开辟了新方向。

---

## 24. 肿瘤取样条件扰动透明细胞肾细胞癌的代谢图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213938](https://pubmed.ncbi.nlm.nih.gov/41213938)
**期刊：** Nature communications
**PMID：** 41213938
**DOI：** 10.1038/s41467-025-65676-1

### 第一部分 原文与翻译

**英文原标题：** Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.

**英文摘要原文：**
Human isotopic tracer studies are key for in vivo studies of cancer metabolism. Yet, the effects of sampling conditions on the tissue metabolome remain understudied. Here, we perform a C-glucose study coupled with metabolomic, transcriptomic, and proteomic profiling in patients with clear cell renal cell carcinoma (ccRCC) to assess the impact of ischaemia on tissues sampled intraoperatively and post-surgical resection, where tissues are exposed to varying degrees of warm ischaemia. Although several metabolic features were preserved, including suppressed TCA cycle activity, ischaemia masked other metabolic phenotypes of ccRCC, such as suppressed gluconeogenesis. Notably, normal kidneys were more metabolically susceptible to ischaemia than the ccRCC tumours. Despite their overall stability, ischaemia caused subtle changes in the proteome and transcriptome. Using orthotopic ccRCC-derived xenografts, we evidenced that prolonged ischaemia disrupted the tissue metabolome stability. Overall, minimising tissue ischaemia is pivotal in accurately profiling cancer metabolism in patient studies.

**中文摘要译文：**
人体同位素示踪研究是体内研究癌症代谢的关键。然而，取样条件对组织代谢组的影响仍研究不足。在此，我们对透明细胞肾细胞癌（ccRCC）患者进行了一项¹³C-葡萄糖研究，并结合了代谢组学、转录组学和蛋白质组学分析，以评估缺血对术中和术后切除组织样本的影响，这些组织经历了不同程度的热缺血。尽管包括三羧酸循环（TCA）活性受抑制在内的几种代谢特征得以保留，但缺血掩盖了ccRCC的其他代谢表型，例如糖异生作用受抑制。值得注意的是，正常肾脏组织在代谢上比ccRCC肿瘤组织更容易受缺血影响。尽管蛋白质组和转录组总体上保持稳定，但缺血仍引起了其中的细微变化。通过使用源自ccRCC的原位异种移植模型，我们证明了长时间缺血会破坏组织代谢组的稳定性。总而言之，在患者研究中，最大限度地减少组织缺血对于准确描绘癌症代谢图谱至关重要。

### 第二部分 AI 大师评价

本研究旨在探讨肿瘤组织取样条件，特别是缺血，如何影响透明细胞肾细胞癌（ccRCC）的代谢图谱。研究团队创新性地结合了¹³C-葡萄糖同位素示踪与多组学分析方法，揭示了在体研究中的一个关键问题。其核心发现指出，尽管某些代谢特征稳定，但缺血会掩盖如糖异生受抑制等重要的ccRCC代谢表型，并且正常肾组织比肿瘤更敏感。这项研究极具科研价值，它强调了在进行癌症代谢研究时，标准化并最大限度缩短组织缺血时间对于获取真实、准确数据的至关重要性，对未来相关研究的设计具有重要的指导意义。

---

## 25. USP5通过溶酶体降解途径靶向YBX3/SLC7A11轴调节结直肠癌的铁死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213937](https://pubmed.ncbi.nlm.nih.gov/41213937)
**期刊：** Cell death & disease
**PMID：** 41213937
**DOI：** 10.1038/s41419-025-08146-2

### 第一部分 原文与翻译

**英文原标题：** USP5 regulates ferroptosis in colorectal cancer by targeting the YBX3/SLC7A11 axis through lysosomal degradation.

**英文摘要原文：**
Colorectal cancer (CRC) is the third most common cancer worldwide and a significant public health threat. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising therapeutic target in CRC treatment. Despite its significant clinical potential, the precise regulatory mechanisms underlying ferroptosis, particularly its role in ferroptosis within CRC, remain to be fully elucidated. Previous studies, including our own work, have revealed that various deubiquitinases (DUBs) are involved in regulating cellular processes; however, the specific mechanisms by which these enzymes contribute to ferroptosis in CRC remain unclear. In this study, we identify USP5 as a key regulator of ferroptosis in CRC. Traditionally recognized as a deubiquitinase, USP5 modulates cellular physiological activities through deubiquitination. However, our findings show that USP5, distinct from its conventional deubiquitination function, suppresses ferroptosis by promoting the lysosomal degradation of YBX3 (Y-box binding protein 3). Under normal conditions, YBX3 promotes the degradation of SLC7A11 (solute carrier family 7 member 11). However, USP5 facilitates the degradation of YBX3, leading to the stabilization of SLC7A11 and thereby promoting CRC cell survival and tumor progression. In patient-derived organoid and xenograft models, USP5 knockout significantly increased the sensitivity of cancer cells to ferroptosis and inhibited tumor growth. Moreover, additional knockout of YBX3 restored the stability of SLC7A11, highlighting the complex regulatory network between USP5, YBX3, and SLC7A11. Systematic functional assays and mechanistic studies further confirmed that the USP5/YBX3/SLC7A11 axis is a central pathway for ferroptosis resistance in CRC. These findings provide novel insights into therapeutic strategies for CRC, especially ferroptosis-based treatments.

**中文摘要译文：**
结直肠癌（CRC）是全球第三大常见癌症，也是一个重大的公共卫生威胁。铁死亡是一种铁依赖性的程序性细胞死亡形式，已成为CRC治疗中一个有前景的治疗靶点。尽管其具有巨大的临床潜力，但铁死亡的精确调控机制，尤其是在CRC中铁死亡的作用，仍有待完全阐明。先前的研究，包括我们自己的工作，已经揭示了多种去泛素化酶（DUBs）参与调控细胞过程；然而，这些酶在CRC中促进铁死亡的具体机制仍不清楚。在本研究中，我们将USP5鉴定为CRC中铁死亡的关键调控因子。USP5传统上被认为是一种去泛素化酶，通过去泛素化作用调节细胞的生理活动。然而，我们的研究结果显示，USP5以一种不同于其传统去泛素化功能的方式，通过促进YBX3（Y-box结合蛋白3）的溶酶体降解来抑制铁死亡。在正常情况下，YBX3会促进SLC7A11（溶质载体家族7成员11）的降解。然而，USP5促进了YBX3的降解，从而导致SLC7A11的稳定，进而促进了CRC细胞的存活和肿瘤的进展。在患者来源的类器官和异种移植模型中，敲除USP5显著增加了癌细胞对铁死亡的敏感性，并抑制了肿瘤的生长。此外，额外敲除YBX3恢复了SLC7A11的稳定性，凸显了USP5、YBX3和SLC7A11之间复杂的调控网络。系统的功能性实验和机制研究进一步证实，USP5/YBX3/SLC7A11轴是CRC产生铁死亡抗性的核心通路。这些发现为CRC的治疗策略，特别是基于铁死亡的治疗，提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明去泛素化酶USP5在结直肠癌（CRC）铁死亡调控中的具体作用机制。研究团队通过细胞系、患者源性类器官及异种移植模型，发现了一个创新的分子通路：USP5并非通过其经典的去泛素化功能，而是通过促进YBX3的溶酶体降解来稳定SLC7A11蛋白，从而抑制CRC细胞的铁死亡。这一发现揭示了USP5/YBX3/SLC7A11轴是CRC产生铁死亡抗性的核心通路，不仅深化了对铁死亡调控网络的理解，也为开发靶向USP5以增强铁死亡疗效的CRC治疗新策略提供了重要的理论依据和潜在靶点。

---

## 26. 131个遗传位点阐明鼻息肉与哮喘相关的免疫通路及组织

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213931](https://pubmed.ncbi.nlm.nih.gov/41213931)
**期刊：** Nature communications
**PMID：** 41213931
**DOI：** 10.1038/s41467-025-64847-4

### 第一部分 原文与翻译

**英文原标题：** 131 genetic loci highlight immunological pathways and tissues in nasal polyposis and asthma.

**英文摘要原文：**
The coexistence of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with allergic phenotypes, disease severity and failure of first-line treatment for both asthma and CRSwNP. Recent studies have highlighted shared genetic components for these diseases. To better understand this shared component, we perform genome-wide meta-analyses of asthma (n = 71,481), CRSwNP (n = 9626) and chronic rhinosinusitis without nasal polyposis (CRSsNP, n = 15,448) in FinnGen and UKB (685,602 controls). We detect 131 genomic associations, including 17 novel loci for asthma, 33 novel loci for CRSwNP, and one for CRSsNP. A shared impact on asthma and CRSwNP is observed at 71 loci. A cross-trait meta-analysis using all disorders further implicates 17 loci associated with asthma or asthma and CRSwNP. We also find 17 nonsynonymous associating variants, including a novel TP63 missense variant association with CRSwNP (OR = 1.519 [1.331-1.734]). Gene set analyses confirm enrichment of genes involved with type 2 inflammation, Jak-STAT signaling, and FOXP3 signaling. Our results highlight new shared and separate genetic pathways for CRSwNP and asthma. These provide several avenues of further investigation in functional and epidemiological follow-up, and evidence for immunological and non-immunological mechanisms behind both diseases.

**中文摘要译文：**
哮喘与伴鼻息肉的慢性鼻窦炎（CRSwNP）的共存与过敏表型、疾病严重程度以及这两种疾病一线治疗的失败相关。近期的研究已揭示了这些疾病共有的遗传因素。为更好地理解这一共有的遗传因素，我们在FinnGen和UKB数据库中对哮喘（n = 71,481）、CRSwNP（n = 9626）以及不伴鼻息肉的慢性鼻窦炎（CRSsNP，n = 15,448）进行了全基因组荟萃分析（对照组 n = 685,602）。我们检测到131个基因组关联，其中包括17个新的哮喘位点、33个新的CRSwNP位点以及1个新的CRSsNP位点。在71个位点上观察到了对哮喘和CRSwNP的共同影响。一项利用所有疾病进行的跨性状荟萃分析进一步揭示了17个与哮喘或哮喘与CRSwNP相关的位点。我们还发现了17个非同义关联变异，包括一个与CRSwNP相关的新的TP63错义变异（OR = 1.519 [1.331-1.734]）。基因集分析证实了参与2型炎症、Jak-STAT信号通路和FOXP3信号通路的基因富集。我们的研究结果揭示了CRSwNP和哮喘新的共有及独立的遗传通路。这些发现为功能性和流行病学后续研究提供了多个途径，并为这两种疾病背后的免疫学和非免疫学机制提供了证据。

### 第二部分 AI 大师评价

本研究通过对大规模人群队列（FinnGen和UKB）进行全基因组荟萃分析，旨在揭示哮喘与伴鼻息肉的慢性鼻窦炎（CRSwNP）之间共有的遗传基础。研究成功识别了131个基因组关联，其中包含数十个针对这两种疾病的新遗传位点，并发现71个位点对二者有共同影响。该研究不仅通过坚实的数据证实了2型炎症等关键免疫通路在疾病共病中的核心作用，还发现了新的遗传靶点（如TP63变异），为理解其病理生理机制及开发新的治疗策略提供了重要的遗传学证据和新方向。

---

## 27. LUBAC在T细胞中于TRAF6下游调节CBM复合体功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213928](https://pubmed.ncbi.nlm.nih.gov/41213928)
**期刊：** Nature communications
**PMID：** 41213928
**DOI：** 10.1038/s41467-025-65879-6

### 第一部分 原文与翻译

**英文原标题：** LUBAC modulates CBM complex functions downstream of TRAF6 in T cells.

**英文摘要原文：**
The CARD11-BCL10-MALT1 (CBM) complex drives NF-κB signaling and MALT1 protease activation after T cell receptor (TCR) stimulation, forming a central signaling hub in adaptive immunity. Both linear ubiquitin chain assembly complex (LUBAC), consisting of HOIP, HOIL-1 and SHARPIN, and TRAF6 interact with the CBM complex. Still, the coordinated activity of these E3 ligases in controlling CBM activity remains elusive. Here we demonstrate that LUBAC, unlike TRAF6, is largely dispensable for TCR-induced NF-κB activation in human CD4 T cells. However, HOIP contributes to NF-κB target gene expression and, with TRAF6, modulates MALT1 substrate recognition, influencing T cell responses. Further, LUBAC-mediated conjugation of Met1-linked ubiquitin chains to BCL10 strictly depends on TRAF6, but putative Met1-ubiquitin acceptor lysines in BCL10 serve essential structural roles that limit accessibility within BCL10-MALT1 filaments. Thus, LUBAC acts downstream of TRAF6 to modulate MALT1 substrate recognition and to catalyze BCL10 ubiquitination, which is incompatible with BCL10-MALT1 filament formation.

**中文摘要译文：**
CARD11-BCL10-MALT1 (CBM) 复合体在T细胞受体 (TCR) 刺激后驱动NF-κB信号传导和MALT1蛋白酶活化，构成适应性免疫中的一个核心信号枢纽。由HOIP、HOIL-1和SHARPIN组成的线性泛素链组装复合体 (LUBAC) 以及TRAF6均与CBM复合体相互作用。然而，这些E3连接酶在控制CBM活性方面的协同作用机制仍不清楚。在此，我们证明了与TRAF6不同，LUBAC在人CD4 T细胞中对于TCR诱导的NF-κB活化在很大程度上是可有可无的。但是，HOIP参与NF-κB靶基因的表达，并与TRAF6共同调节MALT1的底物识别，从而影响T细胞应答。此外，LUBAC介导的Met1连接的泛素链与BCL10的缀合严格依赖于TRAF6，但BCL10中推定的Met1泛素受体赖氨酸发挥着关键的结构作用，限制了其在BCL10-MALT1丝状体内的可及性。因此，LUBAC在TRAF6下游发挥作用，调节MALT1的底物识别并催化BCL10的泛素化，而这一过程与BCL10-MALT1丝状体的形成不相容。

### 第二部分 AI 大师评价

本研究旨在阐明E3连接酶LUBAC和TRAF6在T细胞中协同调控CBM信号复合体功能的精确分子机制。研究发现，LUBAC位于TRAF6下游发挥作用，它并非TCR诱导NF-κB活化的必需元件，而是精细调节MALT1的底物识别。关键创新点在于，该研究揭示了LUBAC催化的BCL10泛素化与BCL10-MALT1信号丝状体的形成是相互排斥的，这为理解T细胞信号的精细调控提供了新的视角。这一发现不仅加深了对适应性免疫信号转导的理解，也为相关免疫疾病的治疗提供了潜在的新靶点。

---

## 28. 铅诱导肝细胞的细胞自主性增殖和代谢重编程

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213925](https://pubmed.ncbi.nlm.nih.gov/41213925)
**期刊：** Cell death & disease
**PMID：** 41213925
**DOI：** 10.1038/s41419-025-08134-6

### 第一部分 原文与翻译

**英文原标题：** Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytes.

**英文摘要原文：**
Reprogramming of energy metabolism is widely recognized as a hallmark of cancer cells. However, recent evidence indicates that metabolic reprogramming also occurs in vivo in differentiated rat hepatocytes following administration of the primary mitogen lead nitrate (LN). It remains unclear whether this phenomenon results from a direct action of LN on hepatocytes or is mediated by non-parenchymal liver cells. In our study, we investigated the cell-autonomous effects of LN using immortalized non-tumorigenic rat (RNT) and human (THLE-2) hepatocytes. LN treatment induced cancer-like metabolic features in non-tumorigenic hepatocytes, including increased glycolysis, activation of both oxidative and non-oxidative pentose phosphate pathways (PPP), and reduced oxidative phosphorylation (OXPHOS). Additionally, LN increased several targets of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2), a key regulator of cellular defense against stress. We found that activation of the Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 pathway was associated with increased hepatocyte proliferation. Importantly, silencing NRF2 completely abolished the LN-induced metabolic reprogramming. In contrast, triiodothyronine (T3), a liver mitogen that does not activate NRF2, failed to trigger metabolic reprogramming. Overall, our findings demonstrate that LN directly drives both proliferation and metabolic reprogramming in hepatocytes, independently of microenvironmental or immune signals. NRF2 plays a central role as a key driver of these cancer-like metabolic shifts, even in non-tumorigenic cells.

**中文摘要译文：**
能量代谢重编程被广泛认为是癌细胞的一个标志。然而，近期证据表明，在给予原代促有丝分裂原硝酸铅（LN）后，分化的大鼠肝细胞在体内也会发生代谢重编程。目前尚不清楚这一现象是由LN直接作用于肝细胞，还是由肝脏非实质细胞介导的。在我们的研究中，我们使用永生化的非致瘤性大鼠（RNT）和人（THLE-2）肝细胞，探究了LN的细胞自主性效应。LN处理在非致瘤性肝细胞中诱导了类似癌症的代谢特征，包括糖酵解增加、氧化和非氧化磷酸戊糖途径（PPP）的激活，以及氧化磷酸化（OXPHOS）的减少。此外，LN还上调了转录因子核因子（红细胞衍生2）样2（NRF2）的多个靶标，NRF2是细胞防御应激的关键调节因子。我们发现，Kelch样ECH相关蛋白1（KEAP1）-NRF2通路的激活与肝细胞增殖增加有关。重要的是，沉默NRF2完全消除了LN诱导的代谢重编程。相比之下，三碘甲状腺原氨酸（T3），一种不激活NRF2的肝脏促有丝分裂原，未能引发代谢重编程。总的来说，我们的研究结果表明，LN能独立于微环境或免疫信号，直接驱动肝细胞的增殖和代谢重编程。NRF2在这些即使在非致瘤细胞中也出现的癌样代谢转变中，扮演了关键驱动者的核心角色。

### 第二部分 AI 大师评价

该研究旨在阐明硝酸铅（LN）是对肝细胞产生直接作用，还是通过旁观者效应诱导其增殖和代谢重编程。研究者采用永生化的非致瘤性肝细胞系，发现LN能够独立于微环境信号，直接诱导细胞发生癌性代谢转变并促进其增生。其核心发现是，这一过程完全依赖于KEAP1-NRF2通路的激活，揭示了NRF2在环境毒物诱导的细胞癌前样变中的关键驱动作用。这项工作为理解环境暴露如何启动细胞癌变提供了新的分子机制视角，具有重要的毒理学和肿瘤学意义。

---

## 29. 抑制酪氨酸激酶BMX可增强癌细胞对现有化疗药物的死亡反应，从而克服其凋亡抵抗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213918](https://pubmed.ncbi.nlm.nih.gov/41213918)
**期刊：** Cell death & disease
**PMID：** 41213918
**DOI：** 10.1038/s41419-025-08131-9

### 第一部分 原文与翻译

**英文原标题：** Inhibition of tyrosine kinase BMX increases cell death in response to existing chemotherapeutic agents overcoming apoptotic resistance in cancer.

**英文摘要原文：**
BMX tyrosine kinase has emerged as a novel drug target, the inhibition of which simultaneously decreases proliferative signaling and increases cell death. BMX expression is upregulated in numerous cancers and causes acquired resistance to chemotherapeutic drugs. In addition to being responsive to multiple signaling pathways involved in regulating proliferation, migration, and cell survival, BMX is also a direct and potent negative regulator of BAK that mediates apoptotic resistance. Knockdown of BMX in cancer cells dramatically potentiates BAK activation following DNA damage, rendering cells hypersensitive to killing by otherwise sub-lethal doses of drug irrespective of the mode of drug action. This study aimed to determine whether existing BMX inhibitors could increase cell killing when used in combination with chemotherapeutic agents. We now show this sensitization can be phenocopied using small molecules BMX inhibitors, confirming inhibition of regulators upstream of the apoptotic machinery is a novel strategy to modulate cell death and improve the efficacy of existing chemotherapeutic agents. Analysis of the binding of existing BMX inhibitors BMX-IN-1 and CHMFL-BMX-078 to the BMX kinase domain reveals these molecules' potential limitations, including the high cross-reactivity with other members of the TEC kinase family. This study serves as proof-of-principle for this therapeutic strategy but also highlights the urgent need for more specific molecules to inhibit BMX kinase activity. Created with BioRender.com.

**中文摘要译文：**
BMX酪氨酸激酶已成为一个新兴的药物靶点，抑制该激酶可同时减少增殖信号并增加细胞死亡。BMX在多种癌症中表达上调，并导致对化疗药物的获得性耐药。BMX不仅响应参与调控增殖、迁移和细胞存活的多种信号通路，它还是介导凋亡抵抗的BAK分子的直接而有力的负向调节因子。在癌细胞中敲低BMX，能显著增强DNA损伤后BAK的活化，无论药物作用模式如何，都能使细胞对原本亚致死剂量的药物击杀变得高度敏感。本研究旨在确定，现有的BMX抑制剂与化疗药物联合使用时，是否能增强对癌细胞的杀伤效果。我们现在证明，使用小分子BMX抑制剂可以表型复制这种增敏效应，这证实了抑制凋亡机制上游的调节因子是调控细胞死亡、提高现有化疗药物疗效的一种新策略。对现有BMX抑制剂BMX-IN-1和CHMFL-BMX-078与BMX激酶结构域结合的分析揭示了这些分子的潜在局限性，包括与TEC激酶家族其他成员存在高度交叉反应性。这项研究为此治疗策略提供了原理性验证，但同时也凸显了开发更具特异性的BMX激酶活性抑制分子的迫切需求。由BioRender.com创建。

### 第二部分 AI 大师评价

本研究旨在验证抑制BMX酪氨酸激酶作为一种增强现有化疗药物疗效的潜在策略。研究通过使用小分子抑制剂，成功证明了抑制BMX能够克服癌细胞的凋亡抵抗，使其对亚致死剂量的化疗药物变得敏感。这项工作为联合治疗提供了重要的原理性验证，具有重要的临床转化潜力，但同时也指出现有抑制剂存在脱靶效应，提示未来需要开发更高特异性的BMX抑制剂。

---

## 30. N6-甲基腺苷介导的cLMNB1通过降解FGFR4克服非小细胞肺癌的奥希替尼耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213916](https://pubmed.ncbi.nlm.nih.gov/41213916)
**期刊：** Cell death & disease
**PMID：** 41213916
**DOI：** 10.1038/s41419-025-08124-8

### 第一部分 原文与翻译

**英文原标题：** The N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome osimertinib resistance in non-small cell lung cancer.

**英文摘要原文：**
Osimertinib resistance is the main challenge in treating EGFR-mutant lung adenocarcinoma (LUAD). The role of N6-methyladenosine (m6A) modification of circular RNAs (circRNAs) in osimertinib-resistant LUAD remains largely unknown. We used MeRIP-seq and circRNA-seq to screen for potential circRNA candidates that influence osimertinib resistance. It was observed that circRNA LMNB1 (cLMNB1) increased the sensitivity of LUAD to osimertinib in vitro and in vivo. Mechanistically, cLMNB1 acts as a scaffold between fibroblast growth factor receptor 4 (FGFR4) and E3 ubiquitin-protein ligase CBL (c-Cbl), enhancing the ubiquitin-dependent degradation of FGFR4. Furthermore, METTL3 and YTHDF2 are responsible for increased m6A modification levels and decreased cLMNB1 expression in osimertinib-resistant LUAD without affecting its functions. Our findings demonstrate that cLMNB1, mediated by m6A modification, overcomes osimertinib resistance by destabilizing the FGFR4 protein in LUAD. cLMNB1 with an m6A modification site mutation (cLMNB1-mut) could be a promising nucleic acid drug, as it has shown excellent efficacy in osimertinib-resistant preclinical models of LUAD.

**中文摘要译文：**
奥希替尼耐药是治疗EGFR突变型肺腺癌（LUAD）的主要挑战。N6-甲基腺苷（m6A）修饰的环状RNA（circRNA）在奥希替尼耐药的LUAD中的作用尚不明确。我们利用MeRIP-seq和circRNA-seq筛选了可能影响奥希替尼耐药性的潜在circRNA候选分子。研究发现，环状RNA LMNB1（cLMNB1）在体外和体内均能增加LUAD对奥希替尼的敏感性。从机制上看，cLMNB1作为成纤维细胞生长因子受体4（FGFR4）和E3泛素蛋白连接酶CBL（c-Cbl）之间的支架，促进了FGFR4的泛素依赖性降解。此外，在奥希替尼耐药的LUAD中，METTL3和YTHDF2是导致m6A修饰水平升高和cLMNB1表达降低的原因，且此过程不影响cLMNB1的功能。我们的研究结果表明，由m6A修饰介导的cLMNB1通过破坏LUAD中FGFR4蛋白的稳定性来克服奥希替尼耐药。携带m6A修饰位点突变的cLMNB1（cLMNB1-mut）可能是一种有前景的核酸药物，因为它在奥希替尼耐药的LUAD临床前模型中已显示出卓越的疗效。

### 第二部分 AI 大师评价

本研究旨在阐明N6-甲基腺苷（m6A）修饰的环状RNA在非小细胞肺癌奥希替尼耐药中的作用机制。研究通过高通量测序和分子实验，创新性地发现m6A修饰通过METTL3/YTHDF2依赖的方式下调了cLMNB1的表达，而cLMNB1能作为支架蛋白促进FGFR4的泛素化降解，从而逆转耐药。此项工作揭示了“m6A-cLMNB1-FGFR4”这一全新的耐药调控轴，并证实经修饰的cLMNB1（cLMNB1-mut）作为核酸药物的潜力，为克服奥希替尼耐药提供了极具转化价值的新靶点和治疗策略。

---

## 31. LMO4通过诱导RAB17降解和铁死亡抵抗来促进口腔鳞状细胞癌的进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213908](https://pubmed.ncbi.nlm.nih.gov/41213908)
**期刊：** Cell death & disease
**PMID：** 41213908
**DOI：** 10.1038/s41419-025-08171-1

### 第一部分 原文与翻译

**英文原标题：** LMO4 promotes OSCC progression by inducing RAB17 degradation and ferroptosis resistance.

**英文摘要原文：**
Oral squamous cell carcinoma (OSCC) is an aggressive cancer with limited improvement in patient outcomes despite advances in surgery, chemotherapy, and radiotherapy. The LIM-only protein LMO4 functions as a transcriptional co-regulator and is known to be increased in several epithelial cancers, but its contribution to OSCC has not been well defined. In this study, we found that LMO4 expression was markedly higher in OSCC tissues and was associated with poorer overall survival. Cellular experiments showed that LMO4 enhanced OSCC cell proliferation, migration, and resistance to ferroptosis by promoting the ubiquitin-proteasome-dependent degradation of the tumor suppressor RAB17. Restoration of RAB17 expression reduced these malignant behaviors. In a nude mouse xenograft model, tumors with high LMO4 grew faster and displayed lower RAB17 protein levels. Taken together, our results indicate that LMO4 contributes to OSCC progression through post-translational regulation of RAB17 and ferroptosis control, suggesting that this pathway could serve as a new therapeutic target.

**中文摘要译文：**
口腔鳞状细胞癌（OSCC）是一种侵袭性癌症，尽管在手术、化疗和放疗方面取得了进展，但患者的预后改善有限。LIM-only蛋白LMO4作为一种转录共调节因子，在多种上皮性癌症中已知其表达升高，但其在OSCC中的作用尚未被明确阐明。在本研究中，我们发现LMO4在OSCC组织中的表达显著升高，并且与较差的总生存期相关。细胞实验表明，LMO4通过促进肿瘤抑制因子RAB17的泛素-蛋白酶体依赖性降解，增强了OSCC细胞的增殖、迁移和对铁死亡的抵抗能力。恢复RAB17的表达则减弱了这些恶性行为。在裸鼠异种移植模型中，高表达LMO4的肿瘤生长更快，并显示出较低的RAB17蛋白水平。综上所述，我们的研究结果表明，LMO4通过对RAB17的翻译后调控和铁死亡控制来促进OSCC的进展，提示该通路可能成为一个新的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明LMO4蛋白在口腔鳞状细胞癌（OSCC）中的作用及其分子机制。研究通过临床样本分析、细胞功能实验及动物模型，关键性地发现LMO4通过促进抑癌基因RAB17的降解，从而增强了癌细胞的增殖、迁移及对铁死亡的抵抗能力。这项研究的创新之处在于揭示了“LMO4-RAB17-铁死亡”这一全新的调控轴，不仅深化了对OSCC发病机制的理解，也为该疾病的治疗提供了一个有潜力的靶向通路。

---

## 32. 在前列腺癌雄激素剥夺治疗中，TXNIP的上调调控细胞代谢与细胞周期

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213907](https://pubmed.ncbi.nlm.nih.gov/41213907)
**期刊：** Cell death & disease
**PMID：** 41213907
**DOI：** 10.1038/s41419-025-08128-4

### 第一部分 原文与翻译

**英文原标题：** TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer.

**英文摘要原文：**
Thioredoxin-Interacting Protein (TXNIP) is an arrestin at the crossroad of redox and glycolytic metabolisms. Prostate cancer (PCa) exhibits a unique metabolic profile due to the glycolytic nature of healthy prostate tissue. We hypothesize that TXNIP plays a pivotal role in the progression of PCa to castration-resistant prostate cancer (CRPC), an incurable stage of the disease characterized by profound metabolic reprogramming and independence from androgens. Only a subset of patients progresses to CRPC, and current stratification tools lack robust biomarkers. TXNIP expression is directly suppressed by androgens and diminishes during tumor initiation and progression, as demonstrated in both human samples and a prostate adenocarcinoma mouse model (TRAMP). TXNIP regulates glucose metabolism by sequestering the glucose transporter GLUT1 away from the membrane, shifting metabolism from glycolysis to glutaminolysis. Nuclear-localized TXNIP induces cell cycle arrest through the upregulation of p27 which is downregulated together with TXNIP in CRPC. The response to androgen deprivation therapy (ADT) strongly depends on TXNIP expression. In the murine model, TXNIP levels were significantly higher in ADT responders compared to non-responders. Furthermore, TRAMP-Txnip prostate tumors exhibited a poorer response to ADT, with increased Ki67 and enhanced viability. In clinical samples, all patients on relapse showed low levels of TXNIP and progressed to CRPC. Our findings identify TXNIP as a critical regulator of cell cycle and glucose metabolism in PCa and emphasize for the first time its essential role in mediating therapeutic responses to ADT.

**中文摘要译文：**
硫氧还蛋白相互作用蛋白（TXNIP）是一种位于氧化还原与糖酵解代谢交叉点的抑制蛋白。由于健康前列腺组织具有糖酵解特性，前列腺癌（PCa）表现出独特的代谢特征。我们假设TXNIP在前列腺癌向去势抵抗性前列腺癌（CRPC）的进展中起着关键作用，CRPC是该疾病的一个无法治愈的阶段，其特征是深刻的代谢重编程和对雄激素的非依赖性。只有一部分患者会进展为CRPC，且目前的分层工具缺乏可靠的生物标志物。正如在人类样本和前列腺腺癌小鼠模型（TRAMP）中所证实的，TXNIP的表达受到雄激素的直接抑制，并在肿瘤的发生和发展过程中减少。TXNIP通过将葡萄糖转运蛋白GLUT1从细胞膜上隔离，从而调节葡萄糖代谢，使代谢从糖酵解转向谷氨酰胺分解。定位于细胞核的TXNIP通过上调p27来诱导细胞周期停滞，而在CRPC中p27与TXNIP一同被下调。对雄激素剥夺疗法（ADT）的反应在很大程度上取决于TXNIP的表达水平。在小鼠模型中，ADT应答者的TXNIP水平显著高于非应答者。此外，TRAMP-Txnip前列腺肿瘤对ADT的反应更差，表现为Ki67增加和生存能力增强。在临床样本中，所有复发患者均表现出低水平的TXNIP并进展为CRPC。我们的研究结果将TXNIP确定为前列腺癌中细胞周期和葡萄糖代谢的关键调节因子，并首次强调了其在介导对ADT治疗反应中的重要作用。

### 第二部分 AI 大师评价

本研究创新性地揭示了硫氧还蛋白相互作用蛋白（TXNIP）在前列腺癌雄激素剥夺治疗（ADT）反应中的核心调控作用，连接了细胞代谢重编程与细胞周期控制。通过结合小鼠模型与临床样本分析，研究发现TXNIP的表达水平是预测ADT疗效和向去势抵抗性前列腺癌（CRPC）进展的关键生物标志物。该发现不仅为理解前列腺癌的治疗抵抗机制提供了新视角，也提示TXNIP可能成为改善治疗策略、克服耐药性的潜在新靶点，具有重要的临床转化价值。

---

## 33. 染色质重塑增强HAM患者中MAP3K8的表达：治疗干预的关键发病机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213906](https://pubmed.ncbi.nlm.nih.gov/41213906)
**期刊：** Nature communications
**PMID：** 41213906
**DOI：** 10.1038/s41467-025-64836-7

### 第一部分 原文与翻译

**英文原标题：** Chromatin remodeling enhances MAP3K8 expression in HAM: a key pathogenesis for therapeutic intervention.

**英文摘要原文：**
Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy (HAM) is a debilitating neuroinflammatory disease with no available effective treatments. A hallmark of HAM is the transformation of HTLV-1-infected cells into T helper type 1 (Th1)-like cells, characterized by excessive interferon (IFN)-γ production that drives chronic inflammation. However, the molecular mechanisms fuel this aberrant Th1-like transformation and sustained inflammation remain poorly understood. We hypothesized that HAM-characteristic chromatin remodeling plays a pivotal role in the overexpression of key genes driving inflammatory pathogenesis. Using transcriptomic analysis, chromatin accessibility profiling, and biomarker evaluations across HTLV-1-related diseases, we identify MAP3K8 as a key gene that defines the unique inflammatory profile of HAM. MAP3K8 overexpression promotes Th1-like differentiation and constitutively activates the MEK-ERK signaling pathway. Furthermore, we elucidate the mechanism by which HTLV-1 Tax, Fosl2, and c-Jun collaboratively induce HAM-characteristic chromatin remodeling at the enhancer region of the MAP3K8 locus. Crucially, we demonstrate that mitogen-activated protein kinase kinase (MEK) inhibitors effectively suppress the MAP3K8-MEK signaling cascade and significantly mitigated inflammatory pathogenesis in an ex vivo culture assay. Our findings provide critical insights into the virus-host interactions underpinning HAM and propose the MAP3K8-MEK-ERK axis as a promising therapeutic target for this challenging condition.

**中文摘要译文：**
人类T细胞白血病病毒1型（HTLV-1）相关脊髓病（HAM）是一种尚无有效治疗方法的致残性神经炎症性疾病。HAM的一个标志性特征是HTLV-1感染的细胞转化为1型辅助T细胞（Th1）样细胞，其特点是产生过量的干扰素（IFN）-γ，从而驱动慢性炎症。然而，驱动这种异常的Th1样细胞转化和持续性炎症的分子机制仍不甚明了。我们假设，HAM特有的染色质重塑在驱动炎症发病机制的关键基因过表达中起着关键作用。通过运用转录组学分析、染色质可及性分析以及跨HTLV-1相关疾病的生物标志物评估，我们确定了MAP3K8是定义HAM独特炎症特征的关键基因。MAP3K8的过表达促进了Th1样细胞的分化，并持续激活MEK-ERK信号通路。此外，我们阐明了HTLV-1 Tax、Fosl2和c-Jun协同诱导MAP3K8基因座增强子区域发生HAM特异性染色质重塑的机制。至关重要的是，我们证明了丝裂原活化蛋白激酶激酶（MEK）抑制剂在离体培养实验中能有效抑制MAP3K8-MEK信号级联反应，并显著减轻了炎症发病过程。我们的研究结果为揭示HAM背后病毒与宿主的相互作用提供了关键见解，并提出MAP3K8-MEK-ERK轴是应对这一挑战性疾病的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

该研究旨在揭示人类T细胞白血病病毒1型相关脊髓病（HAM）的关键发病机制。研究综合运用转录组学和染色质可及性分析等前沿技术，创新性地发现由染色质重塑驱动的MAP3K8过表达是定义HAM独特炎症特征的核心。研究不仅阐明了HTLV-1 Tax蛋白协同转录因子调控MAP3K8表达的上游机制，更通过离体实验验证了MEK抑制剂的治疗潜力。这项工作为缺乏有效疗法的HAM提供了明确的分子靶点（MAP3K8-MEK-ERK轴）和潜在的靶向治疗策略，具有重大的临床转化价值。

---

## 34. MZT2B通过增强线粒体功能和COX5B表达促进非小细胞肺癌细胞的恶性表型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213905](https://pubmed.ncbi.nlm.nih.gov/41213905)
**期刊：** Cell death & disease
**PMID：** 41213905
**DOI：** 10.1038/s41419-025-08182-y

### 第一部分 原文与翻译

**英文原标题：** MZT2B promotes malignant phenotypes in NSCLC cells by enhancing mitochondrial function and COX5B expression.

**英文摘要原文：**
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, necessitating the identification of novel therapeutic targets. Here, we identify mitotic spindle organizing protein 2B (MZT2B) as a critical oncogenic driver and potential therapeutic vulnerability in NSCLC. TCGA analysis revealed significant MZT2B upregulation in NSCLC tissues, correlating with adverse clinicopathological features and poor prognosis of patients. Single-cell RNA sequencing analysis confirmed predominant MZT2B enrichment within malignant epithelial cells, particularly in proliferating carcinoma subsets, across primary tumors and metastatic sites (brain, lymph node, pleural effusions). Functional enrichment analyses highlighted MZT2B's association with pathways critical for cellular respiration and mitochondrial ATP synthesis, coupled electron transport. Experimental validation in human NSCLC clinical specimens and various cell types further confirmed consistent MZT2B overexpression. Genetic silencing (via shRNA) or CRISPR/Cas9-mediated knockout of MZT2B in various NSCLC cell types significantly impeded cell viability, proliferation, migration, and invasion, inducing G1-S phase cell cycle arrest, and activating the intrinsic apoptotic pathway. Conversely, MZT2B overexpression promoted aggressive malignant phenotypes of NSCLC cells. Further investigation demonstrated MZT2B's criticality for mitochondrial respiration and overall function, and its silencing or knockout inhibited oxygen consumption rates, ATP production, mitochondrial membrane potential, and cellular redox homeostasis (ROS, GSH/GSSG ratio). Integrated bioinformatic and experimental approaches identified cytochrome c oxidase subunit 5B (COX5B) as a significant downstream effector regulated by MZT2B in NSCLC cells. Restoring COX5B expression or increasing glucose concentration attenuated MZT2B depletion-induced anti-NSCLC cell effects. In vivo studies using subcutaneous xenograft models confirmed that MZT2B knockdown markedly impaired NSCLC tumor growth, reduced proliferation, increased apoptosis, downregulated COX5B expression and diminished mitochondrial function. Collectively, these findings establish MZT2B as a consistently upregulated gene in NSCLC correlating with adverse clinicopathological features and poor prognosis. MZT2B critically regulates mitochondrial function and promotes NSCLC progression, at least partially, through promoting COX5B expression.

**中文摘要译文：**
非小细胞肺癌（NSCLC）仍然是癌症相关死亡的主要原因，因此有必要确定新的治疗靶点。在此，我们确定了有丝分裂纺锤体组织蛋白2B（MZT2B）是NSCLC中的一个关键致癌驱动因子和潜在的治疗弱点。TCGA分析显示，MZT2B在NSCLC组织中显著上调，并与患者的不良临床病理特征和不良预后相关。单细胞RNA测序分析证实，在原发性肿瘤和转移部位（脑、淋巴结、胸腔积液）的恶性上皮细胞中，特别是在增殖性癌细胞亚群中，MZT2B显著富集。功能富集分析突出了MZT2B与细胞呼吸、线粒体ATP合成及偶联电子传递等关键通路相关。在人类NSCLC临床标本和多种细胞类型中的实验验证进一步证实了MZT2B的持续过表达。在多种NSCLC细胞类型中，通过shRNA或CRISPR/Cas9介导的基因敲除对MZT2B进行遗传沉默，显著抑制了细胞的活力、增殖、迁移和侵袭，诱导了G1-S期细胞周期停滞，并激活了内源性凋亡途径。相反，MZT2B的过表达则促进了NSCLC细胞的侵袭性恶性表型。进一步的研究表明，MZT2B对线粒体呼吸和整体功能至关重要，其沉默或敲除抑制了耗氧率、ATP产生、线粒体膜电位和细胞氧化还原稳态（ROS、GSH/GSSG比率）。综合生物信息学和实验方法确定了细胞色素c氧化酶亚基5B（COX5B）是NSCLC细胞中受MZT2B调控的一个重要下游效应子。恢复COX5B的表达或增加葡萄糖浓度可减弱MZT2B耗竭诱导的抗NSCLC细胞效应。使用皮下异种移植模型的体内研究证实，MZT2B敲低显著损害了NSCLC肿瘤的生长，减少了增殖，增加了凋亡，下调了COX5B的表达并削弱了线粒体功能。总而言之，这些发现确立了MZT2B是NSCLC中一个持续上调的基因，与不良的临床病理特征和不良预后相关。MZT2B通过至少部分促进COX5B的表达来关键性地调节线粒体功能并促进NSCLC的进展。

### 第二部分 AI 大师评价

本研究旨在阐明有丝分裂纺锤体组织蛋白2B（MZT2B）在非小细胞肺癌（NSCLC）中的作用及其分子机制。研究综合运用生物信息学分析、单细胞测序以及体内外功能实验，关键性地发现MZT2B在NSCLC中表达上调，并通过调控下游效应分子COX5B来增强线粒体功能，进而促进肿瘤的恶性进展。此项研究的创新价值在于首次揭示了“MZT2B-COX5B-线粒体功能”这一调控轴线，不仅深化了对NSCLC代谢重编程的理解，也为临床治疗提供了一个极具潜力的分子靶点。

---

## 35. 糖酵解酶PGK1磷酸化MORC2赋予胰腺导管腺癌放疗抵抗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213904](https://pubmed.ncbi.nlm.nih.gov/41213904)
**期刊：** Cell death & disease
**PMID：** 41213904
**DOI：** 10.1038/s41419-025-08177-9

### 第一部分 原文与翻译

**英文原标题：** The glycolytic enzyme PGK1 phosphorylates MORC2 to Confer radioresistance in pancreatic ductal adenocarcinoma.

**英文摘要原文：**
Most pancreatic cancer patients exhibit inherent resistance to radiation therapy, and the molecular mechanisms remain poorly understood. Here, we demonstrate that phosphoglycerate kinase 1 (PGK1), a key ATP-producing glycolytic enzyme, plays a critical role in pancreatic ductal adenocarcinoma (PDAC) radioresistance. In response to ionizing radiation (IR), casein kinase 2 (CK2) is activated and phosphorylates PGK1 at S256. Phosphorylated PGK1 interacts with microrchidia CW-type zinc finger 2 (MORC2). Importantly, PGK1 functions as a protein kinase and phosphorylates MORC2 at S711, thereby enhancing the DNA-dependent ATPase activity of MORC2 to facilitate chromatin remodeling and DNA repair. Disruption of CK2-mediated PGK1 phosphorylation or PGK1-dependent MORC2 phosphorylation sensitizes PDAC cells and mouse tumors to IR. Clinically, the levels of PGK1 pS256 and MORC2 pS711, which are mutually correlated, are positively associated with poor survival in radiotherapy-treated PDAC specimens. These findings highlight the critical role of the nonmetabolic functions of PGK1 in DNA damage repair and PDAC radioresistance.

**中文摘要译文：**
大多数胰腺癌患者对放射治疗表现出固有的抵抗性，其分子机制在很大程度上仍不清楚。在此，我们证明了磷酸甘油酸激酶1（PGK1），一种关键的产生ATP的糖酵解酶，在胰腺导管腺癌（PDAC）的放疗抵抗中起着至关重要的作用。为响应电离辐射（IR），酪蛋白激酶2（CK2）被激活并在S256位点磷酸化PGK1。磷酸化的PGK1与微睾症CW型锌指蛋白2（MORC2）相互作用。重要的是，PGK1发挥蛋白激酶的功能，在S711位点磷酸化MORC2，从而增强MORC2的DNA依赖性ATP酶活性，以促进染色质重塑和DNA修复。破坏CK2介导的PGK1磷酸化或PGK1依赖的MORC2磷酸化，可使PDAC细胞和小鼠肿瘤对电离辐射敏感。在临床上，PGK1 pS256和MORC2 pS711的水平相互关联，并且在接受放疗的PDAC患者标本中与较差的生存率呈正相关。这些发现突显了PGK1的非代谢功能在DNA损伤修复和PDAC放疗抵抗中的关键作用。

### 第二部分 AI 大师评价

本研究旨在揭示胰腺导管腺癌（PDAC）放疗抵抗的关键分子机制。研究团队通过一系列实验发现，电离辐射可激活CK2激酶磷酸化糖酵解酶PGK1，而被磷酸化的PGK1会作为蛋白激酶进一步磷酸化下游的MORC2蛋白，最终增强DNA修复能力并导致放疗抵抗。此研究的创新之处在于揭示了PGK1在DNA损伤修复中的非经典、非代谢功能，并阐明了“CK2-PGK1-MORC2”这一全新的信号转导轴，为克服PDAC放疗抵抗提供了极具潜力的治疗靶点和预后生物标志物。

---

## 36. 癌相关成纤维细胞诱导的lncRNA WARS2-IT1通过增强HIF-1α的稳定性赋予结直肠癌放射抗拒性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213902](https://pubmed.ncbi.nlm.nih.gov/41213902)
**期刊：** Cell death & disease
**PMID：** 41213902
**DOI：** 10.1038/s41419-025-08058-1

### 第一部分 原文与翻译

**英文原标题：** Cancer-associated fibroblast-induced lncRNA WARS2-IT1 confers radioresistance of colorectal cancer via enhancing HIF-1α stability.

**英文摘要原文：**
The tumor microenvironment in colorectal cancer (CRC) is marked by a diverse and abundant population of cancer-associated fibroblasts (CAFs), which play a crucial role in radioresistance. Nonetheless, the mechanisms through which CAFs contribute to radioresistance remain unclear. In this study, we demonstrate that CAF, a specific subset of CAFs derived from radioresistant CRC patients, produces higher levels of transforming growth factor-β1 (TGF-β1) compared to CAFs isolated from radiosensitive CRC patients. Through long noncoding RNA (lncRNA) profiling of tumor cells treated with CAF-conditioned medium (CAF-CM), we identify WARS2-IT1 (WARS2 intronic transcript 1), whose expression is directly stimulated by TGF-β1 signaling. This lncRNA serves as a key player in promoting radioresistance and is essential for the TGFβ1-induced radioresistance pathway. Mechanistically, WARS2-IT1 interferes with the interaction between prolyl hydroxylase domain 2 (PHD2) and hypoxia-inducible factor-1α (HIF-1α), preventing the hydroxylation and subsequent degradation of HIF-1α. This process leads to the activation of glycolytic pathways, thereby enhancing radioresistance. Our findings underscore the potential of targeting CAF-driven WARS2-IT1 as a promising strategy to counteract tumor radioresistance in CRC.

**中文摘要译文：**
结直肠癌（CRC）的肿瘤微环境以其多样且丰富的癌相关成纤维细胞（CAFs）群体为特征，这些细胞在放射抗拒中扮演着关键角色。然而，CAFs导致放射抗拒的具体机制仍不清楚。在本研究中，我们证明了源自放疗抵抗性CRC患者的一个特定CAF亚群，与从放疗敏感性CRC患者中分离的CAFs相比，会产生更高水平的转化生长因子-β1（TGF-β1）。通过对经CAF条件培养基（CAF-CM）处理的肿瘤细胞进行长链非编码RNA（lncRNA）谱分析，我们鉴定出WARS2-IT1（WARS2内含子转录本1），其表达受到TGF-β1信号的直接刺激。该lncRNA是促进放射抗拒的关键因子，并且对TGF-β1诱导的放射抗拒通路至关重要。机制上，WARS2-IT1干扰脯氨酰羟化酶结构域2（PHD2）与缺氧诱导因子-1α（HIF-1α）之间的相互作用，从而阻止HIF-1α的羟基化及随后的降解。这一过程导致糖酵解通路活化，进而增强了放射抗拒性。我们的研究结果强调，靶向CAF驱动的WARS2-IT1是克服CRC肿瘤放射抗拒的一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在阐明癌相关成纤维细胞（CAFs）介导结直肠癌（CRC）放射抗拒的具体分子机制。研究团队通过对比放疗抗拒与敏感患者来源的CAFs，结合lncRNA谱分析，成功鉴定出关键分子lncRNA WARS2-IT1。研究的核心发现揭示了一条全新的信号通路：CAFs分泌的TGF-β1上调WARS2-IT1，后者通过抑制PHD2与HIF-1α的互作来稳定HIF-1α，最终激活糖酵解通路并赋予肿瘤细胞放射抗拒性。该研究不仅深化了对肿瘤微环境调控放疗抵抗的理解，更提出了靶向WARS2-IT1作为增敏CRC放疗的潜在新策略，具有重要的临床转化价值。

---

## 37. 德曲妥珠单抗治疗HER2低表达或HER2突变的复发/转移性头颈部分泌腺癌：一项病例系列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213241](https://pubmed.ncbi.nlm.nih.gov/41213241)
**期刊：** Journal of the National Comprehensive Cancer Network : JNCCN
**PMID：** 41213241
**DOI：** 10.6004/jnccn.2025.7104

### 第一部分 原文与翻译

**英文原标题：** Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.

**英文摘要原文：**
Trastuzumab deruxtecan (T-DXd) has shown efficacy in HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) recurrent/metastatic (R/M) secretory gland cancers of the head and neck. However, there are minimal published data regarding the use of T-DXd in HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-mutant tumors. This case series aimed to describe the clinical characteristics and outcomes of patients with HER2-low or HER2-mutant R/M salivary gland cancer (SGC) or lacrimal gland cancer (LGC) who received T-DXd in any line of therapy. Patients included in this series had a confirmed diagnosis of SGC or LGC, were evaluated at the MD Anderson Head and Neck Center, and received at least one dose of T-DXd. HER2 status was evaluated according to ASCO/CAP guidelines for breast cancer as recommended by NCCN. HER2-activating mutations were identified with tissue-based next-generation sequencing. Best overall response to T-DXd per RECIST v1.1 was evaluated for patients with adequate imaging and measurable disease. The final cohort comprised 9 patients (SGC, n=8; LGC, n=1), including 7 with HER2-low and 2 with HER2-mutant tumors. T-DXd was given off-label in 7 patients; 2 received T-DXd on a clinical trial. Among 6 patients who were eligible for RECIST, 4 (66.7%) had a partial response, including 1 complete response in target lesions. The 3 patients who were not eligible for RECIST had oncologist-documented clinical and/or radiographic improvement. The median time on T-DXd among all patients was 8.9 months. T-DXd demonstrated promising and durable antitumor activity. This antibody-drug conjugate should be considered a viable therapeutic option for HER2-low and HER2-mutant R/M SGC/LGC, with potential use in the frontline setting when preferred systemic therapies are unavailable.

**中文摘要译文：**
德曲妥珠单抗（T-DXd）已在HER2阳性（免疫组化[IHC] 3+或IHC 2+/原位杂交[ISH]+）的复发/转移性（R/M）头颈部分泌腺癌中显示出疗效。然而，关于T-DXd在HER2低表达（IHC 1+或IHC 2+/ISH-）或HER2突变肿瘤中的应用，已发表的数据极少。本病例系列研究旨在描述接受T-DXd作为任一线数治疗的HER2低表达或HER2突变的R/M唾液腺癌（SGC）或泪腺癌（LGC）患者的临床特征和结局。本研究纳入的患者均经确诊为SGC或LGC，在MD安德森头颈中心接受评估，并接受了至少一剂T-DXd治疗。HER2状态根据NCCN推荐的ASCO/CAP乳腺癌指南进行评估。HER2激活突变通过基于组织的二代测序进行鉴定。对于有充分影像学资料和可测量病灶的患者，根据RECIST v1.1标准评估了对T-DXd的最佳总缓解。最终队列包括9名患者（SGC，n=8；LGC，n=1），其中7名为HER2低表达，2名为HER2突变肿瘤。7名患者接受了T-DXd的超适应症用药；2名患者通过临床试验接受了T-DXd治疗。在6名符合RECIST评估条件的患者中，4名（66.7%）获得了部分缓解，其中1名患者靶病灶完全缓解。3名不符合RECIST评估条件的患者，经肿瘤科医生记录，也观察到临床和/或影像学上的改善。所有患者接受T-DXd治疗的中位时间为8.9个月。T-DXd展现了有前景且持久的抗肿瘤活性。当首选系统性疗法不可用时，该抗体药物偶联物应被视为HER2低表达和HER2突变的R/M SGC/LGC的可行治疗选择，并有潜力用于一线治疗。

### 第二部分 AI 大师评价

本研究通过一项小样本病例系列分析，首次探讨了德曲妥珠单抗（T-DXd）在HER2低表达或HER2突变的罕见头颈部分泌腺癌（SGC/LGC）中的治疗效果。研究发现，T-DXd在这一既往缺乏有效治疗方案的患者群体中展现了令人鼓舞且持久的抗肿瘤活性。尽管样本量小是其主要局限性，该研究填补了该领域的关键数据空白，为T-DXd在这些罕见肿瘤中的应用提供了重要的初步临床证据，对指导未来临床实践和研究设计具有重要价值。

---

## 38. 基于机器学习利用真实世界和NATALEE试验数据预测HR+/HER2-早期乳腺癌的远处复发风险及瑞波西利治疗效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213110](https://pubmed.ncbi.nlm.nih.gov/41213110)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41213110
**DOI：** 10.1158/1078-0432.CCR-25-1946

### 第一部分 原文与翻译

**英文原标题：** Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.

**英文摘要原文：**
PURPOSE: Despite current standard-of-care endocrine therapy, distant recurrence remains a concern for patients with HR+/HER2- early breast cancer (EBC). Understanding individual recurrence risk would aid in clinical decision making. We used machine learning to identify risk factors and develop recurrence risk prediction models.

EXPERIMENTAL DESIGN: Predictor variables were identified by gradient boosting and used to train models on a large, diverse real-world dataset of patients with stage I-III HR+/HER2- EBC obtained from the US-based, electronic health record-derived deidentified Flatiron Health Research Database. An elastic net-penalized Cox proportional hazards model was validated internally with real-world data and externally with data from the NATALEE trial of ribociclib in patients with HR+/HER2- EBC. Prediction and outcome concordance for distant recurrence and treatment effect were analyzed with Harrell's concordance index (C-index) and integrated Brier score (IBS); model performance over time was determined by dynamic AUC analysis.

RESULTS: The model accurately predicted distant recurrence in the real-world cohort (n=7842; C-index: 0.85 [95% CI: 0.8461-0.8598]; IBS: 0.05 [95% CI: 0.0443-0.0495]) over time (AUC >0.7 through 10 years); internal validation and sensitivity analyses confirmed model performance. External validation with the NATALEE NSAI alone arm yielded a lower but still discriminative performance (C-index: 0.66). Training on NATALEE data improved concordance (C-index: 0.70); the NATALEE-trained model predicted a 3.2% reduction in distant recurrence at 48 months with ribociclib treatment in the real-world cohort.

CONCLUSION: A machine learning model was developed that accurately predicted distant recurrence in HR+/HER2- EBC. The identified predictor variables and developed models may aid risk-based personalized treatment decision making.

**中文摘要译文：**
目的：尽管有当前的标准内分泌治疗，远处复发仍然是HR+/HER2-早期乳腺癌（EBC）患者的一大担忧。理解个体化的复发风险将有助于临床决策。我们使用机器学习来识别风险因素并开发复发风险预测模型。

试验设计：通过梯度提升算法识别预测变量，并使用这些变量在一个大型、多样化的真实世界数据集上训练模型，该数据集来源于美国Flatiron Health研究数据库中经过去识别化的电子健康记录，包含了I-III期HR+/HER2- EBC患者。一个弹性网络惩罚的Cox比例风险模型利用真实世界数据进行了内部验证，并利用瑞波西利治疗HR+/HER2- EBC患者的NATALEE试验数据进行了外部验证。远处复发的预测与结局一致性以及治疗效果通过Harrell一致性指数（C指数）和综合Brier评分（IBS）进行分析；模型的时变性能通过动态AUC分析确定。

结果：该模型在真实世界队列（n=7842；C指数：0.85 [95% CI: 0.8461-0.8598]；IBS：0.05 [95% CI: 0.0443-0.0495]）中准确地预测了远处复发，且其性能随时间保持稳定（10年内AUC >0.7）；内部验证和敏感性分析证实了模型的性能。使用NATALEE试验的非甾体芳香化酶抑制剂（NSAI）单药组进行的外部验证显示，其性能有所下降但仍具区分能力（C指数：0.66）。在NATALEE数据上进行训练后，一致性得到改善（C指数：0.70）；经NATALEE数据训练的模型预测，在真实世界队列中，瑞波西利治疗可在48个月时使远处复发率降低3.2%。

结论：我们开发了一个能够准确预测HR+/HER2- EBC远处复发的机器学习模型。所识别的预测变量和开发的模型可能有助于基于风险的个性化治疗决策。

### 第二部分 AI 大师评价

本研究旨在利用机器学习技术，为HR+/HER2-早期乳腺癌患者开发一个精准的远处复发风险预测模型。该研究的创新之处在于，它不仅使用了大规模的真实世界电子病历数据进行模型训练，还巧妙地结合了关键临床试验（NATALEE）的数据进行外部验证和模型优化，从而增强了模型的泛化能力和临床适用性。研究结果表明，该模型不仅能高效预测复发风险，还能评估瑞波西利（ribociclib）的潜在治疗获益，为实现基于个体风险的精准治疗决策提供了有力工具，具有重要的临床转化价值。

---

## 39. 单次抗EGFR治疗后早期[18F]FDG PET/CT反应可作为晚期结直肠癌患者治疗获益的预测性生物标志物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213105](https://pubmed.ncbi.nlm.nih.gov/41213105)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41213105
**DOI：** 10.1158/1078-0432.CCR-25-1768

### 第一部分 原文与翻译

**英文原标题：** Early [18F]FDG PET/CT response after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer.

**英文摘要原文：**
PURPOSE: Anti-Epidermal Growth Factor Receptor monoclonal antibody (anti-EGFR mAb) therapy improve the clinical outcome of patients with metastatic colorectal cancer (mCRC).. This study assessed the predictive value of early [18F]fluorodeoxyglucose-positron emission tomography/Computed tomography ([18F]FDG PET/CT) after one anti-EGFR mAb treatment in patients with mCRC.

PATIENTS & METHODS: The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and pre-second treatment cycle (2 weeks). Total Lesion Glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold.

RESULTS: Inpatients with RAS/BRAF wt left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with median PFS of 5.7 months (95% CI 5.2-10). Seventy-five patients including right-sided mCRC were eligible for metabolic response analysis. Patients with clinical benefit (n=57) showed a mean decrease in sumTLG of 58% (SD 19%), compared to 1.9% (SD 36%); in those without clinical benefit (n=18) (P =0·003). A threshold of <15% reduction in sumTLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival (PFS) than non-responders (6.5 versus 1·7 months (P<0·001)).

CONCLUSIONS: Selecting patients with left-sided RAS/BRAF wt mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [ 18F]FDG PET/CT identified non-responders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.

**中文摘要译文：**
目的：抗表皮生长因子受体单克隆抗体（anti-EGFR mAb）治疗可改善转移性结直肠癌（mCRC）患者的临床结局。本研究旨在评估mCRC患者接受单次anti-EGFR mAb治疗后，早期[18F]氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描（[18F]FDG PET/CT）的预测价值。

患者与方法：多中心IMPACT-CRC研究（NCT02117466）前瞻性地纳入了接受二线或三线anti-EGFR mAb单药治疗的mCRC患者。在第8周时通过CT依据RECIST 1.1版标准评估临床获益（完全/部分缓解或疾病稳定）。在基线及第二个治疗周期前（第2周）进行[18F]FDG PET/CT扫描。采用预设的数据驱动阈值，评估总病灶糖酵解（TLG）的变化作为预测临床获益的生物标志物。

结果：在RAS/BRAF野生型左半mCRC患者中，临床获益率为92%（31%部分缓解，61%疾病稳定），中位无进展生存期（PFS）为5.7个月（95% CI 5.2-10）。包括右半mCRC在内的75名患者符合代谢反应分析的条件。获得临床获益的患者（n=57）的总TLG（sumTLG）平均下降了58%（SD 19%），而未获益的患者（n=18）平均下降1.9%（SD 36%）（P=0.003）。sumTLG下降小于15%的阈值对临床获益的阴性预测值为100%。代谢反应者的无进展生存期（PFS）长于无反应者（6.5个月 vs 1.7个月，P<0.001）。

结论：筛选左半RAS/BRAF野生型mCRC患者进行anti-EGFR mAb单药治疗，可获得92%的临床获益率。早期[18F]FDG PET/CT能够以100%的准确率识别出无反应者，这在肿瘤突变状态未知时提供了极具前景的临床应用价值。

### 第二部分 AI 大师评价

该前瞻性多中心研究旨在探索早期[18F]FDG PET/CT代谢反应在预测晚期结直肠癌（mCRC）患者接受抗EGFR单药治疗疗效中的价值。研究的关键发现在于，在单次治疗后仅两周，通过评估总病灶糖酵解（TLG）变化，即可精准区分治疗反应者与非反应者。其核心创新价值是验证了总TLG下降小于15%这一阈值具有100%的阴性预测值，能极早期且准确地筛选出无效患者。这项发现具有重要的临床转化潜力，有助于医生快速调整治疗策略，避免无效治疗带来的毒副作用和经济负担，尤其在肿瘤突变状态未知时更显其用。

---

## 40. 一项评估两种剂量的叶酸受体α疫苗在三阴性乳腺癌患者中的安全性与免疫原性的II期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213103](https://pubmed.ncbi.nlm.nih.gov/41213103)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41213103
**DOI：** 10.1158/1078-0432.CCR-25-2763

### 第一部分 原文与翻译

**英文原标题：** A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.

**英文摘要原文：**
PURPOSE: CD4 T cell immunity is associated with improved survival in patients with breast cancer. We previously reported a Phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized Phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without cyclophosphamide pretreatment.

PATIENTS AND METHODS: Patients with triple-negative breast cancer (TNBC) who completed all systemic and local therapy were assigned to receive either Low-dose (825 mg) or High-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored and immunogenicity was evaluated pre- and post-vaccination.

RESULTS: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable to T cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in 8 evaluable patients and were unrelated to the treatment arm. No patients died during the study due to their disease.

CONCLUSIONS: The reduced dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in TNBC or other cancers.

**中文摘要译文：**
目的：CD4 T细胞免疫与乳腺癌患者生存率的提高相关。我们先前报道了一项评估叶酸受体α（FRα）疫苗联合环磷酰胺（CP）给药的I期试验，该试验展示了卓越的安全性与免疫原性。为简化疫苗策略以便于使用，我们在此报告一项随机II期试验的结果，该试验评估了较低剂量疫苗与原始剂量的效果，无论是否联用环磷酰胺预处理。

患者与方法：已完成所有全身及局部治疗的三阴性乳腺癌（TNBC）患者被分配接受低剂量（825毫克）或高剂量（2.5毫克）的疫苗肽联合GM-CSF，共进行六个为期4周的周期，可选择是否在接种前使用CP预处理。研究监测了安全性，并在接种前后评估了免疫原性。

结果：共有80名患者接种了疫苗，其中58名患者可进行免疫原性评估。疫苗接种的耐受性良好，并在83%的患者中诱发了免疫反应。FRα特异性T细胞水平高且持久，与针对破伤风类毒素的T细胞水平相当。两种剂量之间未观察到免疫原性差异。CP预处理也未影响免疫应答。在8名可评估患者中发生了复发，但与治疗组无关。研究期间无患者因疾病死亡。

结论：低剂量的FRα疫苗与原始剂量同样有效，并且无需CP预处理即可产生最大化的免疫反应。这些发现可为未来在TNBC或其他癌症中检验疗效的试验设计提供参考。

### 第二部分 AI 大师评价

本研究旨在优化针对三阴性乳腺癌的叶酸受体α（FRα）疫苗策略，通过一项II期随机试验，评估了更低剂量方案的安全性与免疫原性，并探讨了环磷酰胺预处理的必要性。核心发现表明，低剂量疫苗在诱导特异性T细胞免疫方面与原剂量同样有效，且无需环磷酰胺即可达到最大免疫应答。此项研究的价值在于显著简化了疫苗接种方案，为提高临床可用性和便利性铺平了道路，并为后续在TNBC及其他癌症中开展更大规模的有效性验证试验提供了关键依据。

---

## 41. 降低预后良好B系急性淋巴细胞白血病患儿诱导治疗中柔红霉素的剂量：AIEOP-BFM ALL 2009 III期临床试验结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213101](https://pubmed.ncbi.nlm.nih.gov/41213101)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41213101
**DOI：** 10.1200/JCO-25-01357

### 第一部分 原文与翻译

**英文原标题：** Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

**英文摘要原文：**
PURPOSE: Modern ALL therapy aims to reduce toxicity, while maintaining and improving the current high cure rates. Acute and late sequelae of anthracyclines are of major concern. The AIEOP-BFM ALL 2009 trial aimed to clarify the need for anthracyclines in low-risk patients.

PATIENTS AND METHODS: After 2 weeks of induction therapy, which included two daunorubicin (DNR) doses once weekly (30 mg/m each) as part of a 4-drug therapy, patients age 1-17 years with newly diagnosed non-high-risk B-ALL either positive for  or with rapid treatment response, as assessed by induction day-15 evaluation, were randomly assigned to receive either two additional doses of DNR (control arm [CA]) or no further DNR during induction (experimental arm [EA]). Patients treated as randomly assigned were included in the primary analysis on noninferiority in event-free survival (EFS). Adverse reactions of special interest (ARSI) were analyzed in the as-treated population.

RESULTS: Of 6,136 patients enrolled in AIEOP-BFM ALL 2009, 2,514 patients (41.0%) were eligible for this random assignment, with 82.7% actually randomly assigned (EA: n = 1,040 and CA: n = 1,039). The 5-year EFS was 92.5% (SE 0.8%) in CA and 92.2% (SE 0.9%) in EA. Accordingly, cumulative incidence of relapse was 5.8% (SE 0.7%) and 5.7% (SE 0.7%), and overall survival was 97.6% (SE 0.5%) and 97.4% (SE 0.5%) in CA and EA, respectively. Life-threatening and fatal ARSI were similar in the two arms, but there was a three times lower incidence of invasive fungal infections in the EA (0.5%  1.5%,  = .02).

CONCLUSION: A reduced DNR dose during induction did not compromise the outcome of patients with favorable prognostic factors but did diminish infectious toxicity indicated by the lower rate of invasive fungal infections.

**中文摘要译文：**
目的：现代急性淋巴细胞白血病（ALL）疗法旨在降低毒性，同时维持并提高当前的高治愈率。蒽环类药物的急性和远期后遗症是主要关切点。AIEOP-BFM ALL 2009试验旨在明确低风险患者中蒽环类药物的必要性。

患者与方法：在为期2周的诱导治疗（作为四药方案的一部分，包含每周一次，每次30 mg/m²的两次柔红霉素（DNR）给药）后，年龄在1-17岁、新诊断的非高危B系ALL患者，若ETV-RUNX1融合基因阳性或根据诱导第15天评估显示治疗反应迅速，则被随机分配接受额外两次DNR给药（对照组[CA]）或在诱导期间不再接受DNR（实验组[EA]）。按随机分配接受治疗的患者被纳入无事件生存期（EFS）的非劣效性主分析。特别关注的不良反应（ARSI）在按实际治疗（as-treated）的人群中进行分析。

结果：在入组AIEOP-BFM ALL 2009试验的6136名患者中，2514名患者（41.0%）符合随机分配条件，其中82.7%被实际随机分配（实验组：n = 1040；对照组：n = 1039）。对照组的5年EFS为92.5%（SE 0.8%），实验组为92.2%（SE 0.9%）。相应地，对照组和实验组的累积复发率分别为5.8%（SE 0.7%）和5.7%（SE 0.7%），总生存率分别为97.6%（SE 0.5%）和97.4%（SE 0.5%）。两组中危及生命和致命的ARSI相似，但实验组的侵袭性真菌感染发生率低三倍（0.5% vs 1.5%，P = .02）。

结论：在诱导治疗期间减少DNR剂量并未损害具有良好预后因素患者的治疗结局，反而通过降低侵袭性真菌感染率表明其减轻了感染性毒性。

### 第二部分 AI 大师评价

本研究是一项大规模III期非劣效性临床试验，旨在探讨对预后良好的B系急性淋巴细胞白血病患儿，在诱导治疗中减少蒽环类药物柔红霉素剂量的可行性。研究关键发现，与标准剂量组相比，减少柔红霉素剂量并未影响患儿的无事件生存率和总生存率，证明了其非劣效性。更重要的是，减量方案显著降低了侵袭性真菌感染的发生率，这为优化低风险患儿治疗方案、实现“减毒增效”提供了高级别循证医学证据，对临床实践具有重要的指导价值。

---

## 42. 立于船头之人。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213094](https://pubmed.ncbi.nlm.nih.gov/41213094)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41213094
**DOI：** 10.1200/JCO-25-01442

### 第一部分 原文与翻译

**英文原标题：** The Man at the Bow.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

由于本文献无摘要，且标题《立于船头之人》具有文学色彩，推测这可能是一篇社论、评论或人物特写，而非原创性研究。文章可能聚焦于临床肿瘤学领域的某位先驱人物，或探讨该领域面临的挑战与未来方向。其价值可能更多地体现在思想启发和人文关怀上，而非提供直接的临床证据或科研数据。

---

## 43. 一项在晚期肝细胞癌患者中开展的瑞戈非尼联合帕博利珠单抗一线治疗的多中心、剂量定义/扩展1b期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213032](https://pubmed.ncbi.nlm.nih.gov/41213032)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41213032
**DOI：** 10.1097/HEP.0000000000001585

### 第一部分 原文与翻译

**英文原标题：** A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

**英文摘要原文：**
BACKGROUND AND AIMS: Combinations including an immune checkpoint inhibitor are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). We investigated the safety of regorafenib plus pembrolizumab as first-line systemic therapy for advanced HCC.

APPROACH AND RESULTS: This was a dose-defining/expansion phase 1b study in adults with advanced HCC without prior systemic treatment. Patients received regorafenib 80 or 120 mg/day for 3 weeks plus pembrolizumab 200 mg every 3 weeks in 4-week cycles (rego-80/pembro or rego-120/pembro): rego-80/pembro in the dose-defining phase; rego-80/pembro or rego-120/pembro in two dose-expansion cohorts. The primary objective was to assess safety; antitumor activity was a secondary objective. The MTD of regorafenib was 120 mg/day plus pembrolizumab; 4/19 patients receiving rego-120/pembro experienced DLTs (grade 3 increased aspartate aminotransferase [AST] with grade 1/2 increased bilirubin [n=2], and grade 3 rash [n=2]). The most common treatment-emergent adverse events (TEAEs) in the overall safety cohort (n=57) were diarrhea (53%) and fatigue (51%). The most common grade ≥3 TEAEs were increased AST (18%) and hypertension (16%). Dose modifications due to study drug-related adverse events were less frequent with rego-80/pembro than with rego-120/pembro. The objective response rate (ORR) in 54 response-evaluable patients was 31% and the disease control rate (DCR) was 89%. Exploratory analyses suggested an association between lower angiogenesis and transforming growth factor-β signalling before treatment and response.

CONCLUSION: Treatment with rego/pembro is feasible in patients with advanced HCC with a manageable safety profile. ORR and DCR are promising and consistent with other immunotherapy combinations in this setting.

**中文摘要译文：**
背景与目的：包含免疫检查点抑制剂的联合方案是晚期肝细胞癌（HCC）的首选一线治疗。我们旨在研究瑞戈非尼联合帕博利珠单抗作为晚期HCC一线全身性治疗的安全性。

方法与结果：这是一项在未经系统性治疗的晚期HCC成年患者中进行的剂量定义/扩展1b期研究。患者接受瑞戈非尼80或120毫克/天，持续3周，联合帕博利珠单抗200毫克，每3周一次，周期为4周（rego-80/pembro或rego-120/pembro）：在剂量定义阶段使用rego-80/pembro；在两个剂量扩展队列中使用rego-80/pembro或rego-120/pembro。主要研究终点是评估安全性；抗肿瘤活性是次要研究终点。瑞戈非尼联合帕博利珠单抗的最大耐受剂量（MTD）为120毫克/天；接受rego-120/pembro治疗的19名患者中有4名出现剂量限制性毒性（DLTs）（3级天冬氨酸转氨酶[AST]升高伴1/2级胆红素升高[n=2]，以及3级皮疹[n=2]）。在总体安全性队列（n=57）中，最常见的治疗期间出现的不良事件（TEAEs）是腹泻（53%）和疲劳（51%）。最常见的≥3级TEAEs是AST升高（18%）和高血压（16%）。因研究药物相关不良事件导致的剂量调整，在rego-80/pembro组中比rego-120/pembro组更少见。在54名可评估疗效的患者中，客观缓解率（ORR）为31%，疾病控制率（DCR）为89%。探索性分析表明，治疗前较低的血管生成和转化生长因子-β信号通路与治疗反应之间存在关联。

结论：对于晚期HCC患者，瑞戈非尼联合帕博利珠单抗的治疗是可行的，且安全性可控。其ORR和DCR数据颇具前景，并与该领域其他免疫联合疗法的数据一致。

### 第二部分 AI 大师评价

该研究是一项1b期临床试验，旨在探索靶向药瑞戈非尼与免疫检查点抑制剂帕博利珠单抗联合作为晚期肝细胞癌一线治疗的安全性与初步疗效。研究通过剂量定义与扩展队列，成功确定了联合方案的最大耐受剂量，并证实了其安全性特征是可控的。此疗法展现出颇具前景的抗肿瘤活性，其客观缓解率与疾病控制率与当前其他免疫联合疗法的数据相当，为后续开展更大规模的III期临床研究提供了有力支持，有望为晚期肝癌患者提供新的一线治疗选择。

---

## 44. 通过影像生物标志物解码肿瘤异质性可预测肝细胞癌患者对TACE联合免疫及靶向治疗的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213031](https://pubmed.ncbi.nlm.nih.gov/41213031)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41213031
**DOI：** 10.1097/HEP.0000000000001593

### 第一部分 原文与翻译

**英文原标题：** Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus Immunotherapy and targeted therapy in HCC.

**英文摘要原文：**
BACKGROUND AIMS: This study aims to quantify intratumor heterogeneity (ITH) and identify prognostic imaging biomarkers in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with immune checkpoint inhibitor plus molecular targeted therapy (TACE-ICI-MTT).

METHODS: This multicenter cohort study included 742 patients with unresectable HCC who received first-line TACE-ICI-MTT from January 2018 to December 2022. Radiomic features representing global tumor regions (GTR) and ITH were extracted from pre-treatment computed tomography scans. A composite GTR-ITH score was generated using principal component analysis to integrate both GTR- and ITH-related features. Ensemble learning with multiple machine learning algorithms was employed to predict treatment response. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC), and survival outcomes were compared between model-defined risk groups using Kaplan-Meier analysis and the log-rank test. To reveal the biological relevance of the radiomic score, immune infiltration patterns were characterized using bulk RNA sequencing data from The Cancer Imaging Archive.

RESULTS: Following feature selection, 17 GTR- and 27 ITH-related radiomic features were retained to construct the GTR-ITH score. The model demonstrated high discriminative performance, with AUCs of 0.94 in the training set, 0.82 in the internal validation set, and 0.83 in the independent test set. The GTR-ITH score was strongly associated with treatment response (OR 34.39; p<0.001) and independently predicted overall survival (HR 0.63; p=0.004). Patients classified as GTR-ITH low-risk consistently showed significantly prolonged progression-free survival and overall survival. The GTR-ITH low-risk group also exhibited an immune-inflamed microenvironment characterized by enriched plasma cells and M1 macrophages, and reduced M2 macrophage infiltration.

CONCLUSIONS: An imaging radiomic biomarker capturing both global and intratumoral heterogeneity robustly predicts response and survival in HCC patients treated with TACE-ICI-MTT, and reflects underlying immune microenvironment phenotypes.

**中文摘要译文：**
背景与目的：本研究旨在量化肿瘤内异质性（ITH），并为接受经动脉化疗栓塞联合免疫检查点抑制剂及分子靶向治疗（TACE-ICI-MTT）的肝细胞癌（HCC）患者寻找预后性影像生物标志物。

方法：这项多中心队列研究纳入了742名在2018年1月至2022年12月期间接受一线TACE-ICI-MTT治疗的不可切除HCC患者。从治疗前的计算机断层扫描图像中提取代表肿瘤全局区域（GTR）和肿瘤内异质性（ITH）的影像组学特征。采用主成分分析法整合GTR与ITH相关特征，构建了一个复合GTR-ITH评分。研究采用集成学习方法，结合多种机器学习算法来预测治疗反应。通过受试者工作特征曲线下面积（AUC）评估模型性能，并使用Kaplan-Meier分析和对数秩检验比较模型定义的风险组之间的生存结局。为了揭示该影像组学评分的生物学相关性，研究使用了来自癌症影像档案库（The Cancer Imaging Archive）的批量RNA测序数据来表征免疫浸润模式。

结果：经过特征筛选，保留了17个GTR相关和27个ITH相关的影像组学特征来构建GTR-ITH评分。该模型表现出很高的区分性能，在训练集中AUC为0.94，内部验证集中为0.82，独立测试集中为0.83。GTR-ITH评分与治疗反应密切相关（OR 34.39; p<0.001），并且是总生存期的独立预测因素（HR 0.63; p=0.004）。被归类为GTR-ITH低风险的患者，其无进展生存期和总生存期均显著延长。GTR-ITH低风险组还表现出一种免疫炎症微环境，其特征是浆细胞和M1巨噬细胞富集，而M2巨噬细胞浸润减少。

结论：一个能同时捕捉肿瘤全局和瘤内异质性的影像组学生物标志物，可以有力地预测接受TACE-ICI-MTT治疗的HCC患者的疗效和生存期，并能反映其潜在的免疫微环境表型。

### 第二部分 AI 大师评价

本研究通过分析治疗前CT影像，创新性地构建了一个结合肿瘤全局特征与内部异质性的影像组学评分（GTR-ITH评分）。研究核心价值在于，该评分能高效预测肝癌患者接受TACE联合免疫与靶向治疗这一复杂方案的疗效及生存结局，其在多中心数据中得到验证，表现出优异的预测性能。更重要的是，研究将影像特征与肿瘤免疫微环境相关联，揭示了评分背后的生物学机制，为临床实现精准、个性化的治疗决策提供了无创、可靠的工具。

---

## 45. 未折叠蛋白反应激酶PERK通过SAM合成及H3K4me3依赖的PDGFB信号通路支持循环肿瘤细胞团簇的存活与转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212905](https://pubmed.ncbi.nlm.nih.gov/41212905)
**期刊：** Cancer communications (London, England)
**PMID：** 41212905
**DOI：** 10.1002/cac2.70072

### 第一部分 原文与翻译

**英文原标题：** Unfolded protein response kinase PERK supports survival and metastasis of circulating tumor cell clusters via SAM synthesis and H3K4me3-dependent PDGFB signaling.

**英文摘要原文：**
BACKGROUND: Metastasis is the leading cause of cancer-related mortality, with circulating tumor cell (CTC) clusters serving as highly efficient precursors of distant metastasis. Survival of CTC clusters in the bloodstream is the primary contributor to tumor metastasis. However, the underlying mechanisms of how CTC clusters respond to the blood environment and drive metastasis remain elusive. This study aimed to elucidate the potential mechanisms that enable CTC clusters to adapt and survive in the bloodstream.

METHODS: CTC clusters were detected using a microfluidic system in cancer patients, as well as in patient-derived xenograft (PDX), cell line-derived xenograft, and syngeneic models. The key molecules responsible for the adaptive survival of CTC clusters were characterized using RNA-sequencing (RNA-seq), gene interference, and flow cytometry. To investigate the underlying mechanisms of adaptive survival, RNA-seq, targeted metabolomics, isotope tracing experiments, chromatin immunoprecipitation (ChIP) sequencing, and immunofluorescence (IF) staining were employed. The therapeutic potential of survival pathway inhibitor combined with chemotherapy drug was evaluated in patient-derived CTCs and the PDX model.

RESULTS: CTC clusters exhibited superior survival and metastatic capacity compared to single CTCs and were associated with adverse clinical outcomes. The unfolded protein response mediator protein kinase R-like endoplasmic reticulum kinase (PERK) was activated in CTC clusters and maintained S-adenosylmethionine (SAM) availability, facilitating their adaptive survival in the bloodstream. Mechanistically, PERK mediated the upregulation of activating transcription factor 4 (ATF4), which enhanced methionine adenosyltransferase 2A (MAT2A) expression, contributing to SAM synthesis. Increased SAM enhanced H3K4me3 modification of the platelet-derived growth factor B (PDGFB) promoter, leading to elevated PDGFB secretion and its accumulation in the intercellular region within CTC clusters. PDGFB functioned as a shared survival signal, triggering the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway via platelet-derived growth factor receptor beta (PDGFRβ), supporting CTC cluster survival in the bloodstream. Inhibition of PERK and PDGFRβ profoundly impaired the survival signaling and suppressed the metastatic dissemination of CTC clusters.

CONCLUSIONS: Our findings revealed a PERK/MAT2A/PDGFB axis that confers adaptive survival capabilities to CTC clusters in the bloodstream. Targeting this survival signaling pathway represents a promising therapeutic strategy for metastatic cancer.

**中文摘要译文：**
背景：转移是癌症相关死亡的主要原因，而循环肿瘤细胞（CTC）团簇是远处转移的高效前体。CTC团簇在血流中的存活是肿瘤转移的主要促成因素。然而，CTC团簇如何响应血液环境并驱动转移的潜在机制仍不明确。本研究旨在阐明使CTC团簇能够在血流中适应并存活的潜在机制。

方法：使用微流控系统在癌症患者以及患者来源的异种移植（PDX）、细胞系来源的异种移植和同基因模型中检测CTC团簇。利用RNA测序（RNA-seq）、基因干扰和流式细胞术对负责CTC团簇适应性存活的关键分子进行了表征。为研究适应性存活的潜在机制，采用了RNA-seq、靶向代谢组学、同位素示踪实验、染色质免疫沉淀（ChIP）测序和免疫荧光（IF）染色。在患者来源的CTC和PDX模型中，评估了存活通路抑制剂联合化疗药物的治疗潜力。

结果：与单个CTC相比，CTC团簇表现出更强的存活和转移能力，并与不良临床结局相关。未折叠蛋白反应介导的蛋白激酶R样内质网激酶（PERK）在CTC团簇中被激活，并维持S-腺苷甲硫氨酸（SAM）的可用性，从而促进其在血流中的适应性存活。从机制上讲，PERK介导了激活转录因子4（ATF4）的上调，从而增强了甲硫氨酸腺苷转移酶2A（MAT2A）的表达，促进了SAM的合成。增加的SAM增强了血小板衍生生长因子B（PDGFB）启动子的H3K4me3修饰，导致PDGFB分泌增加并在CTC团簇内的细胞间区域积聚。PDGFB作为一种共享的存活信号，通过血小板衍生生长因子受体β（PDGFRβ）触发磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（AKT）通路，支持CTC团簇在血流中的存活。抑制PERK和PDGFRβ能显著损害该存活信号通路并抑制CTC团簇的转移扩散。

结论：我们的研究结果揭示了一个PERK/MAT2A/PDGFB轴，该轴赋予了CTC团簇在血流中的适应性存活能力。靶向这一存活信号通路是治疗转移性癌症的一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在揭示循环肿瘤细胞（CTC）团簇在血流中得以存活并高效转移的关键机制。研究团队综合运用微流控技术、多类小鼠模型及多组学分析等前沿方法，首次阐明了一条全新的“PERK/MAT2A/PDGFB”信号轴。该发现创新性地将未折叠蛋白反应、代谢重编程与表观遗传调控联系起来，揭示了CTC团簇内部通过旁分泌共享存活信号的精密网络。这项工作不仅深化了对肿瘤转移生物学的理解，也为开发针对性抗转移治疗策略提供了极具潜力的分子靶点。

---

## 46. 成人代谢功能障碍相关脂肪性肝病：一篇综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212550](https://pubmed.ncbi.nlm.nih.gov/41212550)
**期刊：** JAMA
**PMID：** 41212550
**DOI：** 10.1001/jama.2025.19615

### 第一部分 原文与翻译

**英文原标题：** Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

**英文摘要原文：**
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysfunction-associated steatohepatitis (MASH), which involves fat accumulation and inflammation in the liver. The presence of MASLD is associated with increased morbidity and mortality due to liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers.

OBSERVATIONS: The most common chronic liver disease worldwide, MASLD affects approximately 30% to 40% of the general adult population globally (with varying prevalence across continents), including approximately 60% to 70% of individuals with type 2 diabetes and approximately 70% to 80% of those with obesity. It is typically diagnosed based on an ultrasonographic finding of hepatic steatosis, along with at least 1 of 5 features of the metabolic syndrome (abdominal overweight or obesity, prediabetes or type 2 diabetes, hypertension, elevated level of plasma triglycerides, and low level of high-density lipoprotein cholesterol) for women who consume less than 140 g/wk of alcohol (<2 standard drinks/d) and for men who consume less than 210 g/wk (<3 standard drinks/d) and have no other known causes of steatosis such as use of a particular medication (eg, corticosteroids, tamoxifen, or methotrexate), hepatitis C, or iron overload. Other risk factors for MASLD include older age (≥50 years) and male sex (male:female ratio approximately 2). The Fibrosis-4 index (a scoring system incorporating age, serum levels of aspartate aminotransferase and alanine aminotransferase, and platelet count) and vibration-controlled transient elastography (a noninvasive imaging technique) are commonly used to stage hepatic fibrosis in patients with MASLD. Cardiovascular disease is the leading cause of death, followed by certain extrahepatic cancers (primarily gastrointestinal, breast, and gynecologic cancer) and liver-related complications, including cirrhosis, hepatic decompensation (ascites, hepatic encephalopathy, or variceal bleeding), and hepatocellular carcinoma. First-line treatment of MASLD involves behavioral modifications (including hypocaloric low-carbohydrate and low-fat diets, physical exercise, and avoidance of alcohol) and management of type 2 diabetes, obesity, hypertension, and hyperlipidemia. Bariatric surgery should be considered for patients with MASLD and a body mass index greater than 35. Resmetirom (a liver-directed, thyroid hormone receptor β-selective agonist) and subcutaneous semaglutide (a glucagon-like peptide-1 receptor agonist) are conditionally approved by the US Food and Drug Administration (FDA) for the treatment of adults with MASH who have moderate to advanced fibrosis.

CONCLUSIONS: A highly prevalent condition among adults worldwide, MASLD is associated with liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. First-line treatment includes behavioral modifications, including a weight-reducing diet, physical exercise, and avoidance of alcohol. Resmetirom and semaglutide are conditionally FDA-approved medications for the treatment of adults with MASH and moderate to advanced fibrosis.

**中文摘要译文：**
重要性：代谢功能障碍相关脂肪性肝病（MASLD）涵盖了一系列肝脏疾病，从单纯性脂肪变（特征为肝脏脂肪堆积但无炎症）进展到代谢功能障碍相关脂肪性肝炎（MASH），后者涉及肝脏的脂肪堆积和炎症。MASLD的存在与肝脏相关并发症、肝细胞癌、心血管疾病以及某些肝外癌症导致的发病率和死亡率增加有关。

观察：作为全球最常见的慢性肝病，MASLD影响全球约30%至40%的普通成年人群（各大陆患病率不一），其中包括约60%至70%的2型糖尿病患者和约70%至80%的肥胖症患者。其典型诊断依据是超声检查发现肝脏脂肪变，并满足代谢综合征5项特征中的至少1项（腹部超重或肥胖、糖尿病前期或2型糖尿病、高血压、血浆甘油三酯水平升高、高密度脂蛋白胆固醇水平降低），同时需排除其他已知脂肪变病因，如使用特定药物（例如，皮质类固醇、他莫昔芬或甲氨蝶呤）、丙型肝炎或铁过载，且女性每周酒精摄入量低于140克（<2个标准饮酒单位/天），男性低于210克（<3个标准饮酒单位/天）。MASLD的其他风险因素包括高龄（≥50岁）和男性（男女比例约为2:1）。纤维化-4指数（一种结合了年龄、血清天冬氨酸转氨酶和丙氨酸转氨酶水平以及血小板计数的评分系统）和振动控制瞬时弹性成像（一种无创影像技术）常用于对MASLD患者的肝纤维化进行分期。心血管疾病是首要死因，其次是某些肝外癌症（主要为胃肠道癌、乳腺癌和妇科癌症）以及肝脏相关并发症，包括肝硬化、肝功能失代偿（腹水、肝性脑病或静脉曲张出血）和肝细胞癌。MASLD的一线治疗涉及行为干预（包括低热量、低碳水化合物和低脂肪饮食，体育锻炼，以及戒酒）和对2型糖尿病、肥胖症、高血压和高脂血症的管理。对于体重指数大于35的MASLD患者，应考虑进行减重手术。瑞司美替罗（一种肝脏靶向的甲状腺激素受体β选择性激动剂）和皮下注射司美格鲁肽（一种胰高血糖素样肽-1受体激动剂）已获得美国食品药品监督管理局（FDA）的有条件批准，用于治疗伴有中度至重度纤维化的成人MASH患者。

结论：MASLD是全球成年人中一种高度流行的疾病，与肝脏相关并发症、肝细胞癌、心血管疾病和某些肝外癌症相关。一线治疗包括行为干预，涵盖减轻体重的饮食、体育锻炼和戒酒。瑞司美替罗和司美格鲁肽是FDA有条件批准的药物，用于治疗伴有中度至重度纤维化的成人MASH患者。

### 第二部分 AI 大师评价

该篇发表于《美国医学会杂志》的综述系统性地阐述了成人代谢功能障碍相关脂肪性肝病（MASLD）的流行病学、诊断标准、风险因素、临床结局及治疗策略。文章重点强调了MASLD与代谢综合征的密切关联及其导致的肝内外严重并发症，并总结了从生活方式干预到减重手术的阶梯式管理方案。此文的突出价值在于及时整合了最新获批药物（如瑞司美替罗和司美格鲁肽）的临床应用信息，为临床医生提供了关于这一全球高发疾病的权威、前沿的诊疗指导，具有重要的临床参考意义。

---

## 47. 耐药胶质母细胞瘤的半胱氨酸成瘾性及其通过特制硒化合物的靶向治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212520](https://pubmed.ncbi.nlm.nih.gov/41212520)
**期刊：** Neuro-oncology
**PMID：** 41212520
**DOI：** 10.1093/neuonc/noaf265

### 第一部分 原文与翻译

**英文原标题：** Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds.

**英文摘要原文：**
BACKGROUND: Cysteine is a multifunctional amino acid that can be oxidized affecting disulfide bond formation, redox signaling, and protein function. Reactive oxygen species (ROS) and the metabolic environment dictate cysteine uptake and oxidation status - especially in redox sensitive pathways. As many chemotherapeutic agents increase ROS, including the standard for glioblastoma (GBM), temozolomide (TMZ), we hypothesized that TMZ-resistant (TMZ-R) GBM would have increased ROS affecting cysteine reactivity that could be therapeutically targeted.

METHODS: Here, to study the metabolic state within drug sensitive and resistant GBM, we used metabolite tracing with 13C-Cyst(e)ine, specialized cysteine reactivity proteomics and CRISPR screening with drug treatments to determine the efficacy of targeting cysteine metabolic pathways with our designer selenium drug in both patient derived cell lines and patient derived xenograft GBM orthotopic models.

RESULTS: We show that TMZ-R have increased cyst(e)ine uptake, cysteine reactivity, and sensitivity to selenium (Se)-containing compounds - which can bind cysteine - in vitro and in vivo. We show that in TMZ-R models selenium compound treatment increases the need for thioredoxin reductases where co-treatment of Se compounds and the thioredoxin inhibitor auranofin significantly improves overall survival in mouse models.

CONCLUSIONS: Overall, our findings show a unique metabolic environment in TMZ-R models where designer brain penetrant Se-containing compounds target cysteine reactivity within proteins necessary for cancer cell survival and hold therapeutic potential.

**中文摘要译文：**
背景：半胱氨酸是一种多功能氨基酸，其氧化可影响二硫键的形成、氧化还原信号传导及蛋白质功能。活性氧（ROS）和代谢环境决定了半胱氨酸的摄取和氧化状态——尤其是在氧化还原敏感通路中。由于包括胶质母细胞瘤（GBM）标准治疗药物替莫唑胺（TMZ）在内的许多化疗药物会增加活性氧，我们假设耐替莫唑胺（TMZ-R）的GBM会因活性氧增加而影响半胱氨酸的反应性，从而可被作为治疗靶点。

方法：在本研究中，为探究药物敏感和耐药GBM的代谢状态，我们利用13C-胱氨酸/半胱氨酸进行代谢物追踪，结合特异性半胱氨酸反应性蛋白质组学和CRISPR筛选，在患者来源的细胞系和患者来源的异种移植GBM原位模型中，评估我们设计的硒药物靶向半胱氨酸代谢通路的疗效。

结果：我们发现，在体外和体内模型中，耐替莫唑胺的GBM表现出增加的胱氨酸/半胱氨酸摄取、更高的半胱氨酸反应性，以及对可与半胱氨酸结合的含硒（Se）化合物的敏感性增强。我们证明，在耐替莫唑胺模型中，硒化合物治疗增加了细胞对硫氧还蛋白还原酶的需求，因此联合使用硒化合物与硫氧还蛋白抑制剂金诺芬能显著提高小鼠模型的总生存期。

结论：总而言之，我们的研究结果揭示了耐替莫唑胺GBM模型中独特的代谢环境，其中特制的、可穿透血脑屏障的含硒化合物能靶向癌细胞生存所必需蛋白质中的半胱氨酸反应性，展现出巨大的治疗潜力。

### 第二部分 AI 大师评价

本研究聚焦于耐药胶质母细胞瘤（GBM）的关键难题，创新性地提出了“半胱氨酸成瘾”这一代谢脆弱性。研究通过代谢追踪和蛋白质组学等前沿技术，证实了耐替莫唑胺的GBM对半胱氨酸摄取和反应性存在高度依赖。其核心发现是，特制的脑渗透性硒化合物能有效靶向这一特性，并与硫氧还蛋白抑制剂产生协同效应，为克服GBM耐药性提供了一种全新的、具有临床转化潜力的靶向治疗策略。

---

## 48. MEN1/DAXX/ATRX突变的胰腺神经内分泌肿瘤分子亚型可解释其生物学差异性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212394](https://pubmed.ncbi.nlm.nih.gov/41212394)
**期刊：** Endocrine pathology
**PMID：** 41212394
**DOI：** 10.1007/s12022-025-09889-6

### 第一部分 原文与翻译

**英文原标题：** Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability.

**英文摘要原文：**
About 40% of non-functioning (NF) Pancreatic Neuroendocrine Tumors (PanNETs) harbour mutations in MEN1, often co-occurring with DAXX/ATRX. While the ADM group (MEN1 and DAXX/ATRX co-mutated) exhibits homogeneous genetic and epigenetic features and a consistent risk of relapse, it shows considerable variability in treatment response, suggesting an underlying molecular diversity. In this study we aimed to elucidate the molecular mechanisms underlying this heterogeneity of ADM PanNETs by integrating transcriptomic (n = 36) and DNA methylation (n = 93) data. First, DNA methylation discriminates ADM-PanNET from PanNET mutated only in MEN1 (α-like), revealing enhancer, peri-centromeric, and telomeric methylation changes associated with alternative lengthening of telomeres and increased chromosomal instability. Transcriptomic analysis further revealed three distinct ADM subtypes: ADM hypoxic, ADM NST (No Special Type), and ADM immunosuppressive. The ADM hypoxic subtype is characterized by strong hypoxia signature, likely regulated epigenetically. The ADM NST subtype appears to be primarily driven by epigenetic changes that promote proliferation. Notably, the ADM immunosuppressive subtype, although significantly smaller (< 2.5 cm, p = 0.023), exhibits strong immune and metastasis-like signatures, suggesting a uniquely aggressive biology despite its reduced size. By defining these three novel ADM subtypes, our study provides a refined framework for understanding PanNET heterogeneity. This classification underscores potential diagnostic markers and highlights distinct biological vulnerabilities that may inform the development of subtype-tailored therapeutic strategies.

**中文摘要译文：**
约40%的无功能性胰腺神经内分泌肿瘤（PanNETs）存在MEN1基因突变，且常与DAXX/ATRX突变同时发生。尽管ADM组（MEN1和DAXX/ATRX共突变）在遗传和表观遗传特征上表现出同质性，且复发风险一致，但其治疗反应却存在显著差异，这提示其背后存在潜在的分子多样性。本研究旨在通过整合转录组学（n = 36）和DNA甲基化（n = 93）数据，阐明导致ADM PanNETs异质性的分子机制。首先，DNA甲基化分析可将ADM-PanNET与仅有MEN1突变的PanNET（α-样）区分开来，揭示了与端粒替代性延长和染色体不稳定性增加相关的增强子、着丝粒周围和端粒区域的甲基化变化。转录组学分析进一步揭示了三种不同的ADM亚型：ADM缺氧型、ADM非特殊型（NST）和ADM免疫抑制型。ADM缺氧型亚型的特点是具有强烈的缺氧信号特征，这可能受到表观遗传调控。ADM非特殊型亚型似乎主要由促进增殖的表观遗传学变化所驱动。值得注意的是，ADM免疫抑制型亚型虽然肿瘤体积显著较小（< 2.5 cm, p = 0.023），但表现出强烈的免疫和转移样信号特征，表明尽管尺寸较小，其仍具有独特的侵袭性生物学行为。通过定义这三种新的ADM亚型，本研究为理解PanNET的异质性提供了一个更为精细的框架。这一分类不仅凸显了潜在的诊断标志物，也揭示了不同的生物学弱点，可为制定针对特定亚型的治疗策略提供信息。

### 第二部分 AI 大师评价

该研究旨在揭示MEN1/DAXX/ATRX共突变（ADM）的胰腺神经内分泌肿瘤（PanNETs）内部存在的分子异质性。通过整合转录组与DNA甲基化多组学数据，研究团队成功将ADM型PanNETs划分为三种全新的分子亚型：缺氧型、非特殊型和免疫抑制型。这一发现极具创新性，它不仅解释了为何同一遗传背景的肿瘤在临床上表现各异，更重要的是，为开发针对不同亚型生物学特性的精准诊断标志物和靶向治疗策略奠定了坚实基础，对推动PanNETs的个体化治疗具有重要价值。

---

## 49. 通过HER2表达缺失和结合丧失介导的德曲妥珠单抗(T-DXd)耐药机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212147](https://pubmed.ncbi.nlm.nih.gov/41212147)
**期刊：** Cancer discovery
**PMID：** 41212147
**DOI：** 10.1158/2159-8290.CD-25-0647

### 第一部分 原文与翻译

**英文原标题：** Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding.

**英文摘要原文：**
T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mechanisms. Through a molecular characterization of paired pre- and post-T-DXd treatment patient specimens, we found that 49% cases had major decreases in HER2 expression at progression, among them, 52% exhibited complete HER2 loss. Using isogenic model systems, we demonstrated that decreases in HER2 expression corresponded to reductions in T-DXd internalization and major increases in drug IC50 for tumor growth inhibition. We further identified and validated HER2 mutations in the trastuzumab binding interface (V597M and P593R) that promoted T-DXd resistance. As a strategy to overcome impaired T-DXd binding and internalization, we tested low dose combinations of T-DXd with TROP2-directed ADCs and found these could more uniformly deliver DXd payloads and thereby overcome resistance mediated by HER2 loss.

**中文摘要译文：**
在HER2阳性和HER2低表达的转移性乳腺癌中，德曲妥珠单抗（T-DXd）具有显著的临床益处。然而，大多数患者随着时间的推移会出现治疗耐药，但其耐药机制尚不明确。通过对T-DXd治疗前后的配对患者样本进行分子特征分析，我们发现49%的病例在疾病进展时HER2表达显著下降，其中52%的病例表现为HER2完全丧失。利用同基因模型系统，我们证明了HER2表达的下降与T-DXd内化减少以及肿瘤生长抑制的药物IC50值显著增加相关。我们进一步鉴定并验证了曲妥珠单抗结合界面上的HER2突变（V597M和P593R），这些突变促进了T-DXd的耐药。作为一种克服T-DXd结合与内化受损的策略，我们测试了低剂量T-DXd与靶向TROP2的ADC药物的组合，发现这种组合能更均匀地递送DXd载荷，从而克服由HER2丢失介导的耐药。

### 第二部分 AI 大师评价

本研究精准地探讨了德曲妥珠单抗(T-DXd)在乳腺癌治疗中出现耐药的关键机制。通过分析临床配对样本并结合同基因模型，研究有力地揭示了HER2表达的下调乃至完全丧失是导致耐药的主要原因，并鉴定出影响药物结合的关键HER2突变。该研究的创新之处在于不仅阐明了耐药的分子基础，还前瞻性地提出了联合靶向TROP2的ADC药物作为克服耐药的潜在策略，为后续的临床研究和联合用药方案设计提供了重要的实验依据和新思路。

---

## 50. 在伴有晚期慢性肝病的代谢功能障碍相关脂肪性肝病患者中，ANTICIPATE-NASH模型在临床事件风险分层方面优于组织学评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41212130](https://pubmed.ncbi.nlm.nih.gov/41212130)
**期刊：** Gastroenterology
**PMID：** 41212130
**DOI：** 10.1053/j.gastro.2025.08.020

### 第一部分 原文与翻译

**英文原标题：** The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.

**英文摘要原文：**
BACKGROUND & AIMS: The reference for risk stratification and clinical trial selection of metabolic dysfunction-associated steatotic liver disease (MASLD) patients is fibrosis degree by histology. The noninvasive ANTICIPATE-NASH models have been validated for risk prediction of clinically significant portal hypertension (CSPH) and liver-related events (LRE). We assessed whether these models provide better risk stratification of events than histology.

METHODS: A multicenter cohort 1, including 699 biopsy specimen-proven F3-F4 patients with MASLD was evaluated. The end point was LRE (hepatic decompensation, hepatocellular carcinoma, transplantation, or liver-related death). We assessed (Cox regression) whether histology provided added value to ANTICIPATE-NASH and whether model predictions differed in F3/F4 patients. Results were validated in cohort 2 (1396 F3-F4 patients) from 4 clinical trials using the clinical regulatory end point.

RESULTS: In cohort 1, F3 and F4 were equally distributed. There were 56 LREs (8.0%) during follow-up, concentrated in F4 (51 LREs). The ANTICIPATE-NASH model showed excellent discrimination (C statistic, 0.93) for LRE, higher than histology (C statistic, 0.67). Model calibration was excellent. Adding histology did not improve model prediction. Thresholds of ANTICIPATE-NASH above which F3 patients developed LREs and below which F4 patients did not were identified. Results were reproduced in cohort 2 with the regulatory end point, with higher model discrimination (C statistic, 0.84) compared with histology (C statistic, 0.64).

CONCLUSIONS: In MASLD patients with F3/F4, the noninvasive ANTICIPATE-NASH models provide better risk stratification of clinical events than histologic classification. These models could be very useful for clinical trials by selecting patients at risk of clinical events and patients with higher chances of observed cirrhosis regression.

**中文摘要译文：**
背景与目的：对代谢功能障碍相关脂肪性肝病（MASLD）患者进行风险分层和临床试验筛选的参考标准是组织学纤维化分级。无创ANTICIPATE-NASH模型已在预测临床显著性门脉高压（CSPH）和肝脏相关事件（LRE）风险方面得到验证。我们旨在评估这些模型是否比组织学提供更好的事件风险分层。

方法：本研究评估了一个多中心队列1，共纳入699名经活检证实的F3-F4期MASLD患者。研究终点为肝脏相关事件（LRE），包括肝功能失代偿、肝细胞癌、肝移植或肝脏相关死亡。我们采用Cox回归分析评估了组织学检查是否为ANTICIPATE-NASH模型提供了附加价值，以及模型的预测在F3/F4期患者中是否存在差异。研究结果在一个包含来自4项临床试验的1396名F3-F4期患者的队列2中，使用临床监管终点进行了验证。

结果：在队列1中，F3和F4期患者分布均等。随访期间共发生56例LRE（8.0%），主要集中在F4期患者中（51例）。ANTICIPATE-NASH模型对LRE表现出卓越的区分度（C统计量为0.93），高于组织学（C统计量为0.67）。模型的校准度表现优异。添加组织学信息并未改善模型的预测性能。研究确定了ANTICIPATE-NASH模型的阈值，高于该阈值的F3期患者会发生LRE，而低于该阈值的F4期患者则不会。这些结果在队列2中利用监管终点得到了重现，模型的区分度（C统计量为0.84）同样高于组织学（C统计量为0.64）。

结论：在F3/F4期的MASLD患者中，无创ANTICIPATE-NASH模型在临床事件风险分层方面优于组织学分类。这些模型通过筛选具有临床事件风险的患者以及更有可能观察到肝硬化逆转的患者，可能对临床试验非常有用。

### 第二部分 AI 大师评价

该研究的核心目的在于，比较无创ANTICIPATE-NASH模型与传统的组织学评估，在晚期（F3/F4期）代谢功能障碍相关脂肪性肝病（MASLD）患者中对临床事件风险分层能力的优劣。通过对两个大规模多中心队列的分析，研究关键发现ANTICIPATE-NASH模型在预测肝脏相关事件方面的区分度显著优于组织学（C统计量更高）。此项研究的创新价值在于，它为临床实践和新药临床试验提供了一个更精准、无创的风险评估工具，有望替代有创的肝活检来筛选高风险患者，从而优化患者管理和试验效率。

---

## 51. 癌症研究中的观点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41100095](https://pubmed.ncbi.nlm.nih.gov/41100095)
**期刊：** JAMA
**PMID：** 41100095
**DOI：** 10.1001/jama.2024.18984

### 第一部分 原文与翻译

**英文原标题：** Views in the Study of Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据该文献标题及摘要的缺失，本文很可能是一篇述评、社论或观点性文章，而非原创性研究。其核心目的似乎是为癌症研究领域提供宏观的见解或特定的视角，可能探讨了当前研究的方向、挑战或未来趋势。此类文章的价值在于激发学术思考与讨论，引导学界关注某些关键问题，但它本身不提供新的实验数据或研究结果，因此其具体影响需结合全文内容进行判断。

---

## 52. 勘误：Avutometinib ± Defactinib治疗复发性低级别浆液性卵巢癌的疗效与安全性：ENGOT-OV60/GOG-3052/RAMP 201研究的初步分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082694](https://pubmed.ncbi.nlm.nih.gov/41082694)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41082694
**DOI：** 10.1200/JCO-25-02377

### 第一部分 原文与翻译

**英文原标题：** Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇勘误声明，旨在修正已发表的ENGOT-OV60/GOG-3052/RAMP 201研究的初步分析结果。由于没有提供原文摘要，无法对研究的具体方法和发现进行详细评价。然而，从标题可知，原研究聚焦于评估Avutometinib联合或不联合Defactinib治疗复发性低级别浆液性卵巢癌的疗效与安全性，这对于探索该罕见卵巢癌亚型的新型靶向治疗策略具有重要的临床意义。勘误的发布本身也体现了科研过程的严谨性与自我修正机制。

---

## 53. 劳动年龄成年人中筛查发现的心房颤动及其心血管结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40995626](https://pubmed.ncbi.nlm.nih.gov/40995626)
**期刊：** Circulation
**PMID：** 40995626
**DOI：** 10.1161/CIRCULATIONAHA.125.074433

### 第一部分 原文与翻译

**英文原标题：** Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults.

**英文摘要原文：**
BACKGROUND: Early detection of atrial fibrillation (AF) is essential for preventing ischemic stroke and other cardiovascular complications. However, the incidence and prognosis of AF in the general middle-aged population remain unclear. In Japan, annual health screenings for employees include mandatory ECGs, offering a unique opportunity to fill this evidence gap.

METHODS: This retrospective cohort study aimed to evaluate the incidence and subsequent cardiovascular outcomes of screening-detected AF in the general working population in Japan, using the Japan Health Insurance Association database, which covers one-quarter of the working-age population of the country. From individuals 35 to 59 years of age who underwent annual health screenings between April 2015 and March 2020, excluding those with a history of cardiovascular disease, those with initial AF detection upon screening ECGs were identified. The primary outcome was hospitalization for ischemic stroke. The secondary outcomes were all-cause death and hospitalization for heart failure. The association between screening-detected AF and outcomes was evaluated using adjusted subdistribution hazard models compared with matched controls.

RESULTS: Among 9.5 million individuals included in our study, 11 790 initial AF cases (42.4 of 100 000 person-years [95% CI, 41.6-43.1]) were detected. Individuals with AF were older (mean age, 50.9 versus 46.3 years) and more likely to be men (91.6% versus 63.6%) compared with non-AF cases. Among these individuals with screening-detected AF, the 3-year incidences of ischemic stroke, all-cause death, and heart failure were 1.83% (95% CI, 1.57-2.09), 0.78% (95% CI, 0.61-0.95), and 3.87% (95% CI, 3.50-4.24), respectively. Compared with age- and sex-matched controls, individuals with AF had a higher risk of incident ischemic stroke (hazard ratio, 5.38 [95% CI, 4.51-6.42]), all-cause death (hazard ratio, 1.98 [95% CI, 1.66-2.36]), and heart failure (hazard ratio, 18.35 [95% CI, 15.10-22.31]).

CONCLUSIONS: AF was detected in 1 of every 2400 screening ECGs among the middle-aged population in Japan, with higher relative risks of ischemic stroke and heart failure, compared with those without AF. These findings highlight the association of screening-detected AF with stroke and heart failure, warranting further study into AF as an early sign of heart failure and optimal cardiovascular risk reduction strategies after AF detection in the general middle-aged population.

**中文摘要译文：**
背景：早期发现心房颤动（AF）对于预防缺血性卒中和其他心血管并发症至关重要。然而，普通中年人群中房颤的发生率和预后尚不明确。在日本，员工的年度健康筛查包括强制性心电图检查，这为填补这一证据空白提供了独特的机会。

方法：本项回顾性队列研究旨在使用覆盖了日本四分之一劳动年龄人口的日本健康保险协会数据库，评估日本普通劳动人群中筛查发现的房颤的发生率及其后续心血管结局。研究从2015年4月至2020年3月期间接受年度健康筛查的35至59岁个体中，排除了有心血管疾病史的患者，并筛选出在筛查心电图上首次检测到房颤的个体。主要结局为因缺血性卒中住院。次要结局为全因死亡和因心力衰竭住院。研究采用调整后的亚分布风险模型，与匹配的对照组进行比较，评估了筛查发现的房颤与各结局之间的关联。

结果：在我们研究纳入的950万个体中，共检测到11790例初发房颤病例（发生率为每10万人年42.4例[95% CI, 41.6-43.1]）。与非房颤者相比，房颤患者年龄更大（平均年龄50.9岁 vs 46.3岁），且男性比例更高（91.6% vs 63.6%）。在这些筛查发现的房颤患者中，缺血性卒中、全因死亡和心力衰竭的3年发生率分别为1.83%（95% CI, 1.57-2.09）、0.78%（95% CI, 0.61-0.95）和3.87%（95% CI, 3.50-4.24）。与年龄和性别匹配的对照组相比，房颤患者发生缺血性卒中（风险比，5.38 [95% CI, 4.51-6.42]）、全因死亡（风险比，1.98 [95% CI, 1.66-2.36]）和心力衰竭（风险比，18.35 [95% CI, 15.10-22.31]）的风险更高。

结论：在日本中年人群中，每2400次筛查心电图中有1次可检测到房颤，且与无房颤者相比，房颤患者发生缺血性卒中和心力衰竭的相对风险更高。这些发现强调了筛查发现的房颤与卒中及心力衰竭的关联，提示需要进一步研究将房颤作为心力衰竭的早期迹象，并探索在中年人群中发现房颤后最佳的心血管风险降低策略。

### 第二部分 AI 大师评价

本研究基于日本大规模全国性数据库，首次深入探讨了劳动年龄人群中通过筛查发现的心房颤动的发生率及其心血管预后。研究关键发现，筛查出的房颤患者，即使在相对年轻的群体中，其未来发生缺血性卒中、全因死亡，特别是心力衰竭的风险也显著升高，后者的风险比高达18倍以上。此项研究的创新之处在于利用了日本独特的强制性心电图筛查政策，为早期发现房颤的临床意义提供了强有力的真实世界证据，并强调了将筛查所见的房颤视为心衰早期预警信号的重要性，对公共卫生策略制定具有重要参考价值。

---

## 54. 用于肌层浸润性膀胱癌患者的新一代保留膀胱围手术期试验的终点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40934451](https://pubmed.ncbi.nlm.nih.gov/40934451)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40934451
**DOI：** 10.1200/JCO-25-01608

### 第一部分 原文与翻译

**英文原标题：** End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

**英文摘要原文：**
PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To establish standardized outcome measures for evaluating organ preservation strategies in MIBC, the International Bladder Cancer Group (IBCG) and the Global Society of Rare Genitourinary Tumors (GSRGT) assembled an international, multidisciplinary consensus panel.

METHODS: The IBCG and GSRGT gathered global bladder cancer experts and patient advocates to establish a framework for risk-adapted bladder-sparing treatment approaches for MIBC. Working groups reviewed the literature and developed draft recommendations, which were discussed at a live meeting in December 2024 in Milan. This was followed by voting by the members using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented.

RESULTS: Clinical complete response (cCR) definition should encompass the absence of high-grade malignancy on pathology and malignant cells on urine cytology and no evidence of local or metastatic disease on cross-sectional imaging. Although cCR remains immature as a primary or coprimary end point in registrational trials, it could serve as a suitable end point in early-phase studies and risk-adapted investigations. Event-free survival (EFS) remains the preferred primary end point as it could reliably capture the durability of clinically meaningful benefit after omittance of surgical consolidation or chemoradiation. Given the composite nature of EFS, events should be prespecified, evaluated in an intention-to-treat approach, and meticulously collected. Continuous assessment of individual patient preferences should begin at the outset of perioperative therapy discussions, with informed decision making prioritized throughout.

CONCLUSION: The consensus definition of cCR and the framework presented in this study can serve as a foundation for thorough testing of risk-adapted bladder-sparing treatment paradigms for MIBC.

**中文摘要译文：**
目的：肌层浸润性膀胱癌（MIBC）不断演变的治疗格局日益需要新颖的试验设计，以评估旨在保留膀胱的围手术期策略。为建立评估MIBC器官保留策略的标准化结局指标，国际膀胱癌协作组（IBCG）和全球罕见泌尿生殖系统肿瘤学会（GSRGT）组建了一个国际性、多学科的共识专家组。

方法：IBCG和GSRGT召集了全球膀胱癌专家和患者权益倡导者，旨在为MIBC的风险适应性膀胱保留治疗方法建立一个框架。工作组回顾了相关文献并制定了建议草案，这些草案在2024年12月于米兰举行的一次现场会议上进行了讨论。随后，成员们采用改良的德尔菲法进行了投票。会议期间达成≥75%共识的建议得到了进一步完善和呈报。

结果：临床完全缓解（cCR）的定义应包括病理学未见高级别恶性肿瘤、尿细胞学未见恶性细胞，以及断面影像学未见局部或转移性病变证据。尽管cCR作为注册性试验的主要或联合主要终点尚不成熟，但它可以作为早期研究和风险适应性研究的合适终点。无事件生存期（EFS）仍然是首选的主要终点，因为它能可靠地捕捉到在省略巩固性手术或放化疗后具有临床意义的获益的持久性。鉴于EFS的复合性质，应预先规定事件，采用意向性治疗方法进行评估，并进行细致的数据收集。对个体患者偏好的持续评估应从围手术期治疗讨论之初就开始，并在整个过程中优先考虑知情决策。

结论：本研究中提出的cCR共识定义及框架，可为全面检验MIBC风险适应性膀胱保留治疗模式奠定基础。

### 第二部分 AI 大师评价

该研究通过国际多学科专家共识，为肌层浸润性膀胱癌（MIBC）保留膀胱的围手术期临床试验终点设定了标准化框架。其核心贡献在于明确定义了临床完全缓解（cCR）的概念，并确立了无事件生存期（EFS）作为首选主要终点，为评估新疗法提供了统一标准。这项工作对推动风险适应性膀胱保留策略的临床研究具有重要指导意义，有助于规范未来试验设计，确保研究结果的可比性与可靠性，最终惠及寻求保留器官功能的患者。

---

## 55. 左主干PCI术后：计算机断层扫描血管造影还是标准治疗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40886174](https://pubmed.ncbi.nlm.nih.gov/40886174)
**期刊：** Journal of the American College of Cardiology
**PMID：** 40886174
**DOI：** 10.1016/j.jacc.2025.07.060

### 第一部分 原文与翻译

**英文原标题：** Computed Tomography Angiography or Standard Care After Left Main PCI?

**英文摘要原文：**
BACKGROUND: The clinical benefit of routine coronary computed tomography angiography (CCTA) after percutaneous coronary intervention (PCI) for unprotected left main (LM) disease is uncertain.

OBJECTIVES: The authors evaluated whether CCTA-guided follow-up improves clinical outcomes vs symptoms- or ischemia-driven care after LM PCI.

METHODS: PULSE was a prospective, multicenter, open-label randomized trial. A total of 606 patients treated with second-generation drug-eluting stents were enrolled (October 2019 to September 2024) and randomized 1:1 to CCTA at 6 months (experimental) or standard care (control). The primary endpoint was a composite of all-cause death, spontaneous myocardial infarction (MI), unstable angina, or definite or probable stent thrombosis at 18 months. Secondary endpoints included target-lesion revascularization (TLR) and each primary endpoint component.

RESULTS: CCTA was completed in 272/303 experimental patients (89.8%) after a median of 200 days (IQR: 181-270 days). The primary endpoint occurred in 36/303 experimental patients vs 38/303 control patients (11.9% vs 12.5%; HR: 0.97; 95% CI: 0.76-1.23; P = 0.80). Compared with the control arm, the CCTA arm showed a reduced risk of spontaneous myocardial infarction (MI) (0.9% vs 4.9%; HR: 0.26; 95% CI: 0.07-0.91; P = 0.004) and an increased risk of imaging-triggered TLR (4.9% vs 0.3%; HR: 7.7; 95% CI: 1.70-33.7; P = 0.001), whereas clinically driven TLR rates were similar (5.3% vs 7.2%; HR: 0.74; 95% CI: 0.38-1.41; P = 0.32).

CONCLUSIONS: Routine CCTA after LM PCI did not reduce the composite primary endpoint, but was associated with fewer spontaneous MIs and more imaging-triggered revascularizations. Future trials to clarify its value in complex anatomic subsets appear to be warranted. (Angiographic Control vs Ischemia-Driven Management of Patients Treated With PCI on Left Main With Drug-Eluting Stents [PULSE; NCT04144881]).

**中文摘要译文：**
背景：对于无保护左主干（LM）病变行经皮冠状动脉介入治疗（PCI）后，常规进行冠状动脉计算机断层扫描血管造影（CCTA）的临床获益尚不明确。

目的：本研究旨在评估与症状或缺血驱动的治疗相比，CCTA引导的随访能否改善LM PCI术后患者的临床结局。

方法：PULSE是一项前瞻性、多中心、开放标签的随机试验。共纳入606名接受第二代药物洗脱支架治疗的患者（2019年10月至2024年9月），并以1:1的比例随机分为6个月时接受CCTA检查（试验组）或标准治疗（对照组）。主要终点为18个月时全因死亡、自发性心肌梗死（MI）、不稳定性心绞痛或确切或可能的支架内血栓形成的复合终点。次要终点包括靶病变血运重建（TLR）及主要终点中的各单个组分。

结果：试验组303名患者中有272名（89.8%）完成了CCTA检查，中位检查时间为200天（IQR: 181-270天）。试验组303名患者中有36名达到主要终点，对照组303名患者中有38名（11.9% vs 12.5%；HR: 0.97；95% CI: 0.76-1.23；P = 0.80）。与对照组相比，CCTA组的自发性心肌梗死（MI）风险降低（0.9% vs 4.9%；HR: 0.26；95% CI: 0.07-0.91；P = 0.004），而影像学触发的靶病变血运重建（TLR）风险增加（4.9% vs 0.3%；HR: 7.7；95% CI: 1.70-33.7；P = 0.001），但临床驱动的TLR率相似（5.3% vs 7.2%；HR: 0.74；95% CI: 0.38-1.41；P = 0.32）。

结论：LM PCI术后常规行CCTA并未降低复合主要终点事件的发生率，但与更少的自发性心肌梗死和更多的影像学触发的血运重建相关。未来有必要开展试验，以阐明其在复杂解剖亚组中的价值。（PULSE试验；NCT04144881，血管造影控制与缺血驱动管理的左主干药物洗脱支架PCI术后患者研究）。

### 第二部分 AI 大师评价

本研究通过一项前瞻性多中心随机对照试验（PULSE），旨在探讨左主干PCI术后常规行CCTA随访是否优于标准治疗。研究关键发现，尽管常规CCTA未能降低主要复合终点事件的总体风险，但它显著减少了自发性心肌梗死的发生，同时增加了影像学触发的血运重建。这一结果揭示了常规影像学检查在预防硬终点事件（如心梗）方面的潜在价值，也提示了其可能导致更多的干预措施。该研究为高危PCI患者的术后管理策略提供了重要的循证依据，并指出了未来在特定复杂病变亚组中进一步探索的方向。

---

## 56. 粪菌移植口服递送的转化策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40301116](https://pubmed.ncbi.nlm.nih.gov/40301116)
**期刊：** Gut
**PMID：** 40301116
**DOI：** 10.1136/gutjnl-2025-335077

### 第一部分 原文与翻译

**英文原标题：** Translational strategies for oral delivery of faecal microbiota transplantation.

**英文摘要原文：**
Faecal microbiota transplantation (FMT) has emerged as a transformative therapy for  infections and shows promise for various GI and systemic diseases. However, the poor patient acceptability and accessibility of 'conventional' FMT, typically administered via colonoscopies or enemas, hinders its widespread clinical adoption, particularly for chronic conditions. Oral administration of FMT (OralFMT) overcomes these limitations, yet faces distinct challenges, including a significant capsule burden, palatability concerns and poor microbial viability during gastric transit. This review provides a comprehensive analysis of emerging strategies that aim to advance OralFMT by: (1) refining processing technologies (eg, lyophilisation) that enable manufacturing of low-volume FMT formulations for reducing capsule burden and (2) developing delivery technologies that improve organoleptic acceptability and safeguard the microbiota for targeted colonic release. These advancements present opportunities for OralFMT to expand its therapeutic scope, beyond  infections, towards chronic GI conditions requiring frequent dosing regimens. While this review primarily focuses on optimising OralFMT delivery, it is important to contextualise these advancements within the broader shift towards defined microbial consortia. Live biotherapeutic products (LBPs) offer an alternative approach, yet the interplay between OralFMT and LBPs in clinical practice remains unresolved. We postulate that continued innovation in OralFMT and LBPs via a multidisciplinary approach can further increase therapeutic efficacy and scalability by enabling disease site targeting, co-delivery of therapeutic compounds and overcoming colonisation resistance. Realising these goals positions OralFMT as a cornerstone of personalised care across a range of diseases rooted in microbiome health.

**中文摘要译文：**
粪菌移植（FMT）已成为艰难梭菌感染的一种革命性疗法，并对多种胃肠道及全身性疾病显示出应用前景。然而，传统FMT（通常通过结肠镜或灌肠给药）的患者接受度和可及性较差，这阻碍了其广泛的临床应用，尤其是在慢性疾病中。口服FMT（OralFMT）克服了这些局限性，但仍面临独特的挑战，包括显著的胶囊负担、适口性问题以及菌群在胃部转运过程中的存活率低。本篇综述全面分析了旨在推动口服FMT发展的各项新兴策略，具体包括：（1）改进加工技术（如冻干技术），以生产小体积FMT制剂，从而减轻胶囊负担；（2）开发递送技术，以改善感官接受度并保护菌群，实现结肠靶向释放。这些进展为口服FMT提供了机遇，使其治疗范围得以从艰难梭菌感染扩展至需要频繁给药方案的慢性胃肠道疾病。虽然本综述主要关注优化口服FMT的递送方式，但将这些进展置于向明确的微生物菌群发展的更广阔背景下进行探讨至关重要。活体生物治疗产品（LBPs）提供了另一种方法，但口服FMT与LBPs在临床实践中的相互作用关系仍有待阐明。我们推断，通过多学科方法在口服FMT和LBPs领域持续创新，可以通过实现病变部位靶向、治疗性化合物的共同递送以及克服定植抵抗，进一步提高治疗效果和可扩展性。实现这些目标将使口服FMT成为一系列源于微生物组健康的疾病的个性化治疗基石。

### 第二部分 AI 大师评价

该综述聚焦于粪菌移植（FMT）的口服递送这一关键转化领域，系统性地探讨了旨在克服传统FMT局限性的新兴策略。文章重点分析了通过改进加工技术（如冻干）以减少胶囊负担，以及开发新型递送技术以保护菌群活性并实现结肠靶向释放的解决方案。本综述不仅对当前技术进展进行了全面总结，还前瞻性地讨论了口服FMT与活体生物治疗产品（LBPs）的协同发展前景，为推动该疗法在慢性病管理中的广泛应用和实现个性化微生物组治疗提供了重要的思路和方向，具有很高的临床转化价值。

---

## 57. 开发与验证一种人工智能数字病理生物标志物：用于跨多项III期试验预测高风险前列腺癌男性患者从长期内分泌治疗联合放疗中的获益

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40239134](https://pubmed.ncbi.nlm.nih.gov/40239134)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40239134
**DOI：** 10.1200/JCO.24.00365

### 第一部分 原文与翻译

**英文原标题：** Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.

**英文摘要原文：**
PURPOSE: Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration.

METHODS: A multimodal artificial intelligence (MMAI)-derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks.

RESULTS: In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82],  < .001). A significant biomarker-treatment predictive interaction was observed ( = .04) for DM, whereby MMAI biomarker-positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73],  < .001), whereas no treatment benefit was observed for MMAI biomarker-negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84],  = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker-positive men and 0% in MMAI biomarker-negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19],  < .001).

CONCLUSION: To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

**中文摘要译文：**
目的：长期雄激素剥夺治疗（ADT）可改善接受放射治疗（RT）的高风险局限性前列腺癌（PCa）男性患者的生存率。目前需要预测性生物标志物来指导ADT的持续时间。

方法：本研究利用来自六项NRG肿瘤学III期随机放疗试验的治疗前数字前列腺活检图像和临床数据（年龄、前列腺特异性抗原、格里森评分和T分期），训练了一种多模态人工智能（MMAI）衍生的预测性生物标志物，用于区分长期（LT）与短期（ST）ADT的疗效。这款新型MMAI衍生生物标志物旨在预测长期ADT对主要终点——远处转移（DM）的差异化获益。该MMAI生物标志物的预测效用在第七项随机试验RTOG 9202（N = 1,192）中得到验证，该试验将男性患者随机分配至RT + ST-ADT（4个月）组与RT + LT-ADT（28个月）组。研究对远处转移（DM）以及次要终点“因DM死亡”进行了Fine-Gray和累积发生率分析。将非因DM导致的死亡视为竞争风险。

结果：在验证队列中（中位随访时间17.2年），长期ADT显著将远处转移率从26%降低至17%（亚分布风险比[sHR]为0.64 [95% CI, 0.50至0.82]，P < .001）。在远处转移方面，观察到显著的生物标志物-治疗预测性交互作用（P = .04），其中MMAI生物标志物阳性男性（n = 785, 66%）接受长期ADT相比短期ADT后远处转移减少（sHR, 0.55 [95% CI, 0.41至0.73]，P < .001），而在MMAI生物标志物阴性男性中未观察到治疗获益（n = 407; sHR, 1.06 [95% CI, 0.61至1.84]，P = .84）。在MMAI生物标志物阳性男性中，RT + LT-ADT与RT + ST-ADT之间的15年远处转移风险差异估计为14%，而在MMAI生物标志物阴性男性中为0%。无论接受何种治疗，该MMAI生物标志物对远处转移也具有预后价值（sHR, 2.35 [95% CI, 1.72至3.19]，P < .001）。

结论：据我们所知，该MMAI模型是首个经过验证的、可用于指导局限性/局部晚期前列腺癌患者接受放疗时ADT持续时间的预测性生物标志物。大约三分之一的高风险前列腺癌男性患者或可安全地免于额外24个月的ADT及其相关的发病风险。

### 第二部分 AI 大师评价

本研究旨在开发并验证一种多模态人工智能（MMAI）模型，以精准预测高风险前列腺癌患者能否从长期雄激素剥夺治疗（ADT）中获益。该研究创新性地结合了数字病理图像与临床数据，并在高级别的III期临床试验数据中进行了严格验证。其核心发现是，该模型能成功筛选出约三分之一的患者，他们接受短期ADT即可达到与长期ADT相似的疗效，这为实现个体化治疗决策、避免过度治疗及其带来的副作用提供了首个经过验证的有力工具，具有重大的临床转化潜力。

---

## 58. 用于通过数字病理学预测胃肠道癌症预后和辅助治疗获益的基础模型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40168636](https://pubmed.ncbi.nlm.nih.gov/40168636)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40168636
**DOI：** 10.1200/JCO-24-01501

### 第一部分 原文与翻译

**英文原标题：** Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers.

**英文摘要原文：**
PURPOSE: Artificial intelligence (AI) holds significant promise for improving cancer diagnosis and treatment. Here, we present a foundation AI model for prognosis prediction on the basis of standard hematoxylin and eosin-stained histopathology slides.

METHODS: In this multinational cohort study, we developed AI models to predict prognosis from histopathology images of patients with GI cancers. First, we trained a foundation model using over 130 million patches from 104,876 whole-slide images on the basis of self-supervised learning. Second, we fine-tuned deep learning models for predicting survival outcomes and validated them across seven cohorts, including 1,619 patients with gastric and esophageal cancers and 2,594 patients with colorectal cancer. We further assessed the model for predicting survival benefit from adjuvant chemotherapy.

RESULTS: The AI models predicted disease-free survival and disease-specific survival with a concordance index of 0.726-0.797 for gastric cancer and 0.714-0.757 for colorectal cancer in the validation cohorts. The models stratified patients into high-risk and low-risk groups, with 5-year survival rates of 49%-52% versus 76%-92% in gastric cancer and 43%-72% versus 81%-98% in colorectal cancer. In multivariable analysis, the AI risk scores remained an independent prognostic factor after adjusting for clinicopathologic variables. Compared with stage alone, an integrated model consisting of stage and image information improved prognosis prediction across all validation cohorts. Finally, adjuvant chemotherapy was associated with improved survival in the high-risk group but not in the low-risk group (treatment-model interaction  = .01 and .006) for stage II/III gastric and colorectal cancer, respectively.

CONCLUSION: The pathology foundation model can accurately predict survival outcomes and complement clinicopathologic factors in GI cancers. Pending prospective validation, it may be used to improve risk stratification and inform personalized adjuvant therapy.

**中文摘要译文：**
目的：人工智能（AI）在改善癌症诊断和治疗方面展现出巨大潜力。在此，我们提出一种基于标准苏木精-伊红染色组织病理学切片预测预后的人工智能基础模型。

方法：在这项多国队列研究中，我们开发了AI模型，用于通过胃肠道癌症患者的组织病理学图像预测预后。首先，我们基于自监督学习，使用来自104,876张全切片图像的超过1.3亿个图像块训练了一个基础模型。其次，我们微调了深度学习模型以预测生存结局，并在七个队列中进行了验证，其中包括1,619名胃癌和食管癌患者以及2,594名结直肠癌患者。我们进一步评估了该模型预测辅助化疗生存获益的能力。

结果：在验证队列中，AI模型预测胃癌的无病生存期和疾病特异性生存期的一致性指数为0.726-0.797，预测结直肠癌的为0.714-0.757。该模型将患者分为高风险组和低风险组，胃癌患者的5年生存率分别为49%-52%对76%-92%，结直肠癌患者则为43%-72%对81%-98%。在多变量分析中，经临床病理学变量校正后，AI风险评分仍是一个独立的预后因素。与单独使用分期相比，一个整合了分期和图像信息的模型在所有验证队列中均改善了预后预测。最后，对于II/III期胃癌和结直肠癌，辅助化疗与高风险组的生存改善相关，但在低风险组中则不然（治疗-模型交互作用P值分别为.01和.006）。

结论：该病理学基础模型能准确预测胃肠道癌症的生存结局，并对临床病理学因素形成补充。在获得前瞻性验证后，它或可用于改善风险分层，并为个体化辅助治疗提供信息。

### 第二部分 AI 大师评价

该研究构建并验证了一个基于海量数字病理图像的AI基础模型，旨在预测胃肠道癌症患者的预后并指导辅助治疗决策。其核心创新在于采用自监督学习方法训练通用型基础模型，再针对具体任务进行微调，展现了卓越的预后预测能力，其性能独立于并优于传统临床病理因素。该模型不仅能有效进行风险分层，还能识别出最可能从辅助化疗中获益的高风险患者，为实现精准的个体化治疗提供了极具价值的工具，未来经前瞻性研究证实后，有望深刻改变临床实践。

---

## 59. 连接肝细胞癌与髓源性抑制细胞并塑造免疫抑制性肿瘤微环境的ETV5-S100A9前馈环路

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40147932](https://pubmed.ncbi.nlm.nih.gov/40147932)
**期刊：** Gut
**PMID：** 40147932
**DOI：** 10.1136/gutjnl-2025-335078

### 第一部分 原文与翻译

**英文原标题：** ETV5-S100A9 feed-forward loop connecting HCC and MDSCs to shape the immunosuppressive tumour microenvironment.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究标题揭示了一个在肝细胞癌（HCC）中塑造免疫抑制微环境的关键分子机制。研究的核心在于阐明了ETV5和S100A9之间形成的前馈环路，该环路介导了肿瘤细胞与髓源性抑制细胞（MDSCs）的相互作用。此发现具有显著的创新性，因为它提出了一个全新的调控轴。尽管缺乏摘要信息无法评估其具体实验证据，但这一发现为理解HCC的免疫逃逸机制提供了新视角，并提示ETV5-S100A9环路可能成为未来改善HCC免疫治疗效果的潜在靶点。

---

## 60. 介绍“临界可见”的导管内乳头状黏液性肿瘤：在胰腺癌风险与终止长期监测之间的权衡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40139749](https://pubmed.ncbi.nlm.nih.gov/40139749)
**期刊：** Gut
**PMID：** 40139749
**DOI：** 10.1136/gutjnl-2025-334807

### 第一部分 原文与翻译

**英文原标题：** Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文首次提出了“临界可见”导管内乳头状黏液性肿瘤（IPMN）这一新概念，旨在解决临床实践中的一个棘手难题。针对那些影像学上极难明确观察的IPMN病变，临床医生常陷入继续长期监测（担忧癌变风险）与终止监测（减轻患者负担）的两难境地。该研究可能通过提出新的分类标准或管理建议，为这类患者的监测策略提供了新的思路，有助于实现IPMN监测的精准化和个体化，具有重要的临床指导价值。

---

速递结束，祝您工作愉快！